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Novel Roles for the MAPK-interacting serine threonine kinases 
(Mnks) 
 
by Rebecca Stead 
The mitogen activated protein kinase (MAPK)-interacting serine threonine kinases (Mnks) 
are  components  of  the  MEK/ERK  and  p38MAPK  signalling  pathways.  Research  has 
focused on the role of the Mnks in tumorigenesis, inflammatory signalling cascades and 
translation of inflammatory cytokines. The physiological roles of these kinases are still not 
well understood and their functions have yet to be fully elucidated. This prompted the work 
presented  in  this  study  where  the  roles  of  the  Mnks  have  been  investigated  in  the 
phenomenon of rapamycin-induced eIF4E phosphorylation and the role of the Mnks in 
glucose and lipid metabolism. Increased eIF4E phosphorylation has been correlated with 
tumorigenesis  and  a  potential  anti-cancer  therapy,  rapamycin,  increases  eIF4E 
phosphorylation  in  cancer  cells.  The  increase  in  eIF4E  phosphorylation  is  caused  by 
mTORC1  inhibition-dependent  increases  in  Mnk2a  activity.  The  Mnks  are  enriched  in 
tissues  important  for  glucose  metabolism  and  here  a  role  for  the  Mnks  has  been 
established in insulin signalling. Investigation revealed that the Mnks phosphorylate IRS1 
at 5 sites resulting in its stabilization by impairing its proteasome-mediated degradation. 
The  consequence  of  Mnk1/2  double  knockout  in  mice  is  glucose  intolerance  due  to 
reduced IRS1 protein in white adipose tissue. The incidence of type 2 diabetes as a result 
of obesity is rising rapidly but the mechanisms responsible are as yet not fully understood. 
Evidence presented in a patent suggests the Mnks may play a role in lipid metabolism and 
insulin sensitivity. This inspired research presented here showing Mnk2-KO mice exhibit a 
lack of weight gain when fed high fat diets. Interestingly the Mnk2-KO mice were resistant 
to severe diet-induced insulin resistance. This appears to be related to a reduction in 
chronic inflammation usually associated with high fat diet feeding.  ii 
 
Contents 
Contents  ........................................................................................................... ii 
List of tables .................................................................................................. vii 
List of figures  ................................................................................................ viii 
Declaration of Authorship  ............................................................................. xii 
Acknowledgements ...................................................................................... xiii 
Abbreviations ..............................................................................................  - 1 - 
Chapter 1 Introduction ..................................................................................  - 4 - 
1.1 Overview ............................................................................................................  - 5 - 
1.2 Translation .........................................................................................................  - 5 - 
1.2.1 Overview ........................................................................................................... - 5 - 
1.2.2 Initiation  ............................................................................................................. - 6 - 
1.2.3 Elongation and Termination  ............................................................................ - 11 - 
1.2.4 Control of Translation through Signalling Pathways ...................................... - 12 - 
1.3 The MAPK –interacting serine/threonine kinases (Mnks)  ...............................  - 14 - 
1.3.1 Overview ......................................................................................................... - 14 - 
1.3.2 Discovery of the Mnks .................................................................................... - 14 - 
1.3.3 Upstream Pathways – the ERK and p38MAPK cascades  ............................. - 15 - 
1.3.3.1 Ras/Raf/MEK/ERK Pathway .................................................................... - 17 - 
1.3.3.2 p38MAPK Pathway................................................................................... - 17 - 
1.3.4 Structure of the Mnks  ...................................................................................... - 18 - 
1.3.5 Activation of the Mnks and Isoform Differences.  ............................................ - 23 - 
1.3.6 Targets and Binding Partners  ......................................................................... - 25 - 
1.3.6.1 eIF4E  ............................................................................................................ - 25 - 
1.3.6.2 eIF4G ........................................................................................................... - 27 - 
1.3.6.3 hnRNPA1 and PSF.p54
nrb ........................................................................... - 29 - 
1.3.6.4 Sprouty  ......................................................................................................... - 30 - 
1.3.6.5 Potential Substrates..................................................................................... - 31 - 
1.4 Glucose Metabolism in Mammals ...................................................................  - 32 - 
1.4.1 Overview ......................................................................................................... - 32 - 
1.4.2 Glucose Oxidation – The Krebs Cycle ........................................................... - 33 - 1.4.3 Glycogenesis and Glycogenolysis .................................................................. - 34 - 
1.4.4 Gluconeogenesis ............................................................................................ - 35 - 
1.4.5 Regulation of Plasma Glucose Levels ............................................................ - 35 - 
1.4.6 Type 2 Diabetes Mellitus  ................................................................................. - 38 - 
1.5 Lipid Metabolism ............................................................................................. - 39 - 
1.5.1 Overview.......................................................................................................... - 39 - 
1.5.2 Lipogenesis and Fatty Acid Synthesis ............................................................ - 40 - 
1.5.3 Lipolysis and β Oxidation ................................................................................ - 41 - 
1.5.4 Regulation of Lipid Metabolism  ....................................................................... - 42 - 
1.5.5 Adipokines ....................................................................................................... - 44 - 
1.5.6 Obesity and the Metabolic Syndrome  ............................................................. - 47 - 
1.6 Insulin Signalling ............................................................................................. - 54 - 
1.6.1 Overview.......................................................................................................... - 54 - 
1.6.2 Insulin Signalling Cascade  .............................................................................. - 57 - 
1.6.3 Control of Glucose Uptake by Insulin ............................................................. - 58 - 
1.6.4 The Mnks and Insulin Signalling ..................................................................... - 60 - 
1.7 Aims of this Study............................................................................................ - 61 - 
Chapter 2 Methods and Materials ...............................................................  - 62 - 
2.1 Chemicals, Biochemicals, Reagents and Antibodies. .................................... - 63 - 
2.2 Buffers and Solutions. ..................................................................................... - 63 - 
2.3 Molecular Biology. ........................................................................................... - 70 - 
2.3.1 Plasmids. ......................................................................................................... - 70 - 
2.3.2 Transformation of competent E. coli. .............................................................. - 70 - 
2.3.3 Induction, Expression and Preparation of proteins in E. coli.  ......................... - 72 - 
2.3.4 Purification of GST-fusion proteins. ................................................................ - 72 - 
2.3.5 Solubilisation of eIF4E produced in E. coli. .................................................... - 72 - 
2.3.6 Purification of eIF4E  ........................................................................................ - 73 - 
2.4 Cell Biology and Protein Biochemistry  ............................................................ - 73 - 
2.4.1 Mammalian Cell Culture  .................................................................................. - 73 - 
2.4.2 Transient Transfection of Mammalian Cells ................................................... - 74 - 
2.4.3 Gene Silencing using short interfering RNA (siRNA) ..................................... - 74 - 
2.4.4 Cell Harvesting. ............................................................................................... - 74 - 
2.4.5 RNA Isolation .................................................................................................. - 75 - 
2.4.6 m
7GTP Sepharose Pulldowns and Immunoprecipitations ............................. - 75 - 
2.4.7 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blot 
Analysis .................................................................................................................... - 76 - 
2.4.8 Confocal Microscopy  ....................................................................................... - 77 - 
2.4.9 Preparation of cDNA and qPCR ..................................................................... - 77 - iv 
2.4.10 In vitro Mnk Kinase Assays .......................................................................... - 78 - 
2.4.11 Cyanogen Bromide Cleavage ...................................................................... - 78 - 
2.4.12 In vitro PKB Kinase Assays .......................................................................... - 78 - 
2.4.13 In vitro PI3 Kinase Assays  ............................................................................ - 79 - 
2.4.14 In vitro mTOR Kinase Assays....................................................................... - 79 - 
2.4.15 2-deoxyglucose Uptake Assay. .................................................................... - 80 - 
2.4.16 2-deoxyglucose Lipogenesis Assay. ............................................................ - 80 - 
2.5 Animal Experimentation  ...................................................................................  - 81 - 
2.5.1 Transgenic Mouse Assessment ..................................................................... - 81 - 
2.5.2 Animal Husbandry and Diets .......................................................................... - 82 - 
2.5.3 Glucose Tolerance Test.................................................................................. - 82 - 
2.5.4 DEXA Scanning and Organ Removal ............................................................ - 83 - 
2.5.5 Metabolic Cage Assessment .......................................................................... - 83 - 
2.5.6 Tissue and Plasma Analysis  ........................................................................... - 84 - 
Chapter 3 Rapamycin Induces eIF4E Phosphorylation by Increasing the Activity of 
Mnk2a. ................................................................................................  - 90 - 
3.1 Introduction ......................................................................................................  - 90 - 
3.2 Results  ............................................................................................................  - 92 - 
3.2.1 Effect of Rapamycin in PC3 cells. .................................................................. - 92 - 
3.2.1.1 Rapamycin-induced eIF4E phosphorylation can be blocked by inhibiting both 
the p110ʱ and p110β subunits of PI3 kinase, in PC3 cells. ................................... - 93 - 
3.2.1.2 Changes in eIF4E phosphorylation are independent of eIF4G or 4E-BP1 
binding to eIF4E. ...................................................................................................... - 96 - 
3.2.1.3 Increases in eIF4E phosphorylation are correlated to PKB but not ERK 
phosphorylation.  ..................................................................................................... - 100 - 
3.2.2 Role of the Mnks in Rapamycin-induced eIF4E phosphorylation. ............... - 104 - 
3.2.2.1 Rapamycin-induced phosphorylation of eIF4E is dependent on Mnk2 function 
but not Mnk1. ......................................................................................................... - 104 - 
3.2.2.2 eIF4G/eIF4E binding is affected by the loss of either of the Mnks. .......... - 107 - 
3.2.2.3 mTORC1 inhibition increases the activity of Mnk2a independently of T-loop 
phosphorylation.  ..................................................................................................... - 109 - 
3.2.2.4 Rapamycin increases Mnk2a activity through changes to one site in Mnk2a. ...  - 
112 - 
3.2.3 mTORC1 inhibition increases eIF4G/Mnk2 binding but not p-ERK/Mnk2 binding.
  ................................................................................................................................ - 115 - 
3.2.4 Mnk2 positively regulates mTORC1 activity................................................. - 118 - 
3.3 Discussion  ......................................................................................................  - 120 - 
Chapter 4 The Mnks Regulate Insulin Signalling.  ...................................... - 124 - 
4.1 Introduction ....................................................................................................  - 125 - 4.2 Results   .......................................................................................................... - 126 - 
4.2.1 The Mnks are enriched in tissues related to glucose metabolism. .............. - 126 - 
4.2.2 PKB phosphorylation and activity is regulated by the Mnks. ....................... - 128 - 
4.2.3 Assessment of components of the insulin signalling cascade. .................... - 132 - 
4.2.3.1 Mnk1 knockout alters downstream PKB signalling. .................................. - 132 - 
4.2.3.2 Mnk2KO has specific effects on downstream PKB signalling.  .................. - 135 - 
4.2.3.3 Knockout of both Mnks greatly reduces downstream PKB signalling.  ...... - 137 - 
4.2.4 Investigations into glucose uptake in Mnk-KO cells. .................................... - 140 - 
4.2.5 Knockout of the Mnks causes perturbed PI3K activation.  ............................ - 148 - 
4.2.6 Effects of Mnk Inhibitors on 3T3-L1 Cells.  .................................................... - 151 - 
4.2.6.1 Mnk expression in 3T3-L1 cells. ................................................................ - 151 - 
4.2.6.2 Effect of Mnk inhibition on PKB and PI3K activity. .................................... - 153 - 
4.2.6.3 Inhibition of the Mnks leads to a decrease in insulin-stimulated glucose uptake 
and lipogenesis. ..................................................................................................... - 157 - 
4.2.7 Investigations into the mechanism by which the Mnks regulate insulin signalling.
 ................................................................................................................................ - 160 - 
4.2.7.1 IRS1 levels are lower in knockout cells and in response to inhibition of the 
Mnks. ...................................................................................................................... - 160 - 
4.2.7.2 IRS1 is phosphorylated and stabilized by the Mnks.  ................................. - 162 - 
4.2.8 Analysis of Mnk1/2-DKO mice. ..................................................................... - 167 - 
4.2.8.1 Phenotypic investigations of DKO mice.  .................................................... - 167 - 
4.2.8.2 Biochemical analysis of IRS1 levels in DKO mice. ................................... - 170 - 
4.2.8.3 Mnk1/2-DKO mice exhibit glucose intolerance.......................................... - 173 - 
4.3 Discussion ..................................................................................................... - 175 - 
Chapter 5 Mnk2 Knock-out Animals Exhibit a Novel Lipid and Glucose Metabolic 
Profile, and are Protected from Diet-induced Type 2 Diabetes and Weight 
Gain. .................................................................................................  - 178 - 
5.1 Introduction  .................................................................................................... - 179 - 
5.2 Results   .......................................................................................................... - 181 - 
5.2.1 Phenotypic analysis of Mnk2 knockout mice. ............................................... - 181 - 
5.2.2 Studies of tissue from WT and Mnk2-KO mice. ........................................... - 185 - 
5.2.2.1 Determination of organ size in relation to bodyweight from male and female 
WT and Mnk2-KO mice. ......................................................................................... - 185 - 
5.2.2.2 Microscopic analysis of gastrocnemius skeletal muscle from male WT and 
Mnk2-KO mice.  ....................................................................................................... - 191 - 
5.2.2.3 Microscopic analysis of the left lobe of the liver from male WT and Mnk2-KO 
mice. ....................................................................................................................... - 194 - 
5.2.3 Investigations into whole animal lipid homeostasis in WT and Mnk2-KO mice. ... - 
198 - vi 
5.2.3.1 Mnk2-KO mice exhibit an unusual fat distribution.  .................................... - 198 - 
5.2.3.2 Mnk2-KO mice display morphological and biochemical differences in key fat 
storage depots. ...................................................................................................... - 202 - 
5.2.3.3 Mnk2-KO mice display altered levels of plasma lipid metabolites.  ........... - 213 - 
5.2.4 Investigations into whole animal metabolism. .............................................. - 216 - 
5.2.4.1 Mnk2-KO mice exhibit differences in metabolic parameters. ................... - 216 - 
5.2.4.2 Mnk2-KO mice display altered biochemistry of energy regulators in scapular. .  - 
218 - 
5.2.5 Investigations into whole animal glucose homeostasis in WT and Mnk2-KO 
mice. ....................................................................................................................... - 221 - 
5.2.5.1 Mnk2-KO mice show insulin resistance on chow-fed diets but resistant to diet 
induced insulin resistance.  ..................................................................................... - 221 - 
5.2.5.2 Mnk2-KO mice are protected from diet induced glucose intolerance.  ...... - 224 - 
5.2.6 Mnk2-KO mice exhibit a beneficial inflammatory profile in response to high fat 
feeding.................................................................................................................... - 227 - 
5.3 Discussion  ......................................................................................................  - 232 - 
Chapter 6 Final Discussion ....................................................................... - 240 - 
Role of Mnk2a in rapamycin-induced eIF4E phosphorylation ............................  - 241 - 
Regulation of insulin signalling by the Mnks .......................................................  - 241 - 
Role of Mnk2 in whole body glucose and lipid homeostasis  ...............................  - 243 - 
Future directions for research involving the Mnks...............................................  - 245 - 
List of References ................................................................................... - 246 - 
 
 
 
 
 
 
   List of tables 
Table 2.1  Antibodies  84 
Table 2.2  Sequences for primers used for mutagenesis.  86 
Table 2.3  Sequences for primers used in qPCR analysis.                                         87 
Table 2.4  Sequences for primers used for genotyping.                                              88 
Table 2.5  Composition of animals’ diets.                                                                    89 
Table 3.1  Sequences of human and murine Mnk2.  117 
                                          
 viii 
List of figures 
Figure. 1.1   Translation initiation in Eukaryotes.                                                        9 
Figure. 1.2  Upstream MAPK pathways.  16 
Figure. 1.3  The essential structural components of the Mnks.                                            19 
Figure. 1.4  Amino acid sequence of Mnk1a and Mnk2a.                                                    21 
Figure. 1.5  Role of obesity in whole body insulin resistance.                                              49 
Figure. 1.6  Cellular effects of insulin.                                                                              55 
Figure 2.1  IRS1 Fragments  71 
Figure 3.1  Effects of rapamycin on phosphorylation of eIF4E.  94 
Figure 3.2  Effects of rapamycin on proteins associated with eIF4E.                              98 
Figure 3.3  Effects of rapamycin on ERK and PKB.  101 
Figure 3.4  Effects of inhibition of PKB on rapamycin-induced eIF4E 
phosphorylation.                                                                                                             
102 
Figure 3.5  Mnk2 is required for rapamycin-induced phosphorylation of eIF4E in 
MEFs.                                                                                                           
105 
Figure 3.6  Mnk2 is required for rapamycin-induced phosphorylation  
of eIF4E in PC3 cells.   
106 
Figure 3.7  Loss of the Mnks alters eIF4G-eIF4E binding.                                            108 
Figure 3.8  Effects of rapamycin on Mnk2 phosphorylation.  110 
Figure. 3.9  Mnk2 activity increases in response to mTORC1 inhibition.                       111 
Figure 3.10  Rapamycin increases Mnk2a activity through one site Ser437.                 113 
Figure 3.11  Effect of rapamycin on Mnk2-eIF4G-p-ERK binding.                                 116 
Figure 3.12  Effect of Mnk2 on mTORC1 activity.  118 Figure 4.1  Expression of Mnk1 and Mnk2 in different mouse tissues.  127 
Figure. 4.2  Effects of insulin on PKB phosphorylation and activity in  
WT and Mnk knockout MEFs. 
130 
Figure. 4.3  Effect of insulin on the phosphorylation of selected proteins  
in immortalised WT and Mnk1KO cells. 
134 
Figure. 4.4  Effect of insulin on the phosphorylation of selected proteins in  
primary WT and Mnk2KO cells. 
136 
Figure. 4.5  Effect of insulin on the phosphorylation of selected proteins 
 in immortalised WT and Mnk1/2DKO cells. 
138 
Figure 4.6  Effect of insulin on glucose transport into WT and Mnk1KO cells.              142 
Figure 4.7  Effect of insulin on glucose transport into WT and Mnk2KO cells.  144 
Figure 4.8  Effect of insulin on glucose transport into WT and Mnk1/2DKO cells.  146 
Figure 4.9  Insulin signalling is deficient in WT and Mnk-KO cells.  149 
Figure 4.10  Expression of Mnk1 and Mnk2 in differentiated 3T3-L1 cells.  152 
Figure. 4.11  Insulin signalling is decreased in 3T3-L1 cells treated with  
Mnk inhibitors. 
154 
Figure. 4.12  Effect of insulin on the phosphorylation of selected proteins in  
fully differentiated 3T3-L1 cells. 
156 
Figure 4.13  Effect of Mnk inhibitors on insulin-stimulated glucose transport in 
fully differentiated 3T3-L1 cells. 
158 
Figure. 4.14  Regulation of IRS1 by the Mnks.  161 
Figure. 4.15  Phosphorylation of IRS1 by the Mnks.  164 
Figure. 4.16  Stability of IRS1.  166 x 
Figure 4.17  Organ weight data for male WT C57/BL6 and MNK1/2DKO.  168 
Figure. 4.18  Mnk1/2-DKO exhibit changes in IRS1 expression.  171 
Figure. 4.19  Mnk1/2-DKO exhibit impaired glucose tolerance.  741 
Figure 5.1  Bodyweight data for WT C57/BL6 and MNK2KO.  183 
Figure 5.2  Organ weight data for male WT C57/BL6 and MNK2KO.  187 
Figure 5.3  Organ weight data for female WT C57/BL6 and MNK2KO mice.                189 
Figure 5.4  Analysis of the characteristics of muscle from WT and                              
MNK2KO mice. 
192 
Figure 5.5  Analysis of the characteristics of the left lobe of the liver                            
from WT and MNK2KO mice. 
196 
Figure 5.6  DEXA data for male WT C57/BL6 and MNK2KO mice.  199 
Figure 5.7  Quantitative analysis of DEXA data.  200 
Figure 5.8  Organ weights of abdominal white adipose (abdominal adipose) and 
scapular 
brown adipose from WT  and MNK2KO mice. 
205 
Figure 5.9  Analysis of  the characteristics of scapular in WT and MNK2KO 
mice fed chow or high fat diets. 
207 
Figure 5.10  Analysis of  the characteristics of abdominal adipose in WT and 
MNK2KO 
mice fed chow or high fat diets. 
209 
Figure 5.11  Analysis of  the characteristics of abdominal adipose in WT and 
MNK2KO mice. 
211 
Figure 5.12   Fasting levels of plasma proteins in male WT and MNK2KO mice.  214 
Figure 5.13  Metabolic assessment of WT and MNK2KO mice.  217 Figure 5.14  Analysis of  the components of fat utilization of scapular in WT  
and MNK2KO mice. 
219 
Figure 5.15   Fasting levels of plasma proteins in male WT and MNK2KO mice.  223 
Figure 5.16  Assessment of glucose metabolism in WT and MNK2KO mice.  225 
Figure 5.17  Analysis of  the inflammatory characteristics of abdominal adipose in 
WT  
and MNK2KO mice. 
229 
Figure 5.18 
 
 
Analysis of  the inflammatory characteristics of  in WT 
 and MNK2KO mice. 
231 
Figure 5.19  Lipid metabolism in Mnk2KO mice  235 
 
 
 
 
 
 
 
 
 
 
 
 xii 
 
 
Declaration of Authorship 
 
I, Rebecca Stead declare that the thesis entitled Novel Roles of the MAPK-interacting 
serine threonine kinases (Mnks) and the work presented in the thesis are both my own, 
and have been generated by me as the result of my own original research. I confirm that: 
 
  this work was done wholly or mainly while in candidature for a research degree at this 
University; 
  where any part of this thesis has previously been submitted for a degree or any other 
qualification at this University or any other institution, this has been clearly stated; 
  where I have consulted the published work of others, this is always clearly attributed; 
  where I have quoted from the work of others, the source is always given. With the 
exception of such quotations, this thesis is entirely my own work; 
  I have acknowledged all main sources of help; 
  where the thesis is based on work done by myself jointly with others, I have made 
clear exactly what was done by others and what I have contributed myself; 
  none of this work has been published before submission. 
Signed: ……………………………………………………………………….. 
Date:………………………………………… 
  Acknowledgements 
Firstly I would like to thank Professor Chris Proud for giving me the opportunity to study 
for a PhD in his lab. His support and expertise has been invaluable throughout my studies 
and has provided me with the knowledge and skills for my future career. I would also like 
to thank the Gerald Kerkut Trust and Parnell Diabetes Foundation for the funding to 
conduct the research presented in this thesis. 
I would like to express a big thank you to all of the current and past members of the Proud 
lab, their help and support has got me through the good and bad times during this project. 
I would also like to thank the Coldwell lab for their support over the years and their 
willingness to always help me. I especially want to thank Noel Wortham for his readiness 
to help no matter what I asked and he was always happy to not just show me how to do 
something but to explain the science behind it. The animal work conducted during this 
thesis would not have been possible without the expertise provided by Felino 
Cagampang. Felino immediately accommodated the needs of my project and taught me 
vital skills that will be important in my new job. I would also like to thank Valentina 
Iadevaia, Claire Moore and Suzanne Brooks for their teaching and advice with a number 
of the methods used throughout this work. I would also like to express my thanks to Hans 
Schuppe who helped me with all the microscope work throughout this study and I am so 
grateful for being able to share in his knowledge before he passed away.   
A thank you is also reserved for the various friends I have made during my studies. Lisa 
Perry has become one of my close friends and helped me so much with words of 
encouragement and support. I want to thank Sam Bolton for being an amazing friend who 
always wanted to know how I was and for being there for me when needed. Steph Austin 
has been an exceptional friend to me who has supported me and listened to all my 
worries and stresses. Thanks to Scott Kimber for being my friend and taxi. Many thanks to 
the residents of building 85 and SGH including Olivia Larsson, Ben Mulcahy, Adam Hart, 
Garrick Taylor, Kirstin Williamson, Kelly Hooper, Katy Stubbs, Shmma Quaraishe, Nancy 
Wong, Nash Matinyarare, Christine Reitmayer, Jo Bailey and Halina Mikolajek. Thanks 
also to Lorraine Prout for her support.  
I want to thank my mum, dad and brother for their unconditional love and support without 
which I would not be where I am today. I also want to thank my soon to be in-laws from 
the Fountain family who have made me feel one of their own. xiv 
 
This thesis is dedicated to Tom Fountain, my soon to be husband. Without his love I 
would not be the person I am today. Whenever I needed to go to the lab or stay late he 
would always wait for me and supported me unconditionally throughout my studies. For 
this I am always in his debt and will always love him.         - 1 - 
Abbreviations 
β-GP: β-glycerolphosphate 
β-ME: β-mercaptoethanol 
2-DG: 2-Deoxyglucose 
4E-BP: eIF4E-binding protein 
ADP: adenosine diphosphate  
AMP: adenosine monophosphate 
AMPK: AMP-activated protein kinase 
APS: ammonium persulphate 
AS160: Akt substrate of 160kDa 
ATM: adipose tissue macrophage  
ATP: adenosine triphosphate 
BAT: brown adipose tissue  
Bcl-2: B-cell CLL/lymphoma 2 
BCA: bicinchoninic acid 
BSA: bovine serum albumin 
cAMP: cyclic AMP 
CVD: cardiovascular disease   
DMEM: Dulbecco‘s modified Eagle‘s medium 
DMSO: dimethyl sulphoxide 
dNTPs: deoxynucleoside triphosphates 
DTT: dithiothreitol 
eEF: eukaryotic elongation factor 
EGF: epidermal growth factor  
eIF: eukaryotic initiation factor 
eIF4F: eukaryotic initiation factor 4F complex 
EDTA: ethylenediaminetetraacetic acid 
EGTA: ethylene glycol tetraacetic acid 
ER: endoplasmic reticulum  
eRF: eukaryotic release factor 
ERK: extracellular signal-regulated protein kinase 
FBS: fetal bovine serum 
FFA: free fatty acid 
FGF: fibroblast growth factor  
FOXO: forkhead box protein O 
G6P: glucose-6-phosphate  
GAP: GTPase-activating protein - 2 - 
GAPDH: glyceraldehyde-3-phosphate-dehydrogenase 
GDP: guanosine diphosphate 
GEF: guanine nucleotide exchange factor 
GLUT: glucose transporter  
GK: glucokinase   
GPCR: G protein coupled receptor  
GSK3: glycogen synthase kinase 3 
GSV: glucose storage vesicle  
GTP: guanosine triphosphate 
GTT: glucose tolerance test  
h: hours 
HEK 293 cells: Human Embryonic Kidney 293 cells 
hnRNP: heterogeneous nuclear ribonucleoprotein 
IFNγ: interferon gamma  
IGFR: insulin-like growth factor receptor 
IL: interleukin   
IR: insulin resistance 
IRS: insulin receptor substrate 
JNK: c-Jun N-terminal kinase 
LPS: lipopolysaccharide 
m
7GTP: 7-methyl-GTP 
MAPK: mitogen-activated protein kinase 
MCF7 cells: Michigan Cancer Foundation -7 cells 
MCP-1: monocyte chemotactic protein-1 
MEK: mitogen-activated protein kinase kinase 
Met-tRNAi: Methionyl tRNA specialised for initiation 
min: minutes 
MK: MAPK activated kinase  
Mnk: mitogen-activated protein kinase-interacting kinase 
mRNA: messenger RNA 
MSK: MAPK stress activated kinase 
mTOR: mammalian target of Rapamycin 
NEFAs: non-esterified fatty acids 
NES: nuclear export signal 
NLS: nuclear localization signal 
NK cells: natural killer cells 
PABP: poly (A)-binding protein - 3 -   
PBS: phosphate-buffered saline 
PDK: phosphatidyl -dependent kinase 
PH domain: pleckstrin homology domain 
PI3K: phosphatidylinositol 3-kinase 
PIP2: phosphatidylinositol -4, 5- bisphosphate 
PIP3: phosphatidylinositol -3, 4, 5- trisphosphate 
PKA: protein kinase A 
PKB: protein kinase B 
PKC: protein kinase C 
PMA: phorbol myristate acetate 
PP2A: protein phosphatase 2A 
PPAR: peroxisome proliferator-activated receptor  
PRAS40: proline-rich Akt substrate of 40 kDa 
PTEN: phosphatase and tensin homolog deleted on chromosome 10 
qPCR: quantitative real time polymerase chain reaction 
RANTES: regulated on activation normal T cell expressed  
Raptor: regulatory associated protein of mTOR 
Rheb: ras homology enriched in brain 
Rictor: rapamycin-insensitive companion of mTOR 
RSK: p90 ribosomal S6 kinase 
RTK: receptor tyrosine kinase 
S6K: p70 ribosomal protein S6 kinase 
SAT: subcutaneous adipose tissue  
SDS-PAGE: sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
sec: seconds 
SOS: Son of Sevenless 
T1DM: type 1 diabetes mellitus  
T2DM: type 2 diabetes mellitus 
TEMED: tetramethylethylenediamine 
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TNFʱ: tumour necrosis factor alpha  
tRNA: aminoacyl-transfer RNA 
TSC1/2: tuberous sclerosis complex ½ 
UTP: uridine triphosphate  
UTR: untranslated region 
VAT: visceral adipose tissue  
VEGF: vascular endothelial growth factor - 4 - 
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Chapter 1 
Introduction 
 
   - 5 -   
1.1 Overview 
Responses to external and internal changes of the extracellular and intracellular 
environment require a complex web of proteins that communicate changes through 
cascades of phosphorylation as well as various other events. The relationships shared by 
signalling components are very intricate and tightly controlled by proteins within the 
cascade as well as by other regulatory proteins. Cellular signalling is essential for cell 
survival and controls many aspects of cell life such as responses to pathogens, 
hormones, ionic changes as well as overall homeostasis. Dysfunction of cellular signalling 
can lead to a diverse range of conditions including autoimmune diseases, cancer and 
diabetes [1]. Many signalling proteins are not confined to just one pathway and very often 
function in several pathways creating very intricate effects of extracellular and intracellular 
activation or inhibition. One such group of proteins are the mitogen activated protein 
kinase (MAPK)-interacting serine threonine kinases (Mnks), which are the focus of this 
research.   
1.2 Translation  
1.2.1 Overview 
The rate of transcription, nuclear export of mRNA, mRNA stability, rate of translation and 
protein degradation all affect protein levels. The rate of translation is thought to be the 
most important for determining the amount of protein [2]. Characteristics of the mRNA to 
be translated will affect its rate of translation and determine whether it is sequestered or 
rapidly degraded [3]. The rate of translation is also controlled by modification of proteins 
that direct protein synthesis, such modifications include phosphorylation, which is 
especially important. The signalling pathways that regulate phosphorylation of 
translational proteins are therefore of significant interest and their dysregulation can lead 
to disease. The proteins that form the translational machinery may themselves become 
inadequate at their role either through excessive activity or decreased/lack of activity also 
resulting in disease. The process of protein synthesis requires messenger RNA (mRNA), 
which is generated through transcription and RNA processing in the nucleus to produce a 
mature mRNA molecule that is exported to the cytoplasm. mRNA transport into the 
cytoplasm is mediated by sequences in the untranslated regions (UTR) and proteins 
bound to these sequences, this also governs if and when the transcript is translated [4, 5]. 
Assuming there is no reason for the mRNA to be sequestered, it is possible for translation 
to commence. Translation also requires ribosomes, which are complexes made from 
proteins and RNAs, consisting of two major subunits the 40S and 60S, forming an overall - 6 - 
80S unit [6]. There are three important steps that take place during translation: of which 
the first two are stringently regulated by signalling pathways.  
1.2.2 Initiation  
There are two types of cytoplasmic translation: cap-dependent translation and cap-
independent translation; this review only covers the former. Capped mRNA contains an 
m
7GpppX (where X is any nucleotide), which is important for mRNA stability, 
nucleocytoplasmic shuttling and most importantly serves as the site where initiation factor 
complexes assemble in order to commence translation [7]. The initiation of translation is a 
highly complex process and requires a number of initiation factors (eIFs), methionine-
tRNA (Met-tRNA) and the ribosomal subunits.  
The 43S preinitiation complex is a prerequisite for the actual initiation of translation. This 
complex consists of a number of components, including: initiation factors (eIFs), Met-tRNA 
and the 40S subunit of the ribosome (Fig 1.1A). The Met-tRNA must bind to eIF2, which 
has 3 subunits; ʱ –regulates eIF2 through phosphorylation, the β subunit binds eIF5 and 
the  subunit binds Met-tRNA and GTP [8]. The factor eIF2B regulates the association 
between eIF2 with GTP and GDP, functioning as a guanine nucleotide exchange factor 
(GEF) and under periods of translation down regulation associates with phosphorylated 
eIF2ʱ in an inhibitory fashion [9]. Both Met-tRNA and GTP must bind eIF2 to form the 
ternary complex, this then binds to the 40S subunit, again through eIF2γ and also eIF2β 
[9]. The factors eIF1 and eIF1A interact with the 40S subunit, eIF2 and eIF3 functioning to 
stabilise the interaction between the ternary complex and the rest of the preinitiation 
complex.  eIF3 also acts as a scaffold and can bind to the 40S subunit as well as the other 
eIFs [9]. eIF5 is also associated with the 43S preinitiation complex and binds to the 40S 
subunit, eIF2β and eIF2γ [10]. The eIF4F complex is responsible for the association of the 
43S preinitiation complex with the mRNA and produces the 48S initiation complex that is 
then ready to scan for the AUG start codon and begin protein synthesis [3, 8].  
The formation of the eIF4F complex requires the association between the eIF4 factors: 
eIF4E, eIF4G and eIF4A (Fig. 1.1B). The initiation factor that actually binds the cap is 
eIF4E, whose structure resembles that of a clamp [7]. There are 4 different eIF4E forms in 
humans: eIF4E1 (referred to here as eIF4E), eIF4E1b, eIF4E2 (or 4E-HP) and eIF4E3 
[11]. Binding to the cap requires the conserved residues: Trp56, Trp102 and Glu103 
(eIF4E1 mouse). These residues are required for π-π interactions and binding to the 
guanine ring of the mRNA cap via hydrogen bonds, whilst arginine residues function to 
coordinate oxygen from the m
7GTP phosphate groups [7]. The kinetics of eIF4E-mRNA - 7 -   
binding is rapid (decays within ~0.1s) unless there are other binding partners bound to 
stabilize the interactions or eIF4E is bound to eIF4G [12]. 
The role of eIF4G is as a scaffold between the cap and the 40S subunit, through binding 
to eIF4E, eIF3 and eIF4B. There are two forms of eIF4G expressed in cells; eIF4GI and 
eIF4GII, which are then further differentiated as numerous isoforms [13]. The structure of 
eIF4G consists of numerous important domains: the N-terminal domain, which contains 
the poly(A) binding proteins (PABPs) binding region, eIF4E, eIF4A, mRNA and eIF3 
binding sites and the C-terminus, which contains the sites for Mnk binding [14]. The ability 
of eIF4G to bind mRNA and PABP is important for strong  cap binding and is therefore not 
wholly dependent on eIF4E [14]. The PABPs mediate a bridge between the poly A tail and 
the 5’-end of mRNA via eIF4G and eIF4B. Binding of PABPs to eIF4G enhances 
formation of 48S complexes through circularisation of mRNA and increased recruitment of 
the 40S subunit, whilst binding to eIF4B is thought to increase the association of eIF4F 
with the 5’-cap [3]. The binding of eIF4G to eIF3 is important to the bridging role of eIF4G 
between mRNA and the 43S preinitiation complex; however experiments suggest that loss 
of this binding does not affect overall protein synthesis but impinges on specific mRNAs 
resulting in an important point of control for expression of specific proteins [15]. The 
interaction between eIF4E and eIF4G requires the consensus sequence YXXXXLф (ф is 
usually L, but can be M or F) found in the N-terminus of eIF4G and the residue Trp73 in 
eIF4E [7]. The eIF4G/eIF4E association is thought to result in an increased affinity of 
eIF4E for the m
7 cap [14]. An important translational regulator can compete with eIF4G 
binding with eIF4E due to the presence of the eIF4E consensus sequence, these proteins 
are aptly named the eIF4E-binding proteins (4E-BPs). In a hypophosphorylated state 4E-
BPs strongly compete with eIF4G for binding to eIF4E in order to block translation 
initiation. In response to various stimuli, phosphorylation of the 4E-BPs reduces the 
interaction with eIF4E allowing for eIF4E to bind eIF4G and promote initiation [16]. eIF4G 
also binds to eIF4A, which is a DEAD-box RNA helicase that is necessary to unwind any 
secondary structures in the 5’ of the mRNA to ensure easy scanning for the AUG start 
codon. Binding of eIF4A to eIF4G through HEAT-domains results in its activation and the 
removal of secondary structures from the mRNA, which is believed to be required for the 
subsequent binding to the 43S preinitiation complex [14]. eIF4A requires ATP hydrolysis 
for rapid cycles of binding and dissociation in order to remove multiple secondary 
structures and also requires eIF4B, which functions to increase the affinity of eIF4A with 
mRNA [14]. The point at which eIF4F dissociates is unknown, i.e., whether it occurs 
during scanning, or, once the start codon has been recognized. It may remain associated 
with the cap.  - 8 - 
Scanning for the start codon is ATP dependent, when the start codon is recognized there 
is a pause, that, if long, enough allows eIF5 to activate the GTPase within eIF2 (Fig. 
1.1C). This then leads to dissociation of eIF2-GDP and subsequently eIF3 as well as the 
other initiation factors. Following this eIF4B mediates the joining of the 60S subunit to 
form the complete 80S ribosome [3, 8]. 
It must be noted that eIF4E is extremely important in initiation because it must bind to the 
m
7 G cap, without this, cap-dependent translation cannot occur.  
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Figure 1.1 Illustration of cap-dependent translation initiation in mammals. The 43S 
preinitiation complex and the eIF4F complex are assembled followed by the joining of both 
complexes to produce the 48S initiation complex. Adapted from [17].   
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1.2.3 Elongation and Termination 
Elongation requires a different set of proteins called the eukaryotic elongation factors 
(eEFs), of which there are two; eEF1 and eEF2. After initiation, Met-tRNAi is found in the 
peptidyl (P) site and the aminoacyl (A) site is ready for the next tRNA (Fig. 1.1D). The A-
site binds to the next codon of the mRNA and shifts relative to the reading frame [17, 18]. 
Entry of the correct tRNA into the A site is mediated by eEF1A bound to GTP. Once the 
tRNA anticodon binds correctly to the mRNA codon the GTPase activity of eEF1A is 
activated causing a release of GDP and eEF1A to dissociate from the tRNA and 
ribosome. The function of eEF1B (composed of subunits; ʱ, β and γ) is to act as a 
guanine nucleotide exchange factor (GEF) and recycles eEF1A-GDP back to eEF1A-GTP 
ready for another cycle of elongation [18, 19]. The presence of a tRNA in the A site and 
another in the P site, leads to the peptidyl transferase reaction. The 60S ribosome is 
actually an rRNA-based enzyme and thus called a ribozyme. It catalyzes the nucleophilic 
attack of the carbonyl group of the peptidyl-tRNA on the ʱ-amino group of the aminoacyl-
tRNA. The net result of this is that the nascent polypeptide previously bound to the P-site 
tRNA are now joined by a peptide bond to the newly arrived amino acid attached to the A-
site tRNA. The next step is for the sequential movement of the mRNA and tRNA such that 
the A site is freed for the next aminoacyl-tRNA. This process is called translocation and is 
mediated by eEF2 bound to GTP. The hydrolysis of GTP is necessary for the movement 
of the mRNA relative to its interaction with the tRNA [18].  
Elongation continues until a stop codon enters the A site: there are three stop codons that 
signal termination in mammalian cells; UAA, UAG and UGA. All three are recognised by a 
class I release factor (RF) eRF1, and a second class of release factors, eRF3, functions to 
stimulate the GTPase activity of eRF1. 
The mechanism of peptide termination involves eRF1 entering the A site of the ribosome 
and because of its similar structure to tRNA it can recognise the stop codon in the 40S 
subunit and then activate the peptidyl transferase centre in the 60S subunit. However the 
actual recognition of stop codons and activation of hydrolysis are still elusive. It is thought 
that the amino acid sequence, NIKS, in the N-terminus of eRF1 acts as a recognition 
sequence for the stop codon, essentially like an anticodon of tRNA – it is an example of a 
protein mimicking RNA. The C-terminus of eRF1 is believed to bind to eRF3. The exact 
dynamics between eRF1 and eEF3 is not well understood [20, 21]. The overall effect is 
release of the new peptide from the translation machinery. - 12 - 
1.2.4 Control of Translation through Signalling Pathways  
As previously mentioned, translation is regulated by a number of pathways; here two of 
the major pathways are discussed: the mammalian target of rapamycin (mTOR) and 
mitogen-activated protein kinase (MAPK) pathways. 
The mTOR pathway includes mTORC1 and mTORC2; in this thesis, focus will be directed 
at mTORC1 as this is the pathway involved with translation. Both mTORC1 and mTORC2 
contain the mTOR protein amongst others. The mTORC1 complex consists of the mTOR 
protein, Raptor, mLST8, Rheb and PRAS40, whilst mTORC2 consists of mTOR, Rictor, 
Sin1 and mLST8 [22]. Activation of the mTORC1 pathway occurs through hormones, 
growth factors, cytokines and neuropeptides, acting at their respective receptors and 
leading to activation of a number of cellular pathways that then alter the activity of 
mTORC1. A classic example of mTORC1 signalling involves its control by insulin. 
Activation of the insulin receptor elicits the conventional insulin receptor/IRS1/PI3K 
pathway (discussed in section 1.6.2, Fig. 1.6), which in turn leads to protein kinase B 
(PKB) activation. Full activation of PKB requires that Thr
308 and Ser
473 are phosphorylated 
[23, 24]. Activated PKB then phosphorylates Tuberous Sclerosis complex 2 (TSC2), which 
is found in a heterodimeric complex with TSC1; this phosphorylation leads to an inhibition 
of the activity of the TSC2/TSC1 complex. Under basal conditions TSC2/TSC1 is active 
and acts as a GTPase activating protein (GAP) towards Rheb. Rheb is a small GTPase 
and when TSC2/TSC1 is active Rheb associates with GDP and is inactive. When growth 
factor signalling (i.e. insulin) is activated the inhibition of TSC2/TSC1 in turn blocks its 
GAP activity towards Rheb thus shifting towards the active Rheb-GTP form [25]. The 
actual mechanism of Rheb activation of mTORC1 is not yet understood; however GTP 
must be bound to Rheb to elicit mTORC1 kinase activity. For mTORC1 to phosphorylate 
its substrates these targets must bind to a separate polypeptide within the mTORC1 
complex called raptor [26]. The activity of mTORC1 is also reportedly controlled through 
another PKB substrate, PRAS40, phosphorylation by PKB leads to the dissociation of 
PRAS40 from the mTORC1 kinase domain resulting in removal of PRAS40’s inhibitory 
influence [22, 25]. mTORC1 is also controlled by amino acid levels and energy status 
through other pathways, not described here, but details can be found in these papers [22, 
25].  
 
Downstream of mTORC1 are a number of targets related to protein synthesis. Some 
direct mTORC1 targets are translation factors whilst others are downstream of other 
mTORC1 substrates or indirectly regulated by mTORC1. A direct target of mTORC1 are - 13 -   
the eIF4E-binding proteins (4E-BPs), mTORC1 is capable of phosphorylating the 4E-BPs. 
The effect of this is the dissociation of 4E-BPs from eIF4E allowing eIF4E to bind to eIF4G 
and promote cap-dependent translation [25]. Addition of mTOR inhibitors blocks the 
dissociation of 4E-BPs and thus inhibits translation. The best known mTORC1 inhibitor is 
rapamycin, which is an allosteric inhibitor of mTORC1 only. Rapamycin binds to cytosolic 
FKBP12 and is thought to form a complex with the FBP binding region within mTORC1 
although the exact mechanism of inhibition is not yet understood [27]. There are a number 
of mTOR ATP-competitive inhibitors (e.g. PP242) that block both mTORC1 and mTORC2 
activity and strongly inhibit the dissociation of 4E-BPs from eIF4E [28]. There is extensive 
evidence that rapamycin does not block and in fact increases phosphorylation of eIF4E, 
which requires binding to eIF4G in vivo [29-31]. The other major targets of mTORC1 are 
the p70S6 kinases, S6K1 and S6K2, which are phosphorylated and activated by mTORC1 
and phosphorylate substrates including the S6 ribosomal protein, eIF4B and eEF2K. The 
effect of S6 phosphorylation was believed to be related to TOP mRNA synthesis but has 
since been disproven whilst there is evidence from S6 knockout mice that suggests S6 is 
important for cell growth (reviewed [32]). Phosphorylation of eEF2K by S6K leads to the 
inhibition of eEF2K and the subsequent dephosphorylation of eEF2 resulting in its 
engagement in translation elongation [33]   
The MAPK pathway, as discussed in section 1.3.3, encompasses a large number of 
cellular signalling kinases and its activation has numerous effects within the cell. Protein 
synthesis can be regulated by both the extracellular regulated (ERK) and p38 MAPK 
pathways through a number of its targets. Translational regulation through both the ERK 
and p38 pathways involves several of the kinases from the MAPK-activated kinase (MK) 
family; this includes MK2, MK3, Mnk1 and Mnk2. Studies show MK2 can regulate mRNA 
stability as a result of p38MAPK activation. The activation of MK2 has been shown as 
necessary for phosphorylation of heterogeneous nuclear ribonucleoprotein A0 (hnRNPA0) 
[34], PABP [35] and tristetraprolin (TTP) [36], all of these are AU rich element (ARE) 
binding proteins that alter the stability of TNFʱ (tumour necrosis factor ʱ) mRNA. 
Therefore by altering the stability of mRNA the rate and efficiency of translation is 
changed. MK2 and MK3 regulate eEF2 kinase (eEF2K) phosphorylation. The 
phosphorylation of eEF2K at Ser
377 results in the decreased activity of eEF2 kinase and 
thus dephosphorylation of eEF2 leading to increases in translation elongation [37].  
The Mnks are also regulators of translation their role in translational control is discussed 
below in detail in section 1.3.6.   - 14 - 
1.3 The MAPK –interacting serine/threonine kinases (Mnks) 
1.3.1 Overview 
The  Mnks  were  discovered  15  years  ago  [38,  39]  and  have  since  been  extensively 
researched in the context of tumorigenesis and inflammatory disease (reviewed [40] and 
see [41-44]). However, the exact physiological role of the Mnks has yet to be identified, 
despite  the  generation  of  Mnk  knockout  mice  [45].  Activation  of  the  Mnks  requires 
stimulation of the MAPK pathway; this involves activation by a wide variety of stimuli and 
can  instigate  different  divisions  of  MAPK  signalling  involving  different  MAPK  proteins. 
These proteins are serine/threonine kinases i.e. they phosphorylate their substrates at 
serine’s and threonine’s, they are also themselves substrates of one another in a cascade 
of activation.  
1.3.2 Discovery of the Mnks 
The discovery of the Mnks was preceded by observations that the translation factor, 
eIF4E, was phosphorylated in response to hormones, growth factors, oncogenic signals, 
cellular stresses (i.e. TNFʱ, LPS, arsenite (reviewed [46]))  and inhibition of phosphatases 
(reviewed[47]). The levels of eIF4E phosphorylation were shown to correlate with changes 
in the cell cycle and overall protein synthesis rates (reviewed [48] see also [49]). Initially 
evidence suggested that eIF4E was phosphorylated on Ser
53 [50] and so research began 
to identify the kinase(s) responsible leading to suggestions that protein kinase C (PKC) 
and p70S6K were responsible [51]. It was later discovered that an alanine mutant of Ser
53 
was still phosphorylated to the same extent as wildtype eIF4E [52], which then led to the 
discovery that Ser
209 was in fact the residue phosphorylated in eIF4E [53]. This then 
triggered further research to determine the kinase(s) responsible for Ser
209 
phosphorylation; this showed that although PKC was capable of eIF4E phosphorylation in 
vitro it was clear there were other kinases involved (reviewed [54]). The increases in 
eIF4E phosphorylation in cells treated with phorbol esters, hormones, mitogens and cells 
expressing transforming ras or src suggested the MAPK pathway was involved because 
inhibition of MEK resulted in decreased eIF4E phosphorylation [55-57]. The most obvious 
kinase responsible for this was ERK and experiments to determine if eIF4E was a 
substrate for ERK showed that this was not the case indicating a substrate of ERK was 
potentially the Ser
209 eIF4E kinase [55]. A two-hybrid system was used to identify the 
substrate of ERK that was responsible for eIF4E phosphorylation and led to the discovery 
of Mnk1 and Mnk2 [38, 39, 58]. The generation of Mnk1/2-DKO mice showed that the 
Mnks were the only kinases responsible for in vivo phosphorylation of eIF4E at Ser
209 [45].           - 15 -   
1.3.3 Upstream Pathways – the ERK and p38MAPK cascades 
The phosphorylation of eIF4E occurs in response to stimuli, which initiate a cascade that 
culminates in the activation of either ERK or p38MAPK. The easiest division between 
different MAPK cascades is their stimuli, cellular stresses such as cytokines, osmotic 
shock and UV radiation activate the p38 MAPKs and c-Jun N-terminal kinases (JNKs), 
whilst growth factors and phorbol esters stimulate the MAPKs known as ERK1 and ERK2. 
There are also two further MAPK groups, ERK3/4 and ERK5. There are several 
differences in these proteins compared to ERK1/2, JNK and p38 MAPKs in terms of their 
distribution, structure and understanding of their function [37]. The MAPK proteins share a 
general cascade of activation in response to extracellular stimuli, which has been termed 
the MAPKKK, MAPKK, MAPK sequence, although stimuli elicit specific responses, there 
is overlap between pathways (Fig. 1.2). The best examples of MAPKKK’s are the MEKK’s 
such as MEKK1, MEKK3, RAF and so forth. These kinases are the points of convergence 
for kinases such as ras and TRAF2 etc, which are activated by various stimuli [59, 60]. 
The role of MAPKKK’s is to phosphorylate their substrates, which are cumulatively known 
as MAPKK’s. Some examples of these kinases are MEK1, MEK2, MKK3, MKK6 [61]. 
These kinases represent a point of branching that allows the activation of specific 
processes dependent on the original stimuli. The MAPKK’s function is to phosphorylate 
MAPK’s such as ERK1/2 and p38MAPK [61], which phosphorylate substrates such as 
other protein kinases that broaden and amplify the effects of the MAPK pathway or 
specific targets such as transcription factors, scaffolding proteins etc.  
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Figure. 1.2. The MAPKKK, MAPKK, MAPK pathway in the activation of ERK and p38 
MAPK pathway and their downstream kinase targets, the MAPK-activated Kinases (MKs). 
Adapted from [37].  
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1.3.3.1 Ras/Raf/MEK/ERK Pathway 
Mitogens can activate both GPCRs (G-protein coupled receptors) and receptor tyrosine 
kinases (RTKs) e.g. epidermal growth factor receptor (EGFR) and the insulin receptor. 
GPCRs are activated by conformational changes caused by ligand binding, which results 
in the exchange of GDP for GTP in the ʱ subunit of the G-protein (heterotrimeric 
consisting of ʱβγ subunits) associated with the receptor [62]. The active ʱ subunit can 
then activate numerous second messengers including phospholipase C, which in turn 
results in the generation of diacylglycerol (DAG) a potent activator of protein kinase C 
(PKC) [62]. Ligand binding to RTKs causes their dimerization and autophosphorylation, 
which culminates in their activation. Once active the phosphorylated tyrosine residues on 
RTKs present docking sites for proteins containing Src homology 2 (SH2) domains [62]. 
Activation of the Ras/Raf/MEK/ERK pathway involves the association of Shc with RTKs 
(through SH2 and phosphotyrosine binding domains (PTB)) and Grb2, which binds to  a 
GEF called son of sevenless (SOS) [63]. The GEF activity of SOS causes the activation of 
the membrane bound protein Ras through the exchange of GDP to GTP [63]. Ras-GTP 
then recruits and activates (through a complex mechanism) Raf a serine/threonine 
MAPKKK. Raf is also phosphorylated and activated by PKC and functions to 
phosphorylate and activate the MAPKKs, MEK1 and MEK2 [63]. These kinases then go 
on to phosphorylate ERK1 and ERK2 on a threonine and a tyrosine residue resulting in 
the activation of ERK1/2, which are serine/threonine kinases [63]. There are over 100 
substrates known for ERK1/2 leading to the ability of these kinases to alter cell growth, 
proliferation, metabolism, transcription, translation and so forth [63].  
1.3.3.2 p38MAPK Pathway  
In the p38 MAPK pathway, stimulation of cell surface receptors leads to activation of a 
variety of MAPKKKs including MEKK 1-4 and others. The MAPKKs downstream 
specifically for p38MAPK are MEK3 and MEK6. There is some difference between MEK3 
and MEK6 such that the former is more selective for the ʱ and β isoforms of p38 whilst the 
latter is non-selective for all isoforms (ʱ, β, γ and ʴ). p38MAPK is activated by MEK3 and 
MEK6 through phosphorylation of a Thr-Gly-Tyr motif located within the activation loop 
[64]. Importantly the p38 MAPK pathway, as stated, overlaps with the ERK pathway in 
some of its targets [37]. Kinases that are substrates of MAPK’s are called MAPK activated 
kinases (MKs) and include the MSKs (MAPK stress activated kinases); MK2, 3 and 5; 
RSKs (ribosomal S6 kinases) and the Mnks (MAPK interacting kinases or MAPK signal - 18 - 
integrating kinases). As can be seen (Fig. 1.2) Mnk1 can be activated by both ERK1/2 and 
p38MAPK, whilst Mnk2 is only activated by ERK1/2.   
1.3.4 Structure of the Mnks 
There are two human genes: MKNK1 and MKNK2 that encode 4 isoforms of the Mnks, 
which are alternatively spliced to produce Mnk1a and Mnk1b, Mnk2a and Mnk2b mRNAs, 
respectively [65, 66]. Whilst in mice MKNK1 and MKNK2 only give rise to Mnk1 
(equivalent of Mnk1a) and Mnk2 (equivalent of Mnk2a). Hence forth Mnk1 and Mnk2 refer 
to the murine forms and human forms are described as Mnk1a, and Mnk2a. As can be 
seen (Fig. 1.3), there are a number of differences between the isoforms, which give rise to 
the differences in their localization and functions. The activity of the Mnks differs 
considerably wherein Mnk1 has low basal activity and is highly activated by ERK1/2 and 
p38MAPK and Mnk2 has high basal activity and is only minimally activated further by 
ERK1/2 [67, 68].  
The general structure of this group of kinases involves an N-terminal polybasic region that 
stipulates nuclear localisation and eIF4G binding followed by a catalytic domain. In the 
longer isoforms, Mnk1a and Mnk2a (and murine Mnk1 and Mnk2) there is also a C-
terminal MAPK binding domain, whilst Mnk1a also contains a C-terminal nuclear export 
signal. All isoforms possess the catalytic domain, which contains the essential features for 
kinase activity. The catalytic domain of most kinases is well conserved and the Mnks 
share some common features, which place them in the Ca
2+/calmodulin-dependent 
kinases (CaMK) group of the main Ser/Thr kinase superfamily; however, they are not 
dependent upon Ca
2+/calmodulin for activation [68]. The general structure of most protein 
kinases is segregated into a bilobal arrangement consisting of an N-terminus and C-
terminus in-between which is a conserved ATP binding pocket [69]. Protein kinases 
contain a conserved sequence of DFG, which is essential for Mg
2+binding and as such 
orientation of ATP [69]. 
However the Mnks present a difference from other kinases here, as they do not have the 
conserved DFG sequence but instead have DFD (Asp
191, Phe
192 and Asp
193 for Mnk1a and 
Asp
226, Phe
227 and Asp
228 for Mnk2a, Fig. 1.4) [68, 69]. Preceding the DFG/D motif are a 
number of important conserved features; in the 3-D structure of kinases the glycine-rich 
loop provides an enclosure for ATP and contacts its γ-phosphate group and a conserved 
lysine residue (Lys
78 for Mnk1a and Lys
113 for Mnk2a) functions to stabilize interactions by 
the DFG/D motif and ATP binding [68, 70, 71]. - 19 -   
 
Figure.  1.3.  The  essential  structural  components  of  the  four  Mnk  isoforms  present  in 
human  cells.  There  are  only  two  Mnks  present  in  mice,  Mnk1  and  Mnk2,  which 
correspond to human Mnk1a and Mnk2a. Adapted from [37].     
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The P+1 loop is a common feature of most kinases, which is necessary for substrate 
binding and occurs at the residue following the site of phosphorylation. In the Mnks this 
occurs after the second threonine of the T-loop (Fig. 1.4) i.e. Thr
202 for Mnk1, Thr
214 for 
Mnk1a and Thr
249 for Mnk2a. Immediately after the P+1 loop is the ʱEF helix, which is 
linked to the ʱF helix via the ʱEF loop, the role of this arrangement is positioning of the 
APE motif, which is essential in autoinhibition and accommodation of activation segment 
phosphorylation residues [68, 71]. The active and inactive conformations of Mnk1a and 
Mnk2a show some striking differences that provide evidence for their differing levels of 
activity. Within the C-terminal lobe is the catalytic loop and activation segment that 
contains the DFD motif and APE motif. The Mnks are again different from the normal 
kinase convention in that their activation loop includes the ʱEF helix and ʱEF/ʱF loop. 
Usually the activation loop involves those residues undergoing reorganization, whereas in 
the Mnks this involves residues within this particular helical structure (Fig. 1.4) [68-70]. 
Another Mnk-specific feature is an insertion (residues 233-237 Mnk1a, 263-267 Mnk2a) 
into the ʱEF helix, which results in changes to the inhibitory interaction of the C-terminal 
lobe with the N-terminal lobe such that, instead of normal kinase intramolecular bonds, the 
Mnks form intermolecular pairings [70]. Residues within the ʱEF helix, Glu
225 of the APE 
motif and Glu
228 of insertion 2, interact with other amino acids in the ʱC regulatory helix, 
Arg
90 and Arg
93. This results in positioning of the activation segment within the N-terminal 
lobe. An additional feature of the Mnks’ autoinhibitory mechanism is the presence of a 
phenylalanine that has a slightly different role in each kinase but functions to block 
important features of the active conformation. In Mnk1a, the residue Phe
230 ( also 
conserved in Mnk2a) is found in the Mnk-specific insert 2 and functions to displace the 
DFD motif through rotation of Asp
191 (Asp
226 for Mnk2a) this then causes the side chain of 
the phenylalanine from the DFD motif (Phe
192 for Mnk1a, Phe
227 for Mnk2a) to occupy a 
hydrophobic pocket created by leucines and valines, which under active conditions is part 
of the ATP site [67, 68].     - 21 -   
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Figure. 1.4. Amino acid sequence of Mnk1a and Mnk2a showing their major features. In 
order of feature: blue box – glycine-rich loop (GR loop), pink box DFD sequence, green 
highlighted residues form the activation segment, red circles are T-loop residues that are 
phosphorylated, orange box APE sequence, purple and burgundy brackets are α helices 
as labelled. Adapted from [70].     - 23 -   
This means that in the inactive Mnk conformation the DFD motif is rotated in a fashion that 
forms a “DFD-out” conformation and results in occupation of the ATP site with a bulky side 
chain, thus blocking ATP entry. A further effect of this arrangement is that Asp
191 becomes 
wedged between Glu
94 and Lys
78. These two residues, along with Asp
170, form an ionic 
pair, which supports ATP binding, thus with Asp
191 wedged between them this blocks ATP 
binding. One of the major differences between Mnk1a and Mnk2a is the greater affinity of 
Mnk2a for ATP, which is linked to the higher basal activity of Mnk2a. The residue Tyr
60 in 
Mnk1a forms hydrogen bonds with the backbone carbonyl of Asp
193 of the DFD motif and 
the backbone amide of Val
227 of insert 2; this likely produces a very stable orientation of 
the inactive conformation [70]. In Mnk2a, Tyr
60 is replaced with His
95, which cannot form 
these interactions, and thus this restrictive arrangement is absent. Furthermore in Mnk1a, 
Thr
97 forms hydrogen bonds to Arg
93 and Phe
230, in Mnk2a Tyr
97 is replaced with Met
132, 
which again cannot form this restrictive structure. These features mean it is likely that ATP 
can leak into Mnk2a encouraging its activation and thus lead to a higher basal activity, 
whereas Mnk1a has a highly restrictive inhibitory conformation that makes this impossible 
[67-70, 72]. The activation of Mnk1a requires phosphorylation at a number of residues, 
which can occur through upstream signalling pathways or autophosphorylation, 
phosphorylation of Mnk2a occurs at shared sites with Mnk1a. 
1.3.5 Activation of the Mnks and Isoform Differences. 
T-loop phosphorylation is essential for the activity of the Mnks but there are distinct 
differences between isoforms, which contribute to the differing levels of activity seen in the 
different isoforms. Another threonine, Thr
332 (Thr
344 in Mnk1a and Thr
379 in Mnk2a) is also 
phosphorylated in both Mnk1 and Mnk2 but has a different role in each protein. Evidence 
suggests the phosphorylation is not necessary for Mnk1 activity and mutations to 
glutamate, aspartate or alanine actually increase the basal and stimulated activity of 
Mnk1. It is suggested that in Mnk1 this residue plays a role in autoinhibition [58, 67]. 
However, in Mnk2, mutation to alanine or aspartate caused a loss of Mnk2 activity 
determined by its ability to phosphorylate the known Mnk substrate eIF4E, suggesting that 
here this residue may be constitutively phosphorylated, which along with other features 
may explain the difference in activity between Mnk1 and Mnk2. Other phosphorylation 
sites identified in Mnk2 include Thr
403, Ser
27, Ser
399, Ser
401 and Ser
173 [73].  
There are other major differences between the four different Mnk isoforms that support the 
disparities seen in their activity. Their activity can be measured in an in vitro kinase assay, 
which involves combing large quantities of either Mnk with recombinant eIF4E and 
radioactive ATP, the incorporation of radioactive ATP into eIF4E can be measured to give 
a quantitative activity of the Mnks. As previously mentioned, Mnk1a has low basal activity - 24 - 
and is greatly stimulated by ERK and p38 MAPK pathways, Mnk2a has a high basal 
activity that is only slightly stimulated by ERK of p38MAPK (and hardly decreased by 
inhibitors of these pathways). The shorter isoforms also show differences, Mnk1b has a 
higher basal activity than Mnk1a (but lower than Mnk2a) and is only very slightly 
stimulated by upstream kinases, whilst Mnk2b has lower basal activity and is not greatly 
stimulated, although it is unclear how this isoform is activated. The most obvious 
difference between the isoforms is that Mnk1a and Mnk2a are both longer such that their 
C-terminus contains a MAPK binding motif, whilst Mnk1b and Mnk2b do not contain this 
C-terminus and as such lack the MAPK binding motif (Fig. 1.2). There are also differences 
between Mnk1a and Mnk2a in the C-terminus and catalytic domain that confer the 
differing MAPK binding profiles. Studies investigating these differences have identified 
clear sequence differences that allow Mnk2 to bind more strongly to active, 
phosphorylated ERK (p-ERK), whilst decreasing its affinity for p38 MAPK [39, 72]. 
Creation of chimeras of the murine Mnk1 and Mnk2 proteins showed that, by adding the 
C-terminus of Mnk2 to the N-terminus plus the catalytic domain of Mnk1, the high basal 
activity of Mnk2 and p-ERK binding was not quite matched. This suggests residues in the 
N-terminus of Mnk2 and/or catalytic domain are necessary for its higher basal activity and 
ability to bind p-ERK along with those in the C-terminus. Binding to p-ERK by Mnk2 also 
adds to the high basal activity because the area Mnk2 binds to in p-ERK causes ERK to 
be protected from dephosphorylation by phosphatases. This explains why Mnk2 remains 
active when cells are treated with MEK and p38 MAPK inhibitors [72]. There is a residue 
in the activation segment of Mnk2 that is required for binding to p-ERK. In Mnk2, Asp
191 
(Asp
238 Mnk2a) has been shown to be an important residue, which in Mnk1 is replaced by 
Ser
191. Evidence shows that an S191D mutation in an Mnk1 mutant chimera protein 
consisting of an Mnk1 N-terminus and Mnk2 C-terminus can bind p-ERK and has a high 
basal activity that is not blocked by MEK and p38 inhibitors, similar to Mnk2a [72]. In 
Mnk1, Ser
191 (Ser
208 Mnk1a) is phosphorylated but is not part of the MAPK binding motif 
and it is not an autophosphorylation site; furthermore, its replacement with a non-
phosphorylatable residue does not abolish Mnk1 activity so it is unlikely this site is 
necessary for activation [72]. 
 
Given the differing affinities of Mnk1 and Mnk2 for ERK and p38 MAPK, it is no surprise 
that their MAPK motifs are different. In Mnk1, the MAPK motif is LARRR, whilst for Mnk2 it 
is LAQRR [72]. Mutational studies and swapping the motifs in the proteins showed that 
LARRR is essential for p38 MAPK binding. Although the Gln in Mnk2 is important for ERK 
binding, it does not confer p-ERK binding by itself, due to the Asp
191 residue in the - 25 -   
activation segment. Phosphorylation of Ser
384 also occurs in the Mnks and is just 
upstream of the MAPK motif. The data show that phosphorylation of this residue 
negatively regulates ERK binding in Mnk1 but does not do so in Mnk2. Ser
387 is also 
phosphorylated in Mnk2 (not Mnk1, where it is replaced by a Cys residue) and appears to 
also be very important for binding to p-ERK [72]. Other residues that have been shown of 
importance to the difference in binding affinities of Mnk2 include Leu
400, which is an 
alanine in Mnk1 and Arg
398 which is also key to p-ERK binding [72].  
 
1.3.6 Targets and Binding Partners  
The Mnks phosphorylate their targets at sites that are rich in basic and serine residues 
[74]; however this does not always denote Mnk phosphorylation and so far all of their 
known targets are phosphorylated on serine residues. 
1.3.6.1 eIF4E 
The major shared target of all the Mnk isoforms is the translation initiation factor eIF4E. 
The Mnks are the major physiological kinases that target this initiation factor and function 
to phosphorylate this protein at Ser
209, although there is controversy over the effect of 
eIF4E phosphorylation on translation initiation and thus the rate of protein synthesis. It is 
now generally accepted that phosphorylation causes the affinity of eIF4E for capped 
mRNA to decrease, however the effect this has on protein synthesis is the subject of 
conflicting models. The accepted model is supported by evidence that suggests the 
decrease in affinity allows for release of translation factors from the translation machinery 
resulting in rapid successive rounds of translation initiation and therefore an increase in 
protein synthesis [75]. This idea relies on successful binding of the 48S initiation complex 
to the 60S subunit before phosphorylation; however there is not yet any evidence 
concerning when during initiation the Mnks phosphorylate eIF4E other than that eIF4G 
must be bound to eIF4E. This suggests that eIF4F complex formation and binding of 
eIF4E to the capped mRNA must have already occurred. Opposing this model is the 
notion that decreasing affinity of eIF4E for capped mRNA leads to a decrease in protein 
synthesis [76]. However the experiments undertaken in this study, involve the 
overexpression of the Mnks resulting in very high levels of eIF4E phosphorylation [76]. 
This is turn would deplete the cellular pool of cap-binding-competent eIF4E because so 
much is phosphorylated leading to the observation of a decrease in the rate of protein 
synthesis.  - 26 - 
There is important evidence that supports the likelihood that phosphorylation of eIF4E 
leads to amplified protein synthesis, such that increased phosphorylation of eIF4E in 
some cancers (especially lymphoma) is necessary for tumorigenesis [77-79]. One 
particular study used both mouse and human samples to analyse the effects of 
expression levels of Mnk1, eIF4E and an antiapoptotic protein, Mcl-1 in models of 
lymphoma. Using phosphorylation deficient eIF4E mutants (S209A), these authors 
showed that this lead to a decrease in tumorigenesis, which was rescued by expression of 
a ‘phosphomimetic’ mutant (S209D) of eIF4E. This supports the importance of eIF4E 
phosphorylation in its oncogenic ability [79]. The authors then assessed the effect of 
overexpression of Mnk1, which was shown to mimic the effect of eIF4E overexpression on 
cancer cell growth. Lymphomas where Mnk1 or eIF4E was overexpressed showed low 
levels of apoptosis compared with control cancer cells. Further experiments, using the 
S209A mutant, showed that eIF4E phosphorylation was involved in resistance to 
apoptosis in these cells. Using Mnk1/2 DKO cells these authors also illustrated that the 
Mnks were necessary for desensitization to apoptosis. One of the targets responsible for 
the low levels of apoptosis was identified as the antiapoptotic protein Mcl-1, which shows 
high levels in eIF4E and Mnk1-expressing cells. Loss of either of these components 
reduced Mcl-1 protein expression and increased sensitivity to apoptosis. Analysis of cells 
transfected with kinase-dead Mnk mutants showed that Mnk inhibition only sensitized 
tumorigenic cells that had deregulated translational machinery [79]. Since the Mnks have 
the unusual DFD motif and Mnk1/2 DKO animals present no overt phenotype, the Mnks 
present an excellent cancer drug target.  
The importance of the Mnks and eIF4E phosphorylation has also been identified in other 
disease states especially inflammatory syndromes; this is not surprising given that Mnk1 
is activated by p38 MAPK and ERK, which are stimulated by cytokines. The consequence 
of many cytokines upon their target cells is the production of inflammatory proteins that 
coordinate responses against challenges to the immune system. The interleukins, IL-2 
and IL-15 selectively cause natural killer (NK) cell proliferation, survival and cytotoxic 
abilities in part through increased protein levels of a common downstream target, the 
transcription factor Ets1. Ets1 is important for the expression of inflammatory cytokines 
such as interferon γ (IFNγ) [80]. A study into the pathways that trigger this showed ERK 
activation results in Mnk1-dependent phosphorylation of eIF4E leading to an increase in 
levels of Ets1. This represents another important target in diseases where NK cells are 
lacking such as HIV and some cancers or where NK activity is deregulated such as 
autoimmune diseases [80]. - 27 -   
The production of pro-inflammatory cytokines is also linked to the Mnk-dependent 
phosphorylation of eIF4E and again this presents a target for immune disorders where 
cytokine release is either excessive or lacking. Experiments with keratinocytes show 
phosphorylation of eIF4E is necessary for the production of the cytokines, TNFʱ, IL-1β 
and IL-6, thus in skin disorders where there is excessive production of these proteins the 
Mnks represent a sensible target for inhibition [44]. Another, similar, example shows that 
type I interferons (IFNs) can instigate JNK activation leading to downstream engagement 
of the ERK pathway, previous studies discarded JNK signalling as playing a role in Mnk 
activation but this was only ever aimed at direct activation of Mnk not as shown here 
through ERK. The data show that JAK1 is necessary for instigation of the ERK-Mnk 
pathway and the resulting phosphorylation of eIF4E vital to the production of the IFN-
stimulated genes (Isg), Isg15 and Isg54. The Isg15 protein is necessary for NK cells 
proliferation whilst Isg54 is required for programmed cell death of virally infected cells. 
Similarly to those examples described above the Mnks again present a useful target in 
disease in this instance for IFN toxicities, cytopenias [81-83]. 
Treatments such as anisomycin can activate the p38 MAPK and ERK pathways. One of 
the downstream proteins induced by this treatment is the CCAAT/enhancer-binding 
protein homologue (CHOP). The CHOP protein is a transcription factor that induces 
expression of various proteins that cause the arrest of the cell cycle usually as a result of 
viral infection. Again activation of the Mnks and phosphorylation of eIF4E is required for 
the increased levels of CHOP protein expression [84].  
1.3.6.2 eIF4G 
Phosphorylation of eIF4E is strongly dependent on the association of eIF4E with eIF4G 
and the binding of the Mnks with eIF4G, as demonstrated by an eIF4G-binding deficient 
eIF4E mutant, whose phosphorylation is strongly impaired in vivo [85]. Similarly mutations 
to the Mnks, which block Mnk-eIF4G binding also decrease eIF4E phosphorylation in vivo. 
The interaction between the Mnks and eIF4G involves specific sequence motifs present in 
each protein. The N-termini of both Mnk1 and Mnk2 contain similar basic sequences, 
which confer binding to eIF4G. In Mnk1 KRR (residues 14-16) and KKR (residues 18-20) 
are both necessary as demonstrated by the loss of Mnk1-eIF4G binding when these 
residues are mutated to alanine [86]. The sequences in Mnk2 required for eIF4G binding 
are KKR (residues 60-62) and KKK (residues 65-67) as illustrated by the mutation to 
alanine residues [87]. Both Mnks bind to a HEAT domain in the C-terminus of eIF4G [85, 
88]. HEAT domains are repeats of two antiparallel ʱ-helical folds (HRs) found in a number 
of proteins and named based on the first four proteins identified to contain this structure 
(Huntingtin, eEF3, protein phosphatase 2A (PP2A) and mTOR) [88, 89]. The HEAT - 28 - 
domain that confers Mnk binding contains 4.5 HRs and within these HRs are two acidic 
and aromatic boxes (AA boxes) whose residues contact the K and R residues in Mnk1 
and Mnk2. Both AA boxes are required for Mnk-eIF4G binding [90].  
The binding of Mnks to eIF4G presents an important checkpoint in the regulation of eIF4E 
phosphorylation and eIF4F complex function. Formation of the eIF4F complex is linked to 
the phosphorylation state of the Mnks and eIF4E as demonstrated by the knockdown of 
PP2A, which lead to an increase in eIF4G and phosphorylated eIF4E precipitating on 
m
7GTP sepharose; furthermore inhibition of the Mnks lead to decreased eIF4G and 
phosphorylated eIF4E in an m
7GTP pulldown assay [91]. Phosphorylation of the linker 
sequences between HEAT domains in eIF4G controls the binding to Mnk1. Casein kinase 
2-ʱ phosphorylates eIF4G at Ser
1239 (found in the interdomain linker between HEAT 
domains) and increases the phosphorylation of eIF4G by ERK1/2 at Ser
1232, this in turn 
results in changes to eIF4A/3/4B binding to eIF4G and increased Mnk1-eIF4G binding, 
therefore serving to regulate translation initiation [92]. Similarly phosphorylation of Ser
1186 
on eIF4G by PKCʱ also increases Mnk1-eIF4G binding [93].The control of translation 
initiation by stimulatory pathways is further linked to the phosphorylation of the T-loop in 
Mnk1, which has been shown to be required not only for activity but also for eIF4G 
binding, as shown by mutation of the Thr
197 and Thr
202 to alanine resulting in the reduction 
of Mnk1-eIF4G binding. Under non-stimulatory conditions the C-terminus of Mnk1 has 
unknown features that inhibit Mnk1-eIF4G binding [94]. This represents another example 
of the tight control of eIF4E phosphorylation by Mnk1. During apoptosis translation is 
downregulated through various pathways, one of which involves the modulation of Mnk1-
eIF4G binding. Caspase-cleaved Pak2/gamma-PAK phosphorylates Mnk1 at Thr
22 and 
Ser
27, which leads to a strong reduction in binding to eIF4G, which would presumably lead 
to reduced eIF4E phosphorylation and a decrease in translation, although the authors do 
not investigate this [95]. The relationship between Mnk2 and eIF4G has been far less 
researched than Mnk1-eIF4G but recent evidence demonstrates a complex signalling 
pathway that regulates eIF4G phosphorylation. The activity of Mnk2 was shown to be 
correlated with decreased phosphorylation of eIF4G at Ser
1108 (a known serum induced 
site) in an unclear mechanism involving serine-arginine-rich kinases and was proposed to 
lead to decreased translation [96]. However given that Mnk2 is highly active under basal 
conditions and eIF4E phosphorylation is correlated with this it remains to be seen as to 
why Mnk2 would negatively regulate translation via eIF4G in an apparent direct 
contradiction to increased eIF4E phosphorylation and subsequent translation initiation. - 29 -   
The intricate relationships between the Mnks, eIF4G, eIF4E and translation initiation 
would benefit from further research especially with regards to regulation of specific 
subsets of mRNA.                    
1.3.6.3 hnRNPA1 and PSF.p54
nrb 
The phosphorylation of eIF4E by the Mnks is one mechanism that alters the expression of 
some mRNAs but there is evidence that the Mnks can regulate the synthesis of other 
mRNAs independently of eIF4E. The mRNAs for many inflammatory cytokines, such as 
TNFʱ, contains sequences within their 3’UTRs that can exert a number of control 
measures upon the mRNA. One such sequence contains a high level of A and U, so these 
regions are called AU rich elements (AREs). The AREs can recruit a subset of proteins 
called ARE-BPs (ARE-binding proteins), which are then able to regulate transport from the 
nucleus to the cytoplasm, regulate message stability and control mRNA translation [97]. 
The production of TNFʱ is controlled by both the MEK/ERK and p38 MAPK cascades. 
The p38 MAPK pathway controls TNFʱ production through MK-2, which acts upon the 
ARE-BPs; TTP (tristetraprolin) [98], HuR [99] and heterogeneous nuclear 
ribonucleoprotein (hnRNP) A0 [100]. The former two proteins modulate TNFʱ mRNA 
stability whilst the latter has a number of nuclear functions. This model explains why 
stability of the mRNA changes in response to the p38 MAPK input but it does not explain 
how the MEK/ERK pathway control protein levels since MK-2 is not activated by ERK. The 
Mnks are also MKs and are downstream of ERK and so represent a potential regulator of 
TNFʱ translation. One such study showed that Mnk1 overexpression resulted in a 4-fold 
dose-dependent increase in a TNFʱ mRNA reporter construct whilst there was no similar 
increases in control mRNA (GAPDH) [42]. Deletion of the ARE in TNFʱ mRNA lead to a 
50% reduction in reporter construct expression compared to full length mRNA and 
analysis of pulldowns of the ARE-BPs bound to TNFʱ showed that the Mnks could 
phosphorylate some of these proteins. Three of them were identified: hnRNP A0, which is 
already known to be phosphorylated by MK-2, JKT BP and hnRNP A1. In vitro 
experiments then confirmed that the Mnks could phosphorylate hnRNP A1, which led on 
to in vivo identification of the phosphorylation sites Ser
192, Ser
310, Ser
311 and Ser
312. The 
next step was to assess the effect of phosphorylation of hnRNP A1 on its function, which 
showed this led to its decreased association with TNFʱ mRNA and a resulting increase in 
TNFʱ protein [42]. This was further supported by addition of the Mnk inhibitor CGP37580 
that reversed these effects. 
Following this new understanding that the Mnks could modulate mRNAs with AREs, 
interest was directed at finding other substrates of the Mnks bound to AREs. The complex 
PSF.p54
nrb was shown to precipitate on an m
7-GTP Sepharose cap resin along with Mnk, - 30 - 
eIF4G and eIF4E [41], which might be a result of by binding to any of these proteins or 
mRNA. Further experimentation using a biotinylated oligoribonucleotide showed that the 
PSF.p54
nrb complex bound to only the ARE-containing oligoribonucleotide. In vitro 
experiments then showed that the Mnks could phosphorylate PSF at Ser
8 and Ser
283; 
interestingly Mnk2 could phosphorylate Ser
8 much more efficiently than Mnk1 suggesting 
this is more likely an Mnk2 specific site. Again it was of interest to determine what effect 
PSF phosphorylation had on TNFʱ mRNA association, and addition of the Mnk inhibitor 
CGP57380 to activated Jurkat T cells was shown to decrease PSF binding to the TNF 
mRNA. This indicates that phosphorylation of PSF.p54
nrb by the Mnks leads to increased 
binding to TNFʱ mRNA. The known functions of PSF-p54
nrb are mostly in nuclear events 
such as transcription, nuclear RNA processing, DNA relaxation and retention of edited 
mRNA and may regulate TNFʱ mRNA in this respect (reviewed [101]) and as such may 
represent a role of Mnk2a or mnk2b in the nucleus.   
  
This provides evidence that the Mnks can control translation of a specific subset of 
mRNAs further providing another potential therapeutic target for disorders such as 
inflammatory bowel disease, rheumatoid arthritis and antigen induced septic shock where 
TNFʱ is overexpressed.  
There is another example of Mnk-dependent modulation of mRNA translation, the 
regulation of the c-Jun mRNA. The authors of the study noticed that phosphorylation of 
eIF4E did not constitute a considerable influence of levels of c-Jun protein and suggest it 
is possible the Mnks are targeting a protein bound to the c-Jun mRNA at initiation thereby 
influencing its translation although do not investigate this further [102]. 
1.3.6.4 Sprouty  
The other known target of the Mnks is a protein that is not involved in translation, 
suggesting these kinases have a translation-independent role. Signalling pathways must 
be regulated otherwise unchecked can lead to a multitude of problems for the cell. 
Signalling pathways are controlled by phosphatases, which switch off phosphate activated 
signalling and small proteins that are either secreted by cells or present in the cell that act 
as antagonists to produce inhibitory feedback loops [103]. An example of a small protein 
signalling antagonist is Sprouty, which functions to regulate RTK signalling. For example, 
it can interfere with epidermal growth factor (EGF) and fibroblast growth factor (FGF) 
signalling by antagonising both the receptors and Ras-dependent activation of ERK ( 
reviewed [104]). Expression of Sprouty is regulated by signalling at the transcriptional - 31 -   
level but it is also evident at the posttranslational level whereby Sprouty phosphorylation 
on tyrosine and serine modulates its stability. Phosphorylation of the former site, Tyr
55, 
leads to increased association of Sprouty with E3 ubiquitin ligase and resulting in its 
degradation, which leads to loss of antagonism of the signalling pathway. The 
phosphorylation of Ser
112 and Ser
121 has been shown to be Mnk-dependent. Addition of 
p38 MAPK and MEK/ERK inhibitors in combination abrogates the phosphorylation of 
these residues in Sprouty, thus since there are no MAPK motifs it is likely that the Mnks 
(or in some instances RSKs) are responsible because they are the only MKs activated by 
both p38MAPK and ERK. Furthermore, six possible Mnk sites (serine and basic rich 
regions) are present in Sprouty. However, the data regarding the function of serine 
phosphorylation of Sprouty are conflicting. In one study, serine phosphorylation was 
shown to have the opposite effect of tyrosine phosphorylation in that serine 
phosphorylation leads to an increased stability of the Sprouty protein and therefore an 
increased ability of Sprouty to antagonize RTK signalling [74]. Use of Mnk inhibitors and 
mutants that are inactive further supported this role because the loss of Mnk activity led to 
an increase in Sprouty degradation. Conversely, constitutively active Mnk mutants 
blocked Sprouty degradation. Further evidence also shows that serine phosphorylation 
blocks Tyr
55 phosphorylation therefore totally blocking ubiquination and subsequent 
degradation of Sprouty. The authors of this paper suggest the isoform responsible is Mnk1 
because it is activated by the ERK and p38MAPK pathways. Interestingly increased 
antagonism of RTK induced Ras-ERK activation by sprouty, may lead to the inactivation 
of Mnk1 in a potential negative feedback loop [74]. Another study presents contradictive 
data, which show Mnk2 phosphorylation of the Ser
112 and Ser
121 sites results in 
association with the E3 ubiquitin ligase Nedd4. This leads to the ubiquination and 
degradation of Sprouty. This would lead to a potentiation of ERK activation and fibroblast 
growth factor signalling [105], which may correlate with the high basal activity of Mnk2a in 
a positive feedback loop. When comparing these studies there is a potential that Mnk1 
and Mnk2 have isoform specific effects on the same substrate and further research would 
benefit from experiments in Mnk1 and Mnk2 single knockout cells.   
1.3.6.5 Potential Substrates  
The classification of the Mnk2 gene and its splice variants arose through a yeast-two 
hybrid experiment using the oestrogen receptor β [66]. This data showed that Mnk2, 
specifically Mnk2b was able to bind to the ligand binding domain of the oestrogen receptor 
ERβ. The authors unfortunately did not assess whether the receptor was an Mnk2b target 
[66]. However the PSF.p54
nrb complex binds to the nuclear hormone receptor family of 
which the oestrogen receptor is a part of and, as mentioned, the Mnks can phosphorylate 
this complex [41]. This would be a novel area of research regarding the functions of Mnk2. - 32 - 
Another reason this maybe interesting, in combination with the evidence for Sprouty 
regulation, comes from a patent for a specific Mnk inhibitor that shows activity against 
Mnks leads to increased insulin sensitivity and fatty acid synthesis [106]. Insulin signalling 
is an RTK induced process and the oestrogen receptor has been shown to have links to 
obesity. Investigation into this, using an Mnk2 knock-out animal would be of great interest. 
 
 
1.4 Glucose Metabolism in Mammals 
1.4.1 Overview 
The absorption and endogenous production/regulation of glucose are essential for overall 
whole body energy homeostasis. Food and drink ingested by mammals are processed at 
numerous points from the mouth to the intestines. The point of entry into the body occurs 
in the intestines where free fatty acids, amino acids and monosaccharide’s are absorbed 
through the enterocyte microvillus of the small intestines [107]. Both amino acids and 
monosaccharides (e.g., glucose) are taken up through active transport by sodium-
dependent transporters. Fructose and galactose are taken up by the liver and converted 
into glucose, which can be released back into circulation, stored as glycogen or used to 
produce ATP. For the purpose of this thesis, the focus will be on glucose transport. 
Glucose is transported across the enterocyte membrane by both Na
+-dependent active 
transport (driven by the Na
+ gradient created by the Na
+/K
+ ATPase at the basal 
membrane of the enterocyte) and facilitated diffusion. At the apical membrane the 
symporter sodium/glucose cotransporter 1 (SLC5A1) binds to two Na
+ ions resulting in a 
conformational change that reveals a glucose binding pocket, which when bound to 
glucose leads to a further conformational change that leads to the release of glucose into 
the cytosol followed by the sodium ions [108]. Galactose is also transported across the 
apical membrane by SLC5A1 whilst fructose is transported by glucose transporter 5 
(GLUT5). At the basal membrane, facilitated diffusion by GLUT2 transports glucose into 
the blood stream [109, 110]. The GLUTs form oligomeric structures, which are formed of 
two dimers to produce a channel through the plasma membrane allowing glucose to 
traverse based on the concentration gradient [111-113]. Once in the bloodstream, glucose 
is taken up in a tissue-specific manner and is tightly regulated by hormones. - 33 -   
1.4.2 Glucose Oxidation – The Krebs Cycle 
Glucose entering the cell is converted to glucose-6-phosphate (G6P) by a family of 
hexose converting enzymes called hexokinases, of which there are 4 isoforms called 
hexokinase I, II III and IV. Hexokinase IV is most commonly referred to as glucokinase 
(GK) and is only found in the pancreas, liver, and intestines [62, 107]. The production of 
G6P requires one molecule of ATP and acts as an inhibitor of hexokinases therefore self-
regulating the reaction [62, 107]. The fate of G6P is dependent on cell type and metabolic 
requirements; here we shall discuss the process of glycolysis and the subsequent 
generation of ATP by the Krebs cycle.  
The glycolysis pathway results in the production of pyruvate, the eventual formation of 
ATP and the reduced form of nicotinamide adenine dinucleotide (NADH) from pyruvate 
during the Krebs cycle [62, 107, 114]. Glycolysis is a 10 step enzymatic process occurring 
in the cytosol, G6P is converted to glyceraldehyde-3-phosphate (GAP) and 
dihydroxyacetone phosphate (DHAP) by two enzymatic processes. DHAP is an isomer of 
GAP and is readily converted into GAP [62]. This means that glucose has been degraded 
into two molecules of GAP. The remaining 5 enzymatic reactions produce 
phosphoenolpyruvate (PEP), which is used by pyruvate kinase to produce one molecule 
of ATP and pyruvate [62, 107, 114]. Overall one glucose molecule will produce a net gain 
of 2 ATP, 2 NADH and 2 pyruvate molecules (since two GAP molecules are produced 
during the conversion of DHAP). The fate of pyruvate is varied depending on cellular 
requirements, for example during exercise the muscle uses pyruvate to generate lactate 
when oxygen is unavailable. During aerobic conditions pyruvate is fed into the Krebs cycle 
– also known as the tricarboxylic acid (TCA) cycle or citric acid cycle.  
In order for cells to generate energy, in the form of ATP, pyruvate is oxidized in an 8 step 
series of reactions. This cycle is not just part of glucose catabolism but also forms a major 
part of fatty acid oxidation and amino acid oxidation. The generation of electron pairs in 
the form of NADH and flavin adenine dinucleotide (FADH2) are used in the mitochondria to 
drive an electrochemical gradient that results in the generation of ATP. Furthermore, since 
this is a cyclic series of reactions and the final product oxaloacetate is both consumed at 
the start of the reaction and generated at the end of the reaction this process continues 
unless any of the products become depleted [62, 107, 114]. In the instance of glucose 
catabolism, the product pyruvate, generated from glycolysis, is used by the multi-enzyme 
complex pyruvate dehydrogenase to generate acetyl-CoA. This occurs in a complex 
multistep process, which overall generates CO2 and NADH. The product acetyl-CoA can 
also be generated by fatty acids, which shall be discussed later. Citrate is the first product 
of the cycle and is produced by condensation of oxaloacetate and acetyl-CoA. The cycle - 34 - 
continues with conversion of citrate back to oxaloacetate, which can then be fed back into 
the cycle [62, 107, 114].  
The NADH and FADH2 produced by glycolysis and the citric acid cycle can yield up to 38 
molecules of ATP during aerobic conditions from just one molecule of glucose. This 
process is tightly regulated by signalling pathways, substrate availability and the levels of 
downstream metabolites and is thus dependent on the metabolic requirements of the cell.      
 
1.4.3 Glycogenesis and Glycogenolysis  
Glycogen is a branched polymer of glucose units bound to glycogenin and can store 400 
mmol of glucose as 0.01µmol of glycogen. This allows storage of vast amounts of fuel 
without affecting the osmolarity of a cell [115]. 
During glycogenesis, G6P is converted to glucose-1-phosphate (G1P) by 
phosphoglucomutase (with the intermediate glucose-1,6-bisphosphate), which is then 
used in a reaction along with uridine triphosphate (UTP). UTP provides the energy for 
converting G1P to uridine diphosphate (UDP)-glucose catalysed by the enzyme UDP–
glucose pyrophosphorylase. The UDP-glucose is then added to a non-reducing end of a 
glycogen chain by glycogen synthase. This requires a glycogen chain to already be 
present, which is achieved by the glycosyltransferase: glycogenin, which extends a chain 
of glucose residues from UDP-glucose creating a basis for glycogen synthase to work 
from [62]. Glycogen is a branched molecule and this is achieved by the enzyme amylo-
(1,4-1,6)-transglycosylase.  
A reversal of glycogen synthesis occurs when there is a requirement for glucose such as 
fasting or exercise. This requires the activation of phosphorylase kinase, which 
phosphorylates and activates glycogen phosphorylase; the enzyme responsible for 
generating G1P from glycogen. Another enzyme, ʱ(1-4) transglycosylase is required to 
ensure suitable glycogen units are available for glycogen phosphorylase to process. The 
subsequent G1P is converted to G6P by phosphoglucomutase in a reversal of the 
reaction described earlier. In the liver plasma glucose can be increased through glucose-
6-phosphatase, which can convert G6P back to glucose, which will diffuse out of the 
hepatocytes into the circulation via GLUT2 [62]. In the muscle G6P is fed into the 
glycolysis pathway in order to generate energy.  - 35 -   
1.4.4 Gluconeogenesis 
Gluconeogenesis is the process of producing glucose from non-carbohydrate substrates 
such as lactate and glucogenic amino acids [116]. Firstly pyruvate must be converted to 
phosphoenylpyruvate (PEP), which requires energy in the form of ATP and GTP as well 
as an intermediate in the form of oxaloacetate. There are two enzymes involved; pyruvate 
carboxylase converts pyruvate into oxaloacetate using ATP and PEP carboxykinase 
(PEPCK) converts oxaloacetate into PEP using GTP [62]. It is important to note this 
occurs in the mitochondria and upon the formation of PEP the pathway moves into the 
cytosol where PEP is converted into a number of intermediates by the glycolysis enzymes 
but in reverse to produce fructose-1,6-bisphosphate. The next step is formation of 
fructose-6-phosphatase by fructose 1,6-bisphosphatase and finally the enzyme 
phosphoglucose isomerase converts this to G6P, which can then be converted to glucose 
by glucose-6 phosphatase [62]. Since only the liver and kidneys express glucose-6-
phosphtase, gluconeogenesis is confined to only these tissues, with some debate about 
the potential for the intestines to also engage in this process [116-118].   
 
1.4.5 Regulation of Plasma Glucose Levels 
The brain uses 60-70% of the body’s glucose at resting levels, which requires very careful 
control of resting plasma glucose through hormonal control during the fed and fasted 
states [114]. Glucose obtained from food is taken up by a number of tissues; the liver 
takes up 40%, the skeletal muscle 30%, adipose tissue 5%, kidneys 10% and the brain 
15%. The fate of glucose and the mechanisms for its continuous regulation are tissue 
specific but are highly coordinated within the body [119].  
Ingestion of a meal and the subsequent absorption of dietary sugars into the blood 
stream, by the intestines, leads to a rapid rise in plasma glucose from fasting levels of 5-
6.1 mmol/L (normal range for human males and mice ) [120] to a level below 7.8 mmol/L 
after 2 hours (during glucose tolerance test (GTT)) [107]. The presence of glucose in the 
intestinal epithelium causes the release of glucagon-like peptide-1 (GLP-1) and gastric 
inhibitory polypeptide (GIP), which enter the circulation and nervous system to prime the 
body for the increase in glucose [121].  
The presence of high levels of plasma glucose after a meals leads to diffusion of glucose 
into the β cells in the Islets of Langerhans in the pancreas via GLUT2. Once inside the cell 
glucose is phosphorylated by GK to produce G6P, this is the rate limiting step for this 
process. The G6P is then fed into the Krebs Cycle. During glucose oxidation in the 
mitochondria intermediates such as malate, glutamate and citrate are released, which are - 36 - 
one of the stimulatory signals for exocytosis of vesicles containing insulin. Another 
pathway required for insulin release is the ATP:ADP ratio, which is also altered due to 
increased activity of the Krebs cycle. An increase in ATP and decrease in ADP results in 
closure of K
+ ATP sensitive channels leading to a depolarization of the cellular membrane 
causing the opening of voltage-gated Ca
2+ channels and the subsequent influx of Ca
2+. 
This is required for exocytosis of vesicles containing insulin. The third pathway required 
for insulin release is triggered by the GLP-1 receptor (GLP-1R) and GIP receptors (GIP-
R), which increases cyclic adenosine monophosphate (cAMP) levels causing the 
activation of protein kinase A (PKA), which also functions in vesicular exocytosis [122].  
Once released, the role of insulin within the body is multifaceted and is discussed in 
greater detail in sections 1.2.4 and 1.6. In terms of plasma glucose regulation, insulin is 
required to bind to cells containing the insulin receptor particularly myocytes in the 
muscle, hepatocytes in the liver and adipocytes in the adipose tissue. The overall effect is 
to increase the uptake of glucose by these cells (discussed in section 1.6) and thus 
clearing plasma glucose. The fate of glucose once taken up by the liver, muscle and 
adipose tissue is different for each organ.  
The liver is the major source of endogenous glucose under fasting conditions due to the 
ability of hepatocytes to store 5-8% of their weight as glycogen. After a carbohydrate rich 
meal, glucose reaches the liver via the hepatic portal vein where hepatocytes take up 
glucose in the same way as the pancreas, GLUT2 being the major isoform responsible in 
the livers of adults [123]. Once inside the cell glucose is phosphorylated to G6P by GK in 
a rate limiting fashion. G6P can then enter one of 3 pathways; glycogen synthesis 
(glycogenesis), the pentose phosphate pathway (to produce NADPH) or glycolysis and 
subsequently the citric acid cycle [62, 123]. The process of glycogenesis is stimulated by 
insulin, which, through the classic IRS1/PKB pathway, inactivates glycogen synthase 
kinase 3 (GSK3) by phosphorylation of residues Ser
9 and Ser
21. GSK3 is responsible 
for inhibitory phosphorylation of glycogen synthase at Ser
641 and Ser
645.The inactivation of 
GSK3 by insulin leads to dephosphorylation of glycogen synthase by protein 
phosphatase-1 and hence its activation [124-126]. G6P and glycogen are both allosteric 
inhibitors of glycogen synthase [126].  
During fasted conditions, when the pancreas senses a reduction in plasma glucose levels 
to below 5mmol/L, glucagon is released from the ʱ-cells, which binds to the glucagon 
receptor present on hepatocytes. Similarly adrenaline acts on β-adrenergic receptors in 
the pancreas to inhibit insulin secretion in situations of exercise or stress and also 
increases glycogenolysis in the liver and muscle [121]. This causes a signalling cascade - 37 -   
that generates cAMP, which activates PKA. The function of PKA is to phosphorylate and 
activate phosphorylase kinase and thus phosphorylate and inhibit glycogen synthase. This 
therefore leads to the production of glucose via glycogenolysis. Another pathway by which 
hepatocytes are able to increase plasma glucose during fasting is gluconeogenesis; this 
pathway is used when liver glycogen stores are depleted. Gluconeogenesis results in the 
production of glucose from pyruvate, which is produced mostly from lactate and 
glucogenic amino acids e.g. alanine [116]. Previously it was thought the liver was almost 
completely responsible for regulating fasting glucose levels. However, the evidence shows 
that the kidney can contribute to glucose homeostasis via gluconeogenesis and there is 
some debate and evidence that the intestines too may partake in gluconeogenesis [116-
118].  
The other major tissue in the body that regulates plasma glucose is skeletal muscle. The 
predominant mechanism of glucose uptake by the muscle is stimulated specifically by 
insulin via facilitated diffusion through GLUT4 (the specifics of the signalling pathway that 
occurs is discussed in section 1.6) and a small amount by GLUT1 [121]. The muscle 
therefore functions to replenish its glycogen stores after carbohydrate rich meals and thus 
clears glucose from the blood. Whilst the liver is responsible for maintaining blood glucose 
during fasting, the muscle uses its glycogen stores during periods of exercise in order to 
generate energy for muscle contraction [107]. There is no glucose-6-phosphatase in 
muscle [127] and so the G6P produced by the glycogen breakdown is fed into the 
glycolysis pathway in order to produce ATP via the Krebs cycle or through anaerobic 
respiration.  
Adipose tissue is responsible for clearing approximately 5% of the plasma glucose after a 
meal and in a similar fashion to muscle expresses GLUT4 and is stimulated by insulin to 
take up glucose [128]. Unlike the muscle or liver, adipose tissue does not store glucose as 
glycogen but instead stores excess glucose as fat. This process is stimulated by insulin 
and is known as lipogenesis, which is discussed in detail later.  
As previously mentioned, the kidneys are another point of both glucose clearance and 
glucose production and therefore contribute to overall whole body glucose homeostasis. 
Unlike the liver, the kidneys are only able to produce glucose via gluconeogenesis since 
they have no capacity to store glycogen. This is controlled not by glucagon but by 
catecholamines, growth hormone and thyroid hormone . Furthermore the kidney uses the 
glucogenic glutamine as a precursor (as well as lactate) whilst the liver uses alanine [119]. 
Consequently during fasting of a duration around 16h, the liver contributes 75-80% of the 
plasma glucose whilst the kidneys are responsible for 20-25% [119]. This is important 
when considering fasting glucose levels after this time period.             - 38 - 
1.4.6 Type 2 Diabetes Mellitus  
Diabetes mellitus is a disease classically defined as either type 1 diabetes (T1DM) or type 
2 diabetes (T2DM). The difference between the types arises from the cause but both are 
clinically diagnosed by fasting glucose >7.0 mmol/L and glucose levels >11.1 mmol/L after 
2h following an oral glucose tolerance test (OGTT) [129]. Diabetes is estimated to affect 
285 million people globally [130] and of those 2.6 million have been diagnosed in the UK 
(2009). The prevalent form in the UK is T2DM, which accounts for 90% of cases [130]. 
The cost of care for diabetic patients by the NHS has risen markedly in the last 10 years. 
From 2000-2008 the cost of dispensed prescriptions rose from £290 million to £591 
million, nearly a 50% increase [131]. In 2008 alone the cost of treatment for diabetes cost 
£708 million, this is almost 10% of the annual NHS diabetes budget [131]. There are, of 
course, other costs to the NHS; hospitalization of patients, out-patient care, complications 
of diabetes etc. The annual budget that covered all diabetes related costs, for 2007-2008, 
was £9 billion [130]. These costs are very high and will inevitably increase rapidly over the 
next 15 years with estimates of 4 million people to be diagnosed by 2025 [130]. The 
prevalence of T2DM is increasing rapidly and has been deemed a 21
st century epidemic. 
A combination of increasingly sedentary lifestyles, obesity and an ageing population are 
believed to be major contributors to this trend [132].     
The major difference between T1DM and T2DM is the cause of increased plasma glucose 
levels. T1DM is simply a result of a destruction or damage of the β cells of the pancreas, 
which leads to a loss of insulin release. Patients with T1DM must carefully monitor blood 
glucose levels and inject insulin in order to maintain their health [107]. For the purpose of 
this thesis, we will focus on T2DM. 
The development of T2DM usually occurs after the age of 30-40 and is associated with 
polycystic ovary syndrome (PCOS), Cushing’s syndrome, acromegaly and other genetic 
factors. However the major cause of T2DM is obesity and the associated metabolic 
syndrome and insulin resistance [107]. We shall discuss obesity and the metabolic 
syndrome in greater detail in the next section as well as the complex molecular 
mechanisms that are thought to be responsible for insulin resistance in diet-induced 
T2DM. Large scale, longitudinal statistical studies have established that there are distinct 
phases in the pathogenesis of T2DM. The first phase in the progression to T2DM is the 
onset of insulin resistance, which is characterised by a decrease in the sensitivity of target 
tissue to the actions of insulin. This is the result of an increase in inflammatory cytokines, 
increased plasma lipid metabolites and changes in hormonal balances that result in 
perturbed insulin signalling within the target tissue and consequently a reduction in - 39 -   
glucose uptake [62, 107, 133]. Generally during the early onset of insulin resistance there 
is a compensatory increase in insulin secretion, which functions to maintain 
normoglycaemia or impaired glucose tolerance [134]. The eventual progression to T2DM 
is prolonged insulin resistance resulting in substantial reductions in glucose uptake by 
target tissues and a reduction in insulin secretion due to β cell dysfunction or T2DM can 
progress simply due to a genetic predisposition towards a deficit in insulin secretion in 
combination with insulin resistance [134].   
The current treatments available for T2DM are dependent on the stage of disease 
progression. Early intervention at the onset of insulin resistance can be achieved simply 
by lifestyle changes in terms of diet and exercise, with a reduction in caloric intake and an 
increase in exercise. However, when this is not appropriate or ineffective, pharmacological 
intervention is required. Two types of drugs are commonly prescribed to T2DM patients, 
metformin and thiazolidinediones (rosiglitazone and pioglitazone) [133]. Metformin 
functions mostly to increase the duration of insulin action, reduce liver gluconeogenesis, 
and increase muscular glucose uptake. The thiazolidinediones are agonists of the 
peroxisome proliferator-activated receptor γ (PPARγ), which is a transcriptional activator 
or insulin target genes including GLUT4 [133]. However the thiazolidinediones have side 
effects, e.g., Avandia (Rosiglitazone) can cause cardiovascular disorders [135], although 
the incidence of this is decreasing due to better understanding and improved patient care. 
Metformin has some side effects including gastrointestinal disruption (diarrhoea, nausea, 
vomiting), vitamin B12 deficiency and lactic acidosis [136]. It is therefore paramount to 
continue with research into the cause of T2DM and the resulting development of cheaper, 
more effective drugs. 
 
1.5 Lipid Metabolism 
1.5.1 Overview 
The processing of dietary lipids is much simpler than that of glucose. Lipid globules are 
coated in bile salts within the intestinal lumen. The bile salts allow for enzymatic digestion 
by lipases to form free fatty acids and monoglycerides (with small amount of diglycerides 
and glycerol), which remain bound to bile salts and form micelles. Micelles are able to 
diffuse across the plasma membrane of the microvilli and once inside the cell are re-
esterified into triglycerides. The cell then repackages triglycerides into chylomicrons or 
lipoproteins in order for them to be transported in the hepatic portal vein to the liver. Both 
the liver and adipose tissue are the major organs responsible for lipid metabolism and 
storage [107].  - 40 - 
 
1.5.2 Lipogenesis and Fatty Acid Synthesis 
The liver and adipose tissue are responsible for clearing approximately 40% and 5-10% of 
plasma glucose, respectively [119]. During periods of glucose levels that exceed those 
needed to meet ATP demand and, in the liver, glycogen storage capacity, there is an 
increase in acetyl-CoA levels, which are then stored as triglycerides (TGs) in the adipose 
tissue and sometimes in the liver [62, 107]. The process by which this occurs is called 
lipogenesis. Excess glucose is converted to pyruvate by glycolysis and subsequently 
acetyl-CoA is generated by pyruvate dehydrogenase as already described. This occurs in 
the mitochondria but the enzymes required for lipogenesis are found in the cytosol and the 
mitochondrial membrane is impermeable to acetyl-CoA so it must be converted to citrate 
by citrate synthase and transported across the mitochondrial membrane by the 
tricarboxylate transport system [62]. Once in the cytosol, citrate must be converted back 
into acetyl-CoA requiring the enzyme ATP-citrate lyase (ACL), which reverses the reaction 
catalysed by citrate synthase and requires the hydrolysis of ATP. This reaction also 
generates oxaloacetate, which is reduced to malate and then decarboxylated to pyruvate, 
which is returned to the mitochondria [62]. Acetyl-CoA in the cytosol can be used in the 
process of fatty acid synthesis by the enzyme acetyl-CoA carboxylase (ACC) to produce 
malonyl-CoA, which is the rate-limiting step of de novo fatty acid synthesis. The next step 
involves the multienzyme complex fatty acid synthase (FAS), which catalyzes the reaction 
of malonyl-CoA and acetyl-CoA with the acyl-carrier-protein (ACP), which forms part of 
the FAS complex [62]. A series of reactions from the acetyl-ACP and malonyl-ACP 
combination is repeated 7 times to produce a chain, which is hydrolysed by palmitoyl 
thioesterase to produce palmitate [62]. Fatty acids that are either synthesised in this 
fashion or obtained from the diet are stored as triglycerides (TGs, also known as 
triacylglycerols) in adipose tissue and in the liver. The synthesis of TGs occurs in both the 
ER and mitochondria. In the mitochondria, glycerol-3-phosphate acyltransferase uses fatty 
acids and glycerol-3-phosphate (generated by glycolysis) to produce lysophosphatidic 
acid. In the ER lysophosphatidic acid is generated from acyl-dihydroxyacetone by acyl-
dihydroxyacetone phosphate reductase. Phosphatidic acid is produced from 
lysophosphatidic acid by 1-acylglycerol-3-phosphate acyltransferase and is then used to 
form DAG by phosphatidic acid phosphatase. Triglycerides are then formed from fatty 
acyl-CoAs (e.g. palmitate) combined with diacylglycerols by the enzyme diacylglycerol 
acyltransferase [62]. In order to prevent immediate reversal of TG synthesis, TGs are - 41 -   
coated in a storage molecule called perilipin (lipid droplet-associated protein), which is 
hormonally regulated [137].    
The regulation of lipogenesis and fatty acid synthesis is tightly controlled by signalling 
pathways and gene expression. Insulin is the major hormone responsible for activating 
lipogenesis whilst glucagon deactivates lipogenesis. Other hormones fine tune fatty acid 
metabolism. ACC is highly controlled by phosphorylation especially phosphorylation of 
Ser
79 by AMP activated protein kinase (AMPK) and Ser
1200 by PKA, which inhibits its 
activity [62, 138]. ACC is also regulated by citrate and palmitate in an allosteric fashion 
such that citrate is activating and palmitate (and other long chain fatty acids) is inhibitory 
[138]. Insulin also regulates the phosphorylation of ATP citrate lyase via activation of PKB. 
ACL is phosphorylated at Thr
446 and Ser
450 by GSK3, which is inactivated by insulin 
leading to the dephosphorylation of ACL. In combination with phosphorylation at Ser
454 by 
PKB there is an insulin-induced increase in ACL activity [139, 140]. The expression of 
genes involved in lipogenesis is also highly regulated by hormones, glucose and fatty 
acids. The major transcription factors responsible for the expression of FAS and ACC are 
the sterol response-element binding proteins (SREBP-1 and SREBP-2), liver X receptors 
and carbohydrate-responsive element-binding protein (chREBP) [138]. The presence of 
fatty acids within a cell regulates the activity of SREBPs. During times of low levels of fatty 
acids an intricate localization pathway is activated resulting in the translocation of 
SREBPs from the ER to the nucleus and subsequent lipogenic gene expression through 
an mTORC1 dependent mechanism [141].    
1.5.3 Lipolysis and β Oxidation 
Lipolysis occurs in three specific processes, which occur in a tissue-specific manner. As 
previously mentioned, triglycerides cannot enter enterocytes or in fact any type of cell. 
Thus, in the intestines the lipolytic enzymes gastric lipase and pancreatic lipase are 
responsible for the generation of free fatty acids (FFAs) that are absorbed by the intestinal 
epithelium. FFAs are not easily dissolved within the blood plasma and are thus 
transported in complex with plasma proteins (discussed later) and at their target tissues 
FFAs are released by lipoprotein lipase (LPL) resulting in non-esterified fatty acids 
(NEFAs), which are either taken up by target tissue or spill over into the blood plasma. 
During periods of low glucose availability, triglycerides stored in adipose tissue are used 
to produce free fatty acids, which can be transported in the blood to be used as energy via 
fatty acid oxidation.  
Lipolysis within the adipocyte is a reversal of TG synthesis as described previously and 
requires three different enzymes. TGs are converted to DAGs by adipose tissue  
triglyceride lipase (ATGL), whose expression and activity is tightly regulated. The - 42 - 
expression of ATGL is increased by transcription factors such as PPARs and FoxO1, 
which are both regulated through complex signalling pathways controlled by insulin, 
glucocorticoids, fasting and food intake [137, 142]. Hormone sensitive lipase (HSL) is the 
next enzyme required for lipolysis and converts DAGs into monoacylglycerols (MGs). As 
with ATGL, HSL is also highly regulated in a phosphorylation and substrate dependent 
fashion. Activation of HSL occurs through the β-adrenergic receptor/PKA signalling 
pathway, PKA directly phosphorylates HSL and also phosphorylates perilipin-1, which 
allows HSL to associate with TGs and DAGs resulting in its full activation [137]. Insulin 
functions to inhibit lipolysis by activating phosphodiesterases, which deactivate PKA. The 
third stage in lipolysis is the hydrolysis of MGs by monoacylglycerol lipase (MGL) and the 
release of FFAs [137]. Both HSL and MGL are expressed ubiquitously and function at 
target tissues to release FFAs. 
In order to generate ATP (and therefore energy) from fat, FFAs must be fed into the Krebs 
cycle as a result of their catabolism in a process called β-oxidation. FFAs in the cytosol 
are acylated by a trio of enzymes called acyl-CoA synthases to produce fatty acyl-CoAs. 
The fatty acyl-CoAs are attached to carnitine, via the acyl group, so they can be 
transported across the mitochondrial membrane by the carnitine carrier protein. Once in 
the mitochondria, the carnitine group is removed leaving the fatty acyl-CoA to enter the β-
oxidation pathway. The fatty acyl-CoA undergoes 4 enzymatic reactions to produce β-
ketoacyl-CoA, NADH and FADH2 (which can be fed into the electron transport chain to 
generate ATP) [62]. The resulting shorter fatty acyl-CoA can then re-enter the pathway to 
be reduced further until just acetyl-CoA is the end product. The acetyl-CoA generated can 
then enter the Krebs cycle and subsequently generate ATP. In the liver, a substantial 
amount of acetyl-CoA is actually used to generate ketone bodies such as acetoacetate 
and D-β-hydroxybutyrate, which are plasma soluble and used especially by the heart, 
brain and muscle when glucose is unavailable [62]. Acetyl-CoA is used in a series of 
reactions to generate acetoacetate and acetyl-CoA. The acetoacetate generated can be 
further reduced to β-hydroxybutyrate by β-hydroxybutyrate dehydrogenase [62].      
1.5.4 Regulation of Lipid Metabolism 
Dietary fats consist mostly of triglycerides but also cholesterol (from animal fat), 
phospholipids and phytosterols (from plants). The composition of dietary triglycerides is 
dependent on their source and includes saturated FAs, monounsaturated FAs and 
polyunsaturated FAs. Saturated FAs are fatty acid chains with no branching and so all the 
carbon atoms are saturated with hydrogen, whilst monounsaturated fats have one double 
bond between chains and similarly polyunsaturated fats contain numerous bonding - 43 -   
between chains [143]. Cholesterol is an essential sterol used in the assembly of 
membranes, and in the synthesis of steroid based hormones and some vitamins [144]. 
The cholesterol found in the intestines is mostly from bile and dead mucosal cells with 
only a small proportion from food [145]. As previously mentioned, fats in the intestines are 
broken down into FAs by lipases and enter the enterocyte via passive diffusion although 
there is also evidence for FA transporters [146]. Within the ER, FAs are re-esterified into 
TGs and cholesterol is also esterified followed by packaging into chylomicrons. In the ER, 
apolipoprotein B-48 (apoB 48) and microsomal triglyceride transport protein (MTTP) 
cooperate to form chylomicrons, which undergo exocytosis into the lymphatic system and 
then subsequently into the bloodstream [146, 147]. When chylomicrons pass through 
adipose, muscle and heart tissue the enzyme lipoprotein lipase causes the release of 
TGs, as FFAs and MGs, from the chylomicrons leaving chylomicron remnants (CRs), 
which are now enriched with cholesterol [62]. At this point, apoE is donated to the CRs, 
which are then released back into the circulation. The FFAs and MGs released from 
chylomicrons are then taken up by the surrounding tissue or enter the general circulation 
as NEFAs [148]. Those FFAs and MGs that enter the surrounding tissue are either fed 
into β oxidation and subsequently the Krebs cycle or re-esterified into TGs for storage. 
The CRs remain in the circulation until they pass the liver where the CRs are then 
endocytosed and degraded to release glycerol and FAs into the cytoplasm, which can 
subsequently be used in β oxidation, membrane synthesis and so forth [144].  
The liver is the major organ responsible for releasing lipids into the bloodstream and as 
such synthesises a variety of lipoproteins capable of carrying TGs and cholesterol. The 
largest of these is very low density lipoprotein (VLDL), which is similar to chylomicrons 
accept that VLDL contain apoB 100 instead of apoB 48 [143]. The hepatic pool of TG 
used in the formation of VLDL is believed to be derived from TGs synthesised from 
excess carbohydrates after a meal, which are then secreted so that the TGs can be stored 
in the adipose tissue [149]. VLDL also contain cholesterol and can be hydrolysed to 
release TGs resulting in the formation of intermediate density lipoproteins (IDL) and low 
density lipoproteins (LDL). Low density lipoproteins (LDL) also contain apoB 100 but 
contain more cholesterol compared with VLDL or chylomicrons. LDLs transport de novo-
synthesized cholesterol to cells that express LDL receptors, which allows these cells to 
take up the cholesterol for steroid hormone biosynthesis or plasma membrane synthesis. 
The final lipoprotein is high density lipoprotein (HDL), which has the opposite function to 
the other LDLs in that HDLs transport cholesterol from the tissues to the liver. [150].  
The control of whole body lipid homeostasis is regulated by substrate availability and 
hormones. Circulating levels of NEFAs and TGs have an impact on both intestinal and 
hepatic secretion of lipoproteins by increasing substrate availability such as after a meal. - 44 - 
Similarly glucose also increases VLDL release by increasing the cellular pool of TGs 
derived from lipogenesis. However periods of prolonged high NEFA and TG levels lead to 
hepatic ER stress and a reduction in lipoprotein secretion [151]. Insulin has been shown to 
decrease lipoprotein production through inhibition of FoxO1 [151]. Glucagon decreases 
plasma levels of TGs and FFAs by reducing TG synthesis in the liver during fasted states. 
The intestinal hormones GLP-1 and GIP also reduce plasma TG levels via differing 
mechanisms by reducing apo B expression, TG absorption or by promoting chylomicron 
clearance, respectively [151]. 
The major regulation of whole body FFAs resides in the function of adipose tissue, which 
is discussed below.     
1.5.5 Adipokines       
Adipose tissue is a dynamic organ that fluctuates in response to food intake and has been 
shown to be major regulator of whole body lipid and glucose homeostasis by functioning 
in a similar fashion to other endocrine organs. Adipose tissue is responsible for the 
synthesis and secretion of a number of factors that have varied effects throughout the 
body and are termed adipokines.  
Leptin is a 16kDa hormone secreted mostly by adipose tissue (but also in small amounts 
from skeletal muscle, liver and intestines) and was discovered as a result of the 
generation of the ob/ob mouse, which is a leptin knockout that presents with severe 
weight gain [152]. Originally it was thought leptin was required to reduce weight gain, 
however it is now evident that leptin increases with weight gain and decreases with weight 
loss [153]. Adipose tissue secretes leptin in response to insulin, glucocorticoids, 
oestrogen, cytokines and feeding whilst cold exposure, fasting, exercise, testosterone, 
noradrenaline and adrenaline all decrease plasma leptin levels [152, 153]. The major 
function of leptin is the regulation of energy expenditure and food intake. Leptin receptors 
(Ob-R) are expressed in high concentrations in the hypothalamus, but also in low levels in 
other tissues such as the β-cells of the pancreas and in skeletal muscle [153]. In the 
hypothalamus, leptin binding to Ob-R results in the association of Janus kinases (JAKs) 
and subsequent activation of signal transducers and activators of transcription (STATs). 
This leads to changes in gene expression and results in reduction in neuropeptide Y and 
agouti-related protein (AGRP) and an increase in prepro-melanocortin (POMC) and 
cocaine- and amphetamine-regulated transcript (CART), which are either orexigenic or 
anorexigenic [152, 153]. Leptin can alter sympathetic stimulation of tissues through 
alteration of noradrenaline and as such increases uncoupling protein -1 (UCP1) - 45 -   
expression in brown adipose tissue [152]. This leads to increased fatty acid oxidation 
through the uncoupling of the proton gradient of mitochondria and thus an increase in 
energy expenditure [62]. Furthermore leptin also has some direct effects within peripheral 
tissues, for example in the skeletal muscle leptin results in the activation of AMPK and 
subsequently increases fatty acid oxidation [145]. In the β cells of the pancreas, leptin 
decreases insulin production and secretion as well as β-cell growth; the decrease in 
insulin output provides a feedback loop since insulin causes leptin release from adipose 
tissue [147]. 
The opposing hormone to leptin is another adipokine called adiponectin, which is solely 
released by adipose tissue. Adiponectin secretion is stimulated by insulin signalling and 
reduced by β-adrenergic signalling. The hormonal effect of adiponectin is the 
augmentation of insulin sensitivity in target tissues such as skeletal muscle and the liver 
[148, 154-156]. The structure of adiponectin is of great consequence.  It can be secreted 
as trimers, hexamers or dodecamers. The dodecamers are termed high molecular weight 
(HMV) forms and the hexamers low molecular weight (LMW) forms. The HMV form of 
adiponectin is the most active and abundant in the plasma [157]. The expression of 
adiponectin mRNA is positively controlled by PPARγ and a complex of FoxO1-C/EBPʱ, 
which are regulated by ERK and GSK3 [154]. The post-translational modifications of 
adiponectin are also vital to its HMV formation. Retention by ER protein 44 (ERp44) is 
critical to HMV formation whilst the ERp44 binding partner Ero-1Lʱ functions to release 
adiponectin in a process regulated by NAD-dependent deacetylase sirtuin-1 (SIRT1) [154, 
157]. The adiponectin receptor comes in two forms called AdipoR1 and AdipoR2, which 
are both expressed in the liver whilst AdipoR1 is expressed in the muscle and 
hypothalamus [148]. In the liver, adiponectin acts via AdipoR1 to activate AMPK resulting 
in decreased lipogenesis and gluconeogenesis whilst AdipoR2 activates PPARʱ leading 
to increased β oxidation [148]. In skeletal muscle, AdipoR1 activates AMPK leading to 
increased β oxidation (through ACC phosphorylation) and increased glucose uptake [157]. 
In the β cells of the pancreas AdipoR1 and AdipoR2 are thought to activate ERK resulting 
in the maintenance of β cell survival and function by increasing insulin synthesis and 
secretion [155]. Adiponectin receptors expressed by adipocytes have been linked to 
decreased TNFʱ and IL-6 release and also lead to increased expression of genes for 
proteins involved in fatty acid oxidation [155].     
 
Two adipokines that have been identified within the last 15 years are resistin and visfatin 
[158, 159]. The physiological roles of these adipokines are not as clearly defined as those 
of leptin or adiponectin and there are some stark differences in both resistin and visfatin 
between mice and humans. Resistin is produced by adipocytes in mice but by adipose - 46 - 
tissue macrophages (ATMs) in humans. Furthermore, the control of resistin expression in 
response to hormones and meal status has not yet been fully elucidated. Glucose and 
glucocorticoids have been shown to increase resistin expression; however mRNA and 
protein levels are not well correlated [157, 160]. The effect of insulin is also not well 
characterised; studies have shown that insulin and TZD treatments can both increase and 
decrease resistin expression [158, 161, 162]. Resistin circulates within the plasma as 
trimers and hexamers, although the physiological relevance of this in not understood 
[157]. The function of resistin is also not well understood but has been reported to 
negatively regulate GLUT4 levels, activate suppressor of cytokine signalling 3 (SOCS3, 
which inhibits insulin signalling) and induce gluconeogenesis in the liver [160]. Resistin 
has also been strongly implicated in an inflammatory role, in both humans and mice 
resistin prolongs TNFʱ, IL-6 and monocyte chemoattractant protein-1 (MCP-1) production 
and also increases the expression of these pro-inflammatory cytokines from immune cells 
[160].  
Similarly to resistin, visfatin is also secreted by immune cells and adipocytes and its 
regulation and function is not completely understood. The first study that classified visfatin 
as an adipokine reported that visfatin mutations result in increased plasma glucose levels 
and also led to insulin-mimetic effects [159]. However, this paper was later retracted [163] 
due to issues about visfatin and insulin receptor binding. Other studies have shown a 
correlation between visfatin levels and hyperglycaemia [164] and other data also showed 
visfatin regulates SIRT1 in β pancreatic cells leading to increased insulin synthesis and 
secretion [165]. Interestingly visfatin is strongly correlated with insulin resistance and 
T2DM but may represent a protective mechanism employed by the body [164].     
 
Adipocytes are able to synthesise and secrete a number of cytokines such as TNFʱ and 
IL-6, although similarly to visfatin and resistin, resident immune cells of adipose tissue are 
responsible for the majority of plasma levels. TNFʱ is a 26kDa protein synthesised in 
response to lipopolysaccharide (LPS) and other bacterial products, IL-1, leptin, insulin and 
nutritional status in both adipocytes and tissue-resident T cells and macrophages [166, 
167]. The longer 26kDa form of TNFʱ is secreted as a membrane bound form and is 
cleaved into a soluble 17kDa form by TNFʱ converting enzyme (TACE) at the plasma 
membrane [167]. The effects of TNFʱ have mostly been studied in terms of obesity and 
insulin resistance and so they will be discussed in the next section. Similarly to TNFʱ, IL-6 
is also expressed by both adipocytes and adipose tissue resident macrophages. It is 
synthesized and released in response to both TNFʱ and exercise. Interestingly, IL-6 has - 47 -   
differing effects in muscle, adipose tissue and liver; furthermore muscle actually releases 
IL-6 in response to exercise. IL-6 causes increased leptin release and decreased 
adiponectin secretion along with decreases in LPL activity and increases in lipolysis. In 
skeletal muscle, IL-6 has been shown to increase glucose uptake and β oxidation [157]. 
However, in hepatocytes and adipocytes IL-6 leads to a reduction in insulin signalling 
[157].     
1.5.6 Obesity and the Metabolic Syndrome  
Obesity is characterised by a BMI over 30kg/m
2; in England 61.3% of adults and 30% of 
children are classified as obese, costing the NHS more than £5 billion per annum [168]. 
Obesity involves increased adiposity resulting in a substantial increase in the incidence of 
T2DM, cardiovascular disease (CVD), cancer and reduced life expectancy [169]. When 
insulin resistance, T2DM or impaired glucose tolerance occurs in combination with two of 
the following: high blood pressure, increased TG levels, abdominal obesity or low HDL, 
this is termed ‘the metabolic syndrome’ and its consequences include CVD or coronary 
heart disease (CHD) [170]. 
The obvious treatment for obesity is weight loss, which can be achieved through surgery, 
pharmacological treatment and lifestyle choice. However, the secondary diseases caused 
by obesity, i.e. T2DM, cardiovascular disease, etc., require anti-diabetic drugs (metformin, 
thiazolidinediones), statins (inhibitors of HMG-CoA reductase and therefore endogenous 
cholesterol production) and anti-hypertension drugs (ACE inhibitors etc). Furthermore the 
complications of metabolic syndrome are numerous and expensive to treat and so further 
research needs to be conducted in order to elucidate the relationship between obesity, 
T2DM and CVD, hopefully leading to cheaper more effective treatments or prophylactic 
measures.  
Obesity is quite clearly a result of overfeeding and a lack of physical activity. There is a 
strong relationship between obesity and diets high in fat and refined carbohydrates (i.e. 
sugar). In the USA, 30% of calories from normal diets are obtained from fat, whilst those 
classified as obese obtain 60% of their calories from fat [171]. In the USA and UK the rise 
in obesity has been shown to be strongly correlated with increased caloric intake, whilst 
energy expenditure (i.e. physical activity) has remained fairly constant [172]. The current 
understanding of the complications associated with obesity is mostly closely related to 
visceral adiposity (VAT). This describes the fat depot found within the abdominal cavity 
and is more metabolically active than subcutaneous fat (SAT, fat under the skin) [173]. 
During the pathogenesis of obesity, the VAT undergoes major changes, which then 
contribute to the occurrence of T2DM and CVD. Increased fat and sugar consumption 
leads to the storage of TGs in adipose tissue, mostly in VAT, resulting in adipocyte - 48 - 
hypertrophy. Increased adipocyte size can lead to an increase in adipogenesis in order to 
store the excess dietary fats and increased fat deposition within the liver, muscle, 
pancreas, heart and kidneys [173, 174]. In turn, this leads to the two major contributors of 
insulin resistance/T2DM and CVD; dyslipidaemia and dysfunctional adipokine release. We 
shall discuss this in detail with regards to the development of T2DM. 
The pathogenesis of T2DM in relation to abdominal obesity is complex and there is still 
much to be learned about the mechanisms involved. The current understanding suggests 
that insulin resistance is caused by dysregulation of adipokines in combination with 
increasing TG and NEFA levels. This is then followed by dysfunction of insulin secretion 
by β pancreatic cells, which culminates in the presentation of T2DM [175]. The current 
theory in the simplest terms is as follows (Fig. 1.5): increased fat intake results in T cell 
and macrophage activation and the expression of inflammatory cytokines and chemokines 
that cause phenotypic switching of adipose tissue macrophages (ATMs) and T cells to 
release pro-inflammatory cytokines leading to local and systemic insulin resistance. 
Adipose tissue dysfunction then leads to further increases in plasma FFAs and TGs along 
with deregulation of adipokines and cytokines, resulting in β-cell dysfunction and therefore 
T2DM [176-178]. - 49 -   
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Figure.  1.5.  Role  of  obesity  in  whole  body  insulin  resistance.  Increased  release  of 
adipokines  from  obese  adipose  tissue  and  resident  immune  cells  leads  to  insulin 
resistance in the adipocyte, skeletal muscle and liver as well as β cell dysfunction and loss 
of insulin secretion culminating in type 2 diabetes. Adapted from [179-181].   - 51 -   
Normal adipose tissue contains ATMs, but it also contains resident T cells of numerous 
lineages including Th1, Th2 and Treg. Obesity causes an infiltration of both macrophages 
and T cells but also leads to an increase in inflammatory phenotypes of those immune 
cells that are already resident within the adipose tissue  [177]. The activation of immune 
cells in response to obesity is not well understood, but is thought to involve chemokines, 
FFAs, hypoxia, adipocyte hypertrophy and adipokines. In lean adipose tissue, a unique 
population of Treg cells (different to Treg cells of other tissues) are present and believed to 
be important in maintaining insulin sensitivity of adipocytes, regulate Th1 cells and 
maintain the phenotype of ATMs [182]. The onset of obesity leads to a reduction in Treg 
cells possibly due to a reduction in adiponectin and increase in leptin, which leads to an 
increase in CD8
+ and CD4
+ Th1 cells [182, 183]. Similarly the increase in FFAs, hypoxia 
and adipocyte hypertrophy results in recruitment of macrophages. FFAs specifically result 
in activation of toll like receptor 4 (TLR4) in macrophages leading to activation the of the 
NF-κB pathway, which is responsible for the expression of pro-inflammatory cytokines 
[176]. The increase in Th1 cells and CD8+ cells results in the release of IFNγ, TNFʱ and 
“regulated on activation normal T cell expressed” (RANTES), which function to recruit and 
polarize macrophages to an M1 phenotype. In normal lean adipose tissue macrophages 
are found in a mostly M2 phenotype. The M2 macrophages are activated by IL-4 and IL-
13 and are characterised by the expression of IL-10, arginase I and IL-1 receptor 
antagonist [176, 177]. However during obesity the large increase in inflammatory 
cytokines and chemokines such as monocyte chemotactic protein-1 (MCP-1) leads not 
only to the infiltration of M1 macrophages but also to the phenotypic switching of M2 to M1 
macrophages and the maintenance of a low grade chronic inflammatory state. M1 
macrophages release TNFʱ, IL-1β, IL-6, which can then result in insulin resistance [176, 
177]. The majority of M1 macrophages are found in “crown-like structures” surrounding 
adipocytes that are dead or dying, this then leads to further increases in FFAs and TGs in 
a spill over fashion [184].   
 
The release of pro-inflammatory cytokines not only maintains ATMs and T cells but also 
results in local and systemic insulin resistance followed by β pancreatic cell dysfunction 
and the progression to T2DM. Locally within the adipocyte, TNFʱ causes insulin 
resistance by facilitating the degradation of insulin receptor substrate 1 (IRS1) and a 
reduction in the expression of adiponectin, GLUT4, C/EBPʱ and PPARγ [184]. The 
combination of a decrease in the inhibitory effect of insulin on lipolysis and the stimulatory 
effect of TNFʱ on lipolysis results in the increased release of FFAs from adipocytes, which 
can act locally on macrophages and adipocytes and also enter the circulation [185]. 
Furthermore, TNFʱ also leads to increases in IL-6, IL-1β, resistin and leptin, which all 
contribute to systemic insulin resistance and β pancreatic cell failure. The presence of - 52 - 
TNFʱ in the circulation results in insulin resistance in both the muscle and liver [186]. 
Within the skeletal muscle, TNFʱ causes insulin resistance in a similar fashion to 
adipocytes, i.e., it increases IRS1 degradation, but TNFʱ also suppresses fatty acid 
oxidation by decreasing AMPK activation resulting in accumulation of TGs, which in itself 
also further contributes to insulin resistance [187, 188]. Hepatic insulin resistance caused 
by TNFʱ involves activation of JNK and PKC, which phosphorylate IRS1 leading to its 
degradation and promotes increased gluconeogenesis and glycogenolysis [189]. The 
effect of IL-6 is complicated: in adipose tissue and the liver IL-6 results in insulin 
resistance in much the same way as TNFʱ does. However in the muscle IL-6 actually 
increases fatty acid oxidation and glucose utilization and so its contribution to whole body 
insulin sensitivity is complex and not yet fully understood [153]. The reduction in 
adiponectin seen in obesity also contributes to insulin resistance. Adiponectin (as 
discussed previously) enhances glucose uptake into muscle along with fatty acid 
oxidation. Furthermore, in the liver, adiponectin reduces gluconeogenesis [153]. Leptin 
resistance occurs during obesity due to the consistently high levels of leptin secreted by 
the enlarged adipocytes. This has been proposed to be caused by perturbed leptin 
signalling, decreased transport across the blood brain barrier and reduced numbers of 
leptin receptors (reviewed [190]). Consequently, this contributes to insulin resistance 
because leptin is required to reduce TG accumulation in liver and muscle [191]. Resistin 
has been associated with obesity and T2DM, there is some evidence of increased 
expression in obesity and this may lead to decreased AMPK activity resulting in changes 
to insulin sensitivity and glucose uptake in target tissues [157, 160]. Finally the increase in 
serum TGs and FFAs contribute to insulin resistance in the obese state. In the muscle 
increased TGs and FFAs are stored as intramyocellular TGs (IMTGs), which can 
contribute to insulin resistance. The intermediates of IMTGs such as ceramides have 
been shown to reduce PKB phosphorylation, whilst DAG, which activates several PKC 
isoforms, leads to down regulation of IRS1 [192]. In the liver, FFAs cause increases in 
DAG and, as in muscle, this leads to PKC activation and subsequent IRS1 degradation. 
FFAs also activate the NF-κB pathway leading to pro-inflammatory cytokine production 
and subsequent insulin resistance [175, 193].   
 
Progression from insulin resistance to T2DM involves many of the above factors and their 
effects on β pancreatic cell function, which is seen as initial hyperinsulinemia followed by 
loss of insulin secretion. The cytokines produced during the chronic inflammatory state of 
obesity result in detrimental changes to β cell function. Pancreatic islets express TNF 
receptor 1(TNFR1) and TNFʱ binding causes a reduction in glucose-stimulated insulin 
secretion (GSIS) and also inhibits IL-1β action, which is required to protect β islets from - 53 -   
glucotoxicity [178]. In combination with IFNγ, TNFʱ causes apoptosis of β cells, whilst 
also interfering with insulin signalling within the islets, a process which is required for β 
cell function and regulation of insulin gene expression [178, 194]. The effects of IL-6 are 
protective towards islet function and insulin secretion. IL-6 receptor signalling increases 
insulin secretion and blocks apoptotic pathways induced by TNFʱ, IFNγ and IL-1β, it is 
therefore possible that increases in IL-6 in obesity are a protective mechanism to alleviate 
the impact of other inflammatory cytokines [178]. Leptin is highly upregulated in obese 
adipose tissue and as well as its role in insulin resistance has been linked to the 
dysfunction of β cells. Leptin acting through the ObRb receptor expressed on β cells, 
reduces insulin secretion and inhibits GSIS through a complex mechanism involving 
increased hyperpolarization of the cell membrane and reductions in cAMP levels [178]. 
Leptin also inhibits apoptosis of islets by modulation of nitric oxide through increasing FA 
oxidation and reducing TG storage, which in turn reduces inducible nitric oxide synthase 
(iNOS) expression. As previously mentioned, obesity leads to a state of leptin resistance, 
which occurs in islets leading to abnormal insulin secretion (hyperinsulinaemia) followed 
by eventual exhaustion and apoptosis of β cells during the progression of T2DM [178]. 
The effects of adiponectin on islets is poorly researched and not well understood. Some 
evidence suggests adiponectin is required for β cell function to correct abnormal insulin 
secretion but not through direct action upon insulin secretion pathways [178]. Similarly to 
the effects on insulin resistance FFAs have a strong role in β cell dysfunction in obesity 
related T2DM. The initial effect of FFAs is an increase in insulin secretion by modulating 
intracellular calcium concentration and activation of PKC; however, prolonged exposure to 
FFAs results in an inhibition of GSIS through changes in β oxidation, increased UCP-2 
expression and modulation of KATP channels [178]. Furthermore, FFAs inhibit insulin 
expression and can induce apoptosis by ER stress in an NO-dependent mechanism and a 
reduction in anti-apoptotic factors (e.g. BCL-2) [178, 195].  
 
Greater understanding of all of the above mechanisms of obesity induced T2DM (and 
CVD) will lead to cheaper, more effective treatments. However global and governmental 
policy on the amount of fat and cost of fatty foods would go a very long way to resolving 
the global epidemic of obesity and its related diseases. 
         
 - 54 - 
1.6 Insulin Signalling 
1.6.1 Overview 
Insulin, as previously discussed, is synthesised by the β-cells of the islets of Langerhans 
within the pancreas. In response to changes in blood glucose levels, as a result of the 
ingestion of food and absorption of glucose by the intestines, insulin is secreted by these 
cells and has numerous effects upon cells that contain either insulin receptors or insulin 
like growth factor receptors (IGFR) [196]. The physiological effects of insulin are general 
anabolic effects on carbohydrate, fat and protein metabolism [196] (Fig. 1.6), but also 
importantly the control of protein synthesis through regulation of translation initiation and 
elongation, in various cell types [197].  
Situations of abnormal insulin signalling can cause a number of diseases including 
diabetes, (and the associated consequences of T2DM such as heart disease and kidney 
disease), cancer, metabolic syndrome and polycystic ovary syndrome [198, 199]. 
Understanding the intricacies of insulin signalling is paramount to identifying novel 
therapeutic targets and root causes of these diseases.  
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Figure.  1.6.  Cellular  effects  of  insulin.  A  simplified  schematic  of  the  insulin  signalling 
cascade and the major signalling components engaged by the insulin receptor. Insulin 
binds to its receptor resulting in its autophosphorylation and activation. This leads to the 
recruitment of insulin receptor substrate 1 (IRS1), which in turn leads to the activation of 
phosphatidylinositol  3-kinase  (PI3K).  PI3K  phosphorylates  PIP2  within  the  plasma 
membrane to produce PIP3, which functions as a docking protein for protein kinase B 
(PKB)  and  phosphoinositide-dependent  kinase  1  (PDK1).  Both  PDK1  and  mTORC2 
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phosphorylate and activate PKB. The activation of PKB results in numerous changes to 
downstream signalling pathways. Abbreviations: tuberos sclerosis complex 2/1 (TSC2/1), 
p70 S6 kinase (S6K), eIF4E binding protein (4EBP), Akt substrate 160 (AS16)), glucose 
transporter 4 (GLUT4). 
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1.6.2 Insulin Signalling Cascade 
The insulin receptor is part of the RTK family and as such shares similarities with other 
receptors in this group. The insulin receptor, along with the IGFR and insulin receptor-
related receptor (IRR) form a subgroup within the RTK family. These receptors are all 
formed from four subunits arranged as dimers that consist of an ʱ and β subunit and are 
distinct from class I RTK’s, which only form dimers after ligand binding [196]. As the RTK 
name suggests these receptors have enzymatic activity and their  subunits can 
allosterically inhibit the β subunit until ligand binding occurs. The effect of ligand binding is 
complex and not fully understood, but it is known that there are two low affinity sites on 
each receptor monomer and binding at site 1 causes crosslinking with the ligand bound at 
site 2 in the other monomer [200]. This in turn causes a conformational change that 
removes the inhibitory influence of the ʱ subunit towards the β subunit [196]. The 
dimerization of the insulin receptor causes the β subunit of one monomer to trans-
phosphorylate tyrosines 1158, 1162 and 1163 of the cytoplasmic domain of the opposing 
monomer. The phosphorylation of these tyrosines causes a conformational change of the 
activation loop, which results in ATP binding and kinase activation [201]. The 
phosphotyrosines within the β subunit of the insulin receptor produce docking sites for 
essential signal-transducing proteins such as the ‘insulin receptor substrates’ (IRS). There 
are four known IRS proteins; 1,2, 3 and 4. Both IRS1 and IRS2 are ubiquitously 
expressed but found to be expressed at the highest levels in the liver, skeletal muscle, 
adipose tissue , kidney, heart, brain and spleen, whereas IRS3 is specific to rodent 
adipose tissue and IRS4 is only found in the brain, thymus, kidney and liver [202, 203]. 
Data from IRS knock-out animals shows IRS1 and IRS2 to be the important isoforms for 
propagation of insulin signalling in relation to glucose uptake and so we shall focus on 
these isoforms from now on [204, 205]. The sequences of IRS1 and IRS2 share 75% 
sequence homology, and share some common binding partners whilst also showing 
differing roles in the insulin-dependent activation of downstream pathways. The N-terminal 
region of both IRS1 and IRS2 contain a pleckstrin homology (PH) domain and phospho-
tyrosine binding domain (PTB), which, are both required for optimal IRS1 phosphorylation 
by the insulin receptor. The PTB domain binds to the NPXY motif within the insulin 
receptor, whilst the PH domain binds to membrane lipids and in an unknown manner 
facilitates IRS1-insulin receptor binding and subsequent tyrosine phosphorylation of IRS1 
[203]. The longer activation period of IRS1 and its ability to tightly bind Grb2 explains how 
IRS1 activates the MAPK pathway, which IRS2 is not capable of due to its transient 
activity [206]. Both IRS1 and another insulin receptor binding protein, Shc, can bind to 
Grb2 and SOS, which results in the activation of the Ras/Raf/MEK pathway and therefore 
consequently ERK (reviewed [207]). Under basal conditions both IRS1 and IRS2 are 
found in intracellular membranes (IM)s along with the p85ʱ subunit of phosphatidylinositol - 58 - 
3-kinase (PI3K), upon insulin stimulation these proteins move to the cytosol [208] and bind 
to the phospho-tyrosines on the insulin receptor. This in turn leads to tyrosine 
phosphorylation of IRS1 at least 8 sites with potential for up to 20 [203, 208]. Numerous 
proteins can bind to the phosphotyrosines of IRS1/2 via SH2 domains including Grb2, 
SHP-2, 14-3-3 protein and most importantly PI3K. PI3K exists in various combinations of 
regulatory and catalytic subunits. The class I PI3Ks consist of 5 different regulatory 
subunits; p85ʱ, p85β, p55ʱ, p55γ and p50ʱ and 4 catalytic subunits p110ʱ, p110β, p110γ 
and p110ʴ (leukocyte specific) [203, 209]. The p85ʱ subunit contains two SH2 domains 
that must both bind to Tyr
612 and Tyr
632 of IRS1 in order for full activation of the catalytic 
p110 subunit. This is achieved by allosteric changes of the p85ʱ subunit caused by the 
SH2 domain binding IRS1 and removing repression of the p110 subunit and its 
subsequent positioning close to the plasma membrane where its substrate is located [210, 
211]. Once activated, PI3K is then able to phosphorylate the membrane lipid 
phosphatidylinositol (4,5) bisphosphate (PIP2) to produce phosphatidylinositol (3,4,5) 
trisphosphate (PIP3), which is a crucial docking point for proteins containing PH domains 
[211, 212]. Two such important proteins are phosphoinositide-dependent kinase 1 (PDK1) 
and PKB, which bind to PIP3 . This causes these two kinases to be in close proximity and 
subsequently PDK1 phosphorylates and activates PKB at Thr
308 within the PKB T-loop, 
which is revealed through conformational changes following PIP3 binding [212, 213]. 
There is a second site in PKB that is thought to prime PKB for Thr
308 phosphorylation, this 
site is Ser
473; however the requirement of this site is highly debatable. The kinase 
responsible for the phosphorylation of Ser
473 was until recently unknown, it has now been 
shown that there are (at least) two kinases responsible. Evidence shows that both DNA 
protein kinase (DNA-PK) and mTORC2 can both phosphorylate this site in response to 
DNA damage or mitogens, respectively [214]. The exact contribution of this site to the 
activity and selectivity of PKB is widely debated but mTORC2 dependent Ser
473 
phosphorylation is thought to be the most relevant [215]. The effect of PKB activation is a 
long list and encompasses cellular events including; protein synthesis, glucose uptake, 
transcription, cellar proliferation, angiogenesis, lipid metabolism and others [215]. 
 1.6.3 Control of Glucose Uptake by Insulin 
Insulin stimulates several signalling pathways, which, as already mentioned, have 
numerous different cellular functions. One such major pathway involving IRS1/PI3K/PKB 
has already been described above; here the specific control of glucose uptake by PKB-
dependent and -independent mechanisms will be discussed. - 59 -   
Insulin-stimulated glucose uptake is mediated by GLUT4, which is part of a family of sugar 
transporters with 14 members [216]. Cellular glucose homeostasis is very intricately 
controlled and involves the regulation of GLUT4 localisation in the Trans-Golgi network 
(TGN). Upon insulin stimulation GLUT4 is translocated to the plasma membrane, followed 
by recycling into either sorting endosomes, recycling endosomes or back to the TGN. We 
shall discuss translocation to the plasma membrane as this is the most relevant to this 
study.  
Under basal conditions GLUT4 can be found in a specialized storage system known as 
GLUT4 storage vesicles (GSVs). The definitive composition of GSVs is still an area of 
active research, the evidence so far indicates that GSVs contain GLUT4, insulin-regulated 
aminopeptidase (IRAP), sortilin, vesicle-associated membrane protein 2 (VAMP2) and 
lipoprotein receptor-related protein 1 (LRP1). These vesicles are retained at their point of 
formation, which is the TGN, the exact mechanism of GSV formation and retention is still 
not well understood. It is thought that multimers of GLUT4, IRAP, sortilin and LRP1 are 
sorted in the TGN and along with adaptor proteins, which are recruited by a GTPase, 
ADP-ribosylation factor 6 (ARF6), allow vesicular budding and clathrin coating to occur 
[216, 217]. Under basal conditions GSVs are thought to be retained in the TGN by the 
activity of RAB31 (a GTPase) and tether containing UBX domain for GLUT4 (TUG) [218, 
219]. There are numerous other RABs that in a cell type-dependent fashion regulate GSV 
formation and sorting, in the muscle RAB8 and RAB14, whilst in adipocytes RAB10 are all 
targets of the RAB GTPase activating protein (GAP) Akt substrate 160 (AS160). GSVs are 
retained in the TGN in part by an inhibitory influence of AS160 on its RABs as well as 
through the actions of TUG and RAB31. Insulin results in a rapid translocation of GSVs to 
the plasma membrane and subsequent glucose uptake. This occurs by both a PKB 
dependent and PKB independent mechanism, PKB activated by insulin through PI3K has 
recently been shown to phosphorylate Akt substrate of 160kDa (AS160) [220]. There are 
six known PKB phosphorylation sites on AS160: Ser
318, Ser
341, Ser
570, Ser
588, Thr
642 and 
Thr
751; however mutation of just four of them, Ser
318, Ser
588, Thr
642, and Thr
751, leads to 
reduced insulin-stimulated glucose uptake [220]. The link between phosphorylation and 
GAP activity is one of debate and so the exact mechanism of AS160 regulated GLUT4 
translocation is not yet clear but it is most likely that the GAP activity of AS160 is reduced 
towards RABs resulting in the release of GSVs from tethering by TUG [220, 221]. AS160 
is a divergent point for other insulin dependent pathways. Both PKC and AMPK regulate 
the binding of AS160 with 14-3-3 proteins. This interaction has been shown to be 
essential to GLUT4 translocation but the mechanism is again unclear [222].  
In order for the GSVs to translocate to the plasma membrane there is a requirement for 
remodelling of the actin-cytoskeleton. For long distance translocation microtubules are - 60 - 
necessary whilst shorter distances requires cortical actin [216, 221]. Insulin is capable of 
modulating this process by altering the ATPase activity of motor proteins such as KIF3, 
KIF5B, MYO1C and MYO5B [216, 221, 223]. Once GSVs are close to the plasma 
membrane, they must be brought to the right compartment, an event which again is 
controlled by insulin. At exocytosis sites within the plasma membrane, there is a 
multimeric complex called the exocyst whose assembly is regulated by the control of the 
association of TC10 with EXO7 by insulin [224]. This process is independent of PKB and 
involves insulin receptor association with adaptor protein with PH and SH2 domains 
(APS), which causes insulin receptor phosphorylation of c-CBL. This leads to increased 
GEF activity of C3G resulting in the activation of the GTPase activity of TC10 [216]. EXO7 
is constitutively associated with the plasma membrane and other exocyst components and 
so association with TC10 leads to its complete formation. [216, 224]. The exocyst 
interacts with RALA, which is found on GSVs and its activity is controlled by PKB through 
the RAL-GAP complex. PKB phosphorylates three sites on the RAL-GAP complex, which 
inhibits the complex resulting in the association of GTP with RALA, its subsequent 
activation and exocyst formation [225].  
The final step in this process involves the dissociation of GSVs from the exocyst and 
fusion with the plasma membrane. Insulin activated PKC phosphorylates RALA resulting 
in its dissociation from the exocyst [226]. This then allows fusion through VAMP2 on 
GSVs and syntaxin 4 (STX4) at the plasma membrane. It is thought this may be regulated 
in a PKB dependent fashion but the substrates and exact mechanism is not yet known 
[216]. Furthermore, there is evidence the insulin receptor mediates tyrosine 
phosphorylation of MUNC18, which is associated with STX4 and that its dissociation from 
STX4 is required for GSV fusion [227].   
 
1.6.4 The Mnks and Insulin Signalling 
Data from two patents claim Mnk2 as a possible treatment target for T2DM; however they 
show opposing data sets using different methods [106, 228]. One patent shows mice 
treated with an Mnk2 inhibitor have increased insulin sensitivity and increased glucose 
uptake [106]. Investigation into the normal expression of Mnk2 showed high levels in the 
muscles and brown adipose tissue [228]. These authors generated a dominant negative 
Mnk2 mouse (Mnk2DN), which involved a T-loop phosphorylation mutant of Mnk2a 
attached to β-actin injected into mouse embryos and implanted into pseudo-pregnant 
females. The offspring selected for their expression of the β-actin-Mnk2 mutant. - 61 -   
Comparison of the Mnk2DN mice to normal WT mice showed them to have increased 
weights [228]. However, this evidence must be treated with caution since the 
overexpressed dominant-negative Mnk2 (Mnk2DN) can bind tightly to p-ERK, causing its 
sequestration and potentially leading to off target effects by inhibiting phosphorylation of 
other ERK targets. This may explain the weight gain and changes in insulin sensitivity. 
This evidence needs to be investigated more thoroughly and should involve the use of 
Mnk2 knock-out (KO) mice instead of Mnk2DN mice, which may provide a more 
conclusive answer. There is no other evidence available that has investigated the 
potential role of the Mnks in the insulin signalling pathway.  
 
1.7 Aims of this Study 
The functional roles of the Mnks are still elusive despite 15 years of research. The 
majority of research focuses on the effect of Mnk-dependent eIF4E phosphorylation in 
tumorigenesis and cytokine signalling pathways. There is evidence that eIF4E 
phosphorylation is increased in response to rapamycin, which may indicate a resistance 
mechanism involving the Mnks. This may explain the less than desirable efficacies of 
rapalogs in clinical trials for cancer therapy. The exact cause of rapamycin-induced eIF4E 
phosphorylation has yet to be established and is investigated in this study. Using a variety 
of approaches including inhibitors of the Mnks, Mnk knockout cells, Mnk knockout mice as 
well as both in vivo and in vitro methods the aim of this work is identify novel functions and 
substrates of the Mnks with specific relation to glucose and lipid metabolism.   
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Chapter 2 
Methods and Materials 
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2.1 Chemicals, Biochemicals, Reagents and Antibodies. 
The majority of chemicals used for these methods were purchased from Sigma-Aldrich, 
Fisher Scientific or Calbiochem. Tissue culture reagents were brought from Invitrogen. 
SDS-PAGE reagents were purchased from Bio-Rad including running and transfers 
buffers and nitrocellulose (0.45μm pore size) membrane. Antibodies can be seen in Table 
2.1. Radiolabelled chemicals were brought from Perkin Elmer. 
2.2 Buffers and Solutions. 
All solutions and buffers were made using milliQ deionised water. The following list 
comprises those used throughout this thesis.  
1X Phosphate Buffered Saline (PBS) 
2mM KH2PO4, pH 7.4 
10mM Na2HPO4 
4 mM KCl 
170 mM NaCl 
 
Luria-Bertani (LB) Broth 
1% (w/v) Bacto®-tyrptone pH 7.5 
0.5% (w/v) Bacto®-yeast extract 
0.5% (w/v) NaCl 
 
LB Agar Plates 
LB broth with 1.5% (w/v) Agar 
 
TAE Buffer 
0.1M Tris-borate pH 8.0 
2mM EDTA 
 
5X Sample Buffer 
62.5 mM Tris- HCl pH 6.8 
7% (w/v) SDS 
20% (w/v) sucrose - 64 - 
0.01% (w/v) Bromophenol Blue 
5% (v/v) β-mercaptoethanol 
 
10X Running Buffer 
25mM Tris 
192mM Glycine 
0.1% (w/v) SDS 
 
Transfer Buffer 
25mM Tris 
192mM Glycine 
20% (v/v) Methanol  
0.02% SDS 
 
Coomassie Blue 
0.1% (w/v) Coomassie Brilliant Blue 
50% (v/v) Methanol 
10% (v/v)  Glacial Acetic Acid 
40% (v/v) H2O 
 
Lysis Buffer A  
20mM Tris-HCl pH 8.0 
100mM KCl 
50% glycerol 
1mM DTT 
1% Triton X-100 
1X protease inhibitor (PI) cocktail (Roche) 
 
Lysis Buffer B 
20mM HEPES-KOH pH 7.5 
50mM β-glycerolphosphate - 65 -   
0.2mM EDTA 
10% glycerol 
1% Triton X-100 
1mM DTT 
1mM Na3VO4  
1X PI cocktail 
  
Lysis Buffer C 
50mM HEPES-KOH pH7.5 
50mM KCl 
1mM EDTA 
0.5% (v/v) Elugent 
1mM DTT 
1X PI cocktail 
 
Lysis Buffer D 
25mM Tris HCl pH 7.6 
50 mM β-GP 
50mM KCl 
1% Triton X-100 
1mM DTT 
0.5mM Na3VO4  
1X PI cocktail 
 
Lysis Buffer E 
50mM Tris HCl pH 7.5 
1mM EDTA 
1mM EGTA 
50mM NaF 
50mM Na2PO4 
270mM sucrose 
1% Triton X-100 - 66 - 
1mM DTT 
250µM okadaic acid 
1X PI cocktail 
1mM Na3VO4 
 
Lysis Buffer F 
20mM Tris-Hcl pH 8.0 
137mM NaCl 
2.7mM KCl 
1mM MgCl2 
1mM CaCl2 
10% glycerol 
1% Igepal 
1mM DTT 
0.5mM Na3VO4  
1X PI cocktail 
 
Lysis Buffer G 
40mM HEPES-KOH pH 7.4 
120mM NaCl 
10mM Na2PO4 
10mM β-glycerolphosphate  
50mM NaF 
0.3% (w/v) CHAPS 
1mM DTT 
0.5mM Na3VO4   
1X PI cocktail 
 
Lysis Buffer H 
50mM Tris HCl pH 8.0 
200mM NaCl - 67 -   
0.5% (w/v) SDS 
5mM EDTA 
0.5mg/ml proteinase K 
 
 
Lysis Buffer I 
20mM Tris-HCl pH 7.5 
10% (w/v) SDS 
5mM DTT 
1X PI cocktail 
 
Dialysis Buffer A 
20mM Tris-HCl pH7.5 
100mM KCl 
5% glycerol 
5mM β-mercaptoethanol 
0.1X PI cocktail 
 
Dialysis Buffer B 
20mM HEPES-KOH pH 7.6 
0.2mM EDTA 
0.5mM DTT 
100mM KCl 
5% glycerol 
0.1X PI cocktail 
 
Column Buffer 
25mM HEPES-KOH pH 7.6 
100mM KCl 
1mM DTT 
 
Refolding Buffer - 68 - 
8M Urea 
50mM HEPES-KOH Ph 7.6 
50mM DTT 
 
Refolding Dialysis Buffer 
5M Urea 
25mM HEPES-KOH pH 7.6 
100mM KCl 
 
Wash Buffer A 
20mM HEPES-KOH pH 7.5 
50mM β-glycerolphosphate 
0.2mM EDTA 
10% glycerol 
 
Wash buffer B 
100mM Tris-HCl pH8.0 
0.5M LiCl 
 
Wash Buffer C 
10mM Tris-Hcl pH 7.6 
150mM NaCl 
1mM EDTA 
 
Wash Buffer D 
20mM HEPES-KOH pH 7.6 
5mM MgCl2 
1mM DTT 
 
Wash Buffer E 
25mM HEPES-KOH pH 7.4 - 69 -   
20mM KCl 
 
Kinase Buffer A 
50mM Tris HCl pH 7.5 
0.1mM EGTA 
10mM β-mercaptoethanol – washes 
0.1% (v/v) β-mercaptoethanol – assay 
 
Kinase Buffer B 
20mM HEPES-KOH pH 7.5 
50mM KCl 
2mM MgCl2  
 
Kinase Buffer C pH 7.2 
20mM β-glycerolphosphate 
5mM sodium pyrophosphate 
30mM NaCl 
1mM DTT  
 
Kinase Buffer D 
25mM HEPES-KOH pH 7.4 
20mM KCl 
10mM MgCl2  
 
Kinase Buffer E 
25mM HEPES-KOH pH 7.4 
50mM KCl 
20% Glycerol 
10mM MgCl2  
4mM MnCl2  
1mM DTT 
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KRH Buffer 
50mM HEPES-KOH, pH 7.4  
136mM NaCl          
4.7mM KCl        
1.25mM MgSO4         
1.25mM CaCl2  
2.3 Molecular Biology. 
2.3.1 Plasmids. 
 HA-GLUT4-GFP was a kind gift from Dr Sam Cushman. pCMV5HA-Mnk1a and 
pCMV5HA-Mnk2a was made by cloning the full length Mnk1a/2a PCR digest into the 
pCMV5 vector after Hind/Xba digest. Full length Mnk1a and Mnk2a were cloned into the 
pEBG6P vector or pGEX3X vector after PCR and EcoR1 digest. pGEX3X-IRS1 fragments 
B-E (Fig. 2.1) (B residues 21-400, C (108-516), D (516-896) and E (899-1235)) were a 
kind gift from Richard Lamb (University of Alberta, Canada). Serine/threonine mutants of 
IRS1 (Ser574Ala, Ser629Ala, Ser766Ala, Thr774Ala, Ser794Ala and S-5-A (Ser574Ala, 
Ser629Ala, Ser766Ala, Thr774Ala and Ser794Ala)) or Mnk2a (Ser74Ala and Ser437Ala) 
were produced by PCR with primers designed to produce the desired mutation (see table 
2.2) using Phusion DNA polymerase (Thermo Scientific). Mammalian expression vectors 
for IRS1 (D) and IRS1 (S-5-A) were created by EcoR1 digestion of GST-IRS1 WT and S-
5-A and insertion into a myc-tagged pCMV3c vector. pET28-eIF4E was made by cloning 
the full length eIF4E PCR product after Nco1-EcoR1 digest into the pET28 vector.  
2.3.2 Transformation of competent E. coli. 
Dependent on the vector and DNA insert either DH5ʱ or BL-21 strains of E. coli were 
used. On ice competent bacteria and 1µg of vector DNA were mixed and left for 12min. 
Samples were then incubated at 37°C for 5min followed by 2min on ice. For 1h samples 
were incubated at 37°C with 1ml LB broth followed by centrifugation at 2,400 g for 5min at 
room temperature. All but 100µl supernatant was removed in which the pellet was 
resuspended and then plated onto agar plates containing the antibiotic to which the vector 
conferred resistance to. Plates were incubated at 37°C overnight and the following day 
plates were stored at 4°C until required and up to 1 month.   - 71 -   
Figure 2.1. Domain structure of IRS1 and the areas covered by pGEX3X-IRS1 fragments. 
PH refers to Pleckstron Homology domain, PTB refers to phospho-tyrosine binding 
domain, Grb2 is the site for Growth factor receptor-bound protein 2 binding and SHP2 is 
the site for protein tyrosine phosphatase, non-receptor type 11 binding
    
PH PTB NH2 COOH PI3K Binding
B (21-400)
C (108-516) D (516-896) E (899-1235)
Grb2 SHP2- 72 - 
2.3.3 Induction, Expression and Preparation of proteins in E. coli. 
Colonies containing the desired vector plus insert, from BL-21 bacteria, were grown 
overnight in 20ml or 50ml of LB plus antibiotic (100µg/ml ampicillin or kanamycin). The 
following day this was added to 200ml or 500ml LB plus antibiotic and grown until OD at 
600nm is 0.5-0.7. Then 0.5-1mM IPTG was added to induce protein expression for 3 
hours at 37°C. Cultures were harvested by spinning at 3,200 g 4°C for 15min, the pellet 
was lysed in 5-10ml lysis buffer A (for IRS1) or lysis buffer B (for the Mnks). Lysozyme 
(10mg/ml) (100µl/100ml culture) was added to samples for 30min on ice followed by 
sonication 6X10 sec 30% power. Soluble protein was isolated by spinning samples at 
18,000 g 15min 4°C and then snap frozen at -80°C.   
2.3.4 Purification of GST-fusion proteins. 
Soluble protein from bacterial lysates and mammalian cell lysates were mixed with 0.5-
1ml glutathione sepharose beads in the respective lysis buffer of the protein and rotated at 
4°C for 1h. The supernatant was removed by gravitational flow through columns at 4°C 
and the beads washed 3X with the bed volume of lysis buffer without Triton. For 
bacterially expressed Mnk1/2 and IRS1 wildtype and mutant proteins, elution from the 
beads was achieved by adding 0.5-1ml lysis buffer (without Triton) plus 20mM glutathione 
creating 3-10 fractions. The fractions were subjected to SDS-PAGE and stained with 
Coomaisse. The fractions containing protein were pooled and dialysed for 2h for IRS1 
then for both IRS1 and the Mnks dialysed overnight in 1litre of dialysis buffer A at 4°C. For 
Mnk1/2 produced in mammalian cells, bound fusion proteins were subjected to 
PreScission protease (cleaves between Gln and Gly in the sequence of 
LeuGluValLeuPheGln/GlyPro and therefore removes the GST tag from tagged proteins) 
overnight at 4°C and the following day the supernatant was collected by spinning samples 
at 3,200 g for 5min at 4°C. Protein concentration was determined and proteins stored at -
80°C. 
2.3.5 Solubilisation of eIF4E produced in E. coli. 
Production of eIF4E was induced in bacteria as described above. Cultures were harvested 
by spinning at 3, 200 g and the pellet was lysed in lysis buffer C then vortexed thoroughly 
to shear cellular DNA. Lysates were then spun at 18, 000 g 10min 4°C and the 
supernatant collected and both this and the inclusion body pellet were snap frozen at -
80°C. The pellet was resuspended in 20ml refolding buffer (for 200ml cultures) and 
dialysed against 20 volumes of refolding dialysis buffer at 4°C for 1h, after this time an - 73 -   
equal volume of  dialysis buffer B  was added to reduce both the urea and DTT 
concentration and left to dialyse for a further hour. Following this a volume of dialysis 
buffer B equal to twice the starting volume was added to further reduce the urea and DTT 
concentration and left for another hour. The cassette was then transferred to 1l dialysis 
buffer B and dialysed for a further 3 hours with the buffer changed every hour. The 
solution was then collected and stored overnight at 4°C.  
   
2.3.6 Purification of eIF4E  
The protein solution was mixed with 0.25-0.5ml m
7 GTP sepharose in a column and 
rotated at 4°C for 1h. The column was then washed with the bed volume 6 times with 
column buffer. eIF4E was then eluted with 10 bed volumes of column buffer with 100μM 
m
7GTP and a small aliquot of each fraction subjected to SDS-PAGE to determine protein 
containing fractions. Those fractions found to contain eIF4E were then pooled and 
dialysed overnight in dialysis buffer A at 4°C and the following day the protein 
concentration was determined and protein stored at -80°C.  
  
2.4 Cell Biology and Protein Biochemistry 
2.4.1 Mammalian Cell Culture 
Prior to use, all buffers and media were warmed to 37°C. Cells were grown in an incubator 
kept at 37C with 5% CO2. PC3, HEK-293  Mnk1-KO (Mnk1-KO Mnk2
+/+), Mnk2-KO 
(Mnk1
+/+ Mnk2-KO) and DKO (Mnk1-KO Mnk2-KO) MEF cells (a kind gift from Dr Rikiro 
Fukunaga, Kyoto University, Japan) were cultured in DMEM (Dulbecco’s Modified Eagles 
Medium, GIBCO) with addition of 10% (v/v) foetal bovine serum (FBS, GIBCO), 100 μg/ml 
penicillin and 0.1 mg/ml streptomycin (GIBCO). Upon 80% confluence, cells were split and 
seeded accordingly for treatments. Briefly cells were washed twice in PBS, then 0.5-1ml 
0.25% trypsin EDTA (GIBCO) was added and left to allow cells to detach. Cells were then 
resuspended in DMEM and seeded accordingly. 3T3-L1 cells (a kind gift from Professor 
Jeremy Tavaré, University of Bristol and Professor Amira Klip, University of Toronto) were 
cultured in DMEM (Sigma) with 10% (v/v) newborn calf serum (NCS, GIBCO), 100 μg/ml 
penicillin and 0.1 mg/ml streptomycin (GIBCO). Upon 80% confluence cells were split as 
described above and seeded accordingly. Once cells reached 100% confluence they were 
left to senesce for 2 days. Cells were then incubated with primary differentiation media 
consisting of DMEM with 10% (v/v) FBS, antibiotic, 166nM insulin, 5μM troglitazone - 74 - 
(PPAR agonist, Tocris), 0.25μM dexamethasone (synthetic glucocorticoid, Sigma) and 
0.5mM IBMX (increases cAMP, Sigma) for 3 days, the latter 3 components induce insulin 
sensitizing genes leading to differentiation. Following morphological changes and lipid 
droplet formation cells were washed twice in PBS then incubated with secondary 
differentiation media consisting of DMEM with 10% (v/v) FBS, antibiotic, 166nM insulin 
and 5μM troglitazone, for a further 3 days. After full differentiation cells were maintained in 
complete DMEM until required for experiments (approx. 8 days post start of 
differentiation).    
2.4.2 Transient Transfection of Mammalian Cells 
HEK293’s, PC3’s, wildtype, Mnk1-KO, Mnk2-KO and DKO MEFs were transfected using 
the Polyethylenimine (PEI) method; 15µl of PEI (1mg/ml dissolved in 20mM HEPES pH 
7.0) was mixed with 1µg of plasmid in 200µl basal DMEM and left for 15min room 
temperature, cells were washed twice in basal DMEM and cells were incubated with 1.5ml 
basal DMEM. The PEI-plasmid mix was topped up to 500µl with complete DMEM (+FBS 
+penn/strep) and added dropwise to cells, after 2h the media was removed and replaced 
with complete DMEM. Gene expression was assessed 24-48h post-transfection.  
 
2.4.3 Gene Silencing using short interfering RNA (siRNA)  
PC3’s, WT MEFs and 3T3-L1 cells were transfected with Mnk1 or Mnk2 siRNA (Human 
Mnk1a: CAAAGAGUAUGCCGUCAAA, Mnk2a: GAACCGUUACUGUGAAUGA, Mouse 
Mnk1: CAUCGUGGAUUCUGACAAG, Mnk2: CCAAAGACCUCACGUCCUU all from 
Dharmacon, Thermo Scientific) using Dharmafect (Dharmacon, Thermo Scientific). For 6-
well plates 5μl (10μM stock) siRNA was added to 195μl DMEM (no additives), in a 
separate tube 5μl Dharmafect reagent (formulation 3 for PC3 cells and formulation 1 for 
MEFs and 3T3-L1’s) was mixed with 195μl DMEM (no additives) both tubes were left for 
5min room temperature after this time the tubes were mixed together and left for a further 
20min room temperature. For each well 1600μl DMEM (with FBS but no antibiotic) was 
added and mixed with the siRNA suspension and 2ml was added to each well. Gene 
knockdown was assessed at 48-72h post-transfection.    
2.4.4 Cell Harvesting. 
After treatment cells were washed 1-3 times in 1X PBS. The desired volume of ice-cold 
lysis buffer D for SDS-PAGE analysis, lysis buffer E for PKB assays, lysis buffer B for Mnk - 75 -   
assays, for PI3 kinase assays lysis buffer F or lysis buffer G for mTOR assays, was added 
to plates and cells scrapped from their dish into a clean microfuge tube. Lysates were 
centrifuged at 17, 000 g at 4°C for 10min. The supernatant was transferred to a new 
microfuge tube and lysates were either prepared for analysis or stored at -80°C. Protein 
concentration was determined using the Bradford method, using Bradford reagent 
(Bradford Laboratories Ltd, Hertfordshire, UK), absorbance was measured at a 595 nm. 
2.4.5 RNA Isolation  
The Trizol
© method was used to isolate RNA from both cells and whole tissue as follows. 
For whole tissue samples 20-50mg of ground tissue was added to 0.5-1ml Trizol reagent 
and homogenised with a dounce homogeniser then centrifuged at 12,000 g
 for 10min at 
4°C. The supernatant was then transferred to a clean microfuge tube with 200μl 
cholorform. To a 6cm dish of cells 1ml of Trizol was added and left for 5min at room 
temperature then transferred to a clean microfuge tube with 200μl cholorform. For both 
cell and tissue samples the trizol/chloroform mixture was vortexed until cloudy then left for 
2-3min at room temperature followed by centrifugation at 12,000 g for 15min at 4°C. The 
clear aqueous layer was then transferred to a clean microfuge tube with 500μl isopropanol 
and mixed then left for 10min room temperature. The RNA was then precipitated by 
centrifugation at 12,000 g for 15min at 4°C. the supernatant was very carefully removed 
and 1ml 80% ethanol was added and the samples vortexed thoroughly followed by 
centrifugation at 7,500 g for 5min at 4°C. The ethanol was then removed and the pellet 
allowed to air dry for 5min followed by resuspension in an appropriate volume of nuclease 
free H2O at stored at -80°C.     
 
2.4.6 m
7GTP Sepharose Pulldowns and Immunoprecipitations  
For m
7 pulldowns one part m
7GTP sepharose beads (GE Healthcare, UK) were diluted 
with one part Sepharose CL-4B (Sigma) allowing for 20µl per sample. The 
bead/Sepharose mixture was washed in 0.5ml lysis buffer A and centrifuged at 4, 700 g 
for 30 s. The supernatant was removed and 20µl of beads aliquoted per sample, 150-
200µg of cell lysate was added and the mixture made up to 0.5ml with lysis buffer D. 
Samples were mixed at 4°C for 1h then centrifuged as previously and the supernatant 
removed. Samples were then washed with 0.5ml lysis buffer D twice, and centrifuged as 
before. For immunoprecipitations 20µl of Protein G beads (GE Healthcare) per sample, 
were washed in either lysis buffer B, D, E or F and centrifuged at 4, 700 g 30 s. The 
supernatant was removed and 200-500µg of cell lysate was added along with either 1µg 
PKB ʱ antibody 1µg HA antibody, 1µg phospho-tyrosine antibody, mTOR kinase assays, - 76 - 
1μl raptor antibody or 1  eIF4G antibody. Samples were mixed at 4°C for 1-3h and then 
centrifuged as previously, followed by removal of the supernatant. Samples that were 
immunoprecipitated for PKB were washed once in 1ml lysis buffer E with 0.5M NaCl then 
washed three times in 0.5ml kinase buffer A and centrifuged as previously. Samples 
immunoprecipitated for HA were washed once in 0.5ml wash buffer A with 1M LiCl, then 
twice in wash buffer A followed by once in kinase buffer B. Samples immunoprecipitated 
for phosphor-tyrosine were washed three times in lysis buffer D, twice in wash buffer B 
and once in both wash buffer C and wash buffer D. Samples immunoprecipitated for 
raptor were washed once in lysis buffer G, twice in lysis buffer G with 150mM NaCl and 
twice in wash buffer E. Samples to be analysed by SDS-PAGE were denatured at 95°C 
for 5 min with 10-20µl of 2X sample buffer for m
7GTP pulldowns or 40µl 5X sample buffer 
for immunoprecipitations. Samples were either used immediately or stored at -20°C. 
Samples to be used in kinase assays were kept on ice until just before the kinase 
reactions were started.  
 
2.4.7 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blot 
Analysis 
SDS-PAGE gels were prepared at, 10%, 12.5% or 13.5 % acrylamide (v/v) and 0.1% N,N 
methylene-bis-acrylamide (v/v). For proteins above 25kDa a 10% or 12.5% gel was used 
for those smaller a 13.5% gel was used. Samples were prepared based on desired protein 
concentration with 5X sample buffer and denatured for 5 min at 95°C, accept for those 
proteins that required purification using an m
7GTP pulldown. Samples were loaded into 
each lane with a prestained protein ladder (Fermentas) in one lane. Gels were run in 
SDS-PAGE running buffer at 180-200V for 40-60min. SDS-acrylamide gels were placed 
on nitrocellulose membrane laid on top of 2 sheets of 3MM Whatman filter paper, 
prewetted with transfer buffer, followed by a further 2 sheets of 3MM Whatman filter 
paper. Proteins were transferred to the membrane by wet blotting at 75V for 90min on ice. 
For detection of 4E-BP1 the membranes were fixed in glutaraldehyde, diluted 1:500 in 
PBST. After transfer the membrane was incubated with blocking buffer 5% (w/v) dried 
semi-skimmed milk in 1X PBS/TBS for 40 min at room temperature to prevent non – 
specific binding of antibody to the membrane. The membrane was then incubated with 
primary antibody (antibodies are described in table 2.1). Primary antibody was removed 
and membrane washed 3 times for 5min in PBST/TBST, membranes were then incubated 
with relevant secondary antibodies at a 1:20000 dilution for 40-60 min at room 
temperature. Excess antibody was removed by washing the membrane 3 times for 5 min - 77 -   
in PBST/TBST. All incubations and washes were performed with constant agitation. 
Antibody – Antigen complexes were detected using the Odyssey Licor scanner.  
2.4.8 Confocal Microscopy 
To visualise GLUT4 translocation to the plasma membrane immortal wildtype, Mnk1-KO 
and DKO MEFs were seeded onto coverslips 24h prior to transfection then transfected 
with HA-GLUT4-GFP and left for 24h. Cells were then starved of serum (DMEM without 
FBS) for 2h 30min and treated with 100nM insulin for 20min. Cells were washed twice 
with 1ml PBS then fixed with 3.7% formaldehyde for 15min at room temperature followed 
by 3 washes with PBS. Coverslips were then incubated with 100µl Hoechst 33342 dye 
(2µM) for 10min room temperature followed by X2 washes in PBS and then incubated with 
100µl Alexa-Fluor 594 wheat germ agglutinin (WGA, 5µg/ml) for 10min room temperature, 
then washed three times in PBS. Coverslips’ were mounted onto slides with Fluoromount 
(Sigma Aldrich) and left to dry. Slides were imaged using a Leica TCS SP2 with the 
multiphoton laser. HA-GLUT4-GFP expressing cells were identified down the microscope 
and then scanned with the multiphoton laser with excitation emissions in the 594nm range 
for the plasma membrane, 488nm for GFP and 760nm for nucleus. The settings were 
optimized and kept the same for each slide.   
2.4.9 Preparation of cDNA and qPCR  
cDNA was prepared using the ImProm-Reverse Transcription kit (Promega) following the 
manufactures method which is described here. In a clean microfuge tube 0.2-0.5μg RNA 
was mixed with 1μl Oligo(dT) and 1μl random primer, the reactions were heated to 70°C 
for 5min followed by addition of 4μl 5X reaction buffer, 4.8μl 25mM MgCl2 1μl 10mM 
dNTPs, 0.5μl RNasin, 1μl reverse transcriptase and made to 15μl with nuclease free H2O. 
The reactions were then incubated at 25°C for 5min followed by 42°C for 60min and then 
70°C 15min. This produces cDNA that was either stored at -20°C or immediately used for 
qPCR. Primer efficiency was determined for each primer and cDNA dilutions were 
produced in serial. For each sample a triplicate reaction was made containing 5μl cDNA, 
4μl nuclease free H2O, 1μl primer (see table 2.3 for sequences) and 10μl 2X Precission 
SYBR green master mix (PrimerDesign). 96-well plates were cycled at  95°C 10min, 
followed by 40 cycles of 95°C 15sec and 60°C 1min followed by a melt curve stage using 
the Applied Biosystems StepOne Plus qPCR machine. The average cycle threshold (CT) 
value of the mRNA of interest was normalised to 18S rRNA and a ΔCT value generated 
by expressing results as fold increase compared to a designated control.    
  - 78 - 
2.4.10 In vitro Mnk Kinase Assays  
15μl of HA immunoprecipitated Mnk was incubated in 25µl kinase buffer B with 1μg 
recombinant eIF4E, 200µM ATP and 1µCi [γ
32P]ATP for 10min at 30°C. The reaction was 
stopped by adding 5µl 4X sample buffer and denatured at 95°C for 5min. For assays with 
IRS1, 200ng Mnk2a (purified from HEK293 cells) was incubated with 2μg recombinant 
IRS1, 100μM ATP, 1µCi [γ
32P]ATP and made up to 20μl with kinase buffer B and left from 
10-30min 30°C. The reaction was stopped by adding 5µl 4X sample buffer and denatured 
at 95°C for 5min.  Samples were run on an SDS-PAGE gel at 200V for 1h, the gel was 
then stained with Coomaisse blue for 30min and then destained (40% MeOH, 10% AcOH, 
50% H2O) for 1h. Gels were dried for 1-2h at 80°C and incubated with phosphor-screen 
and developed with the Typhoon 700 imaging system.  
2.4.11 Cyanogen Bromide Cleavage  
An in vitro Mnk kinase assay against IRS1 was prepared as described above (section 
2.4.10) except after SDS-PAGE gels were destained the fragment corresponding to IRS1 
was excised and equilibrated in 70% formic acid for 30min room temperature. The gel 
slice was then soaked in 100mg/ml cyanogen bromide in 70% formic acid at 37°C 
overnight and kept away from light. The supernatant was then removed to a separate 
microfuge tube and the remaining sample was then dried in a speed vac followed by 
resuspension in 30% formic acid and incubated at 37°C for 30min. The supernatant was 
collected and mixed with the previous supernatant and dried in a speed vac until 
approximately 30µl was remaining, which was then mixed with 10µl sample buffer and 3ul 
5M NaOH and boiled at 95°C 5min. samples were then loaded onto a 4-12% Novex gel 
and run in 1X MES running buffer (Sigma) at 170V for approximately 90min. The gel was 
then stained with Coomaisse blue for 30min, then destained for 2h and dried for 1-2h at 
80°C and incubated with phosphor-screen and developed with the Typhoon 700 imaging 
system.      
2.4.12 In vitro PKB Kinase Assays 
15μl  aliquots of immunoprecipitated proteins were incubated in 25µl kinase buffer A with 
2.5µM PKI (TTYADFIASGRTGRRNAIHD, peptide inhibitor of cAMP dependent protein 
kinase), 30µM Crosstide peptide (GRPRTSSFAEG, includes the consesnsus sequence 
for PKB phosphorylation, a kind gift from Dario Alessi), 10mM magnesium acetate, 100µM 
ATP and 1µCi [γ-
32P]ATP  for 20min. The reaction was stopped by removing 22µl and 
pipetting onto P81 Whatman phosphocellulose paper. Samples were left to air dry and - 79 -   
then washed three times for 5min in 0.85% phosphoric acid followed by once in methanol 
and allowed to air dry. Samples were counted using the Cerenkov method in the 2450 
Micro beta
2 microplate counter.  
2.4.13 In vitro PI3 Kinase Assays  
The phosphatidylinositol (Ptdlns) substrate was prepared as followed, 3ml (10mg/ml stock 
in chloroform) was dried in a speed vac for approximately 30min. the dried film was then 
resuspended in 1ml 1% (w/v) sodium cholate in kinase buffer C and sonicated for 10min 
in a sonicating water bath. 20μl aliquots of immunoprecipitated proteins were incubated in 
40μl kinase buffer C with 20μl Ptdlns cholate substrate and allowed to reach 37°C in a 
heat block. In a separate tube 39μl water, 5μl (30μM) ATP, 5μl (75mM MgCl2) and 0.5μCi 
[γ-
32P]ATP were mixed and allowed to warm to 37°C. The reaction was started by adding 
40μl of the ATP mix to the immunoprecipitate and left for 30min at 37°C. The reaction was 
stopped by adding 450μl chloroform/methanol (1:2) and vortexed thoroughly followed by 
storage at -20°C. The following day a Merck Kieselgel 60 20x20cm thin layer 
chromatography (TLC) plate was dipped into a mixture of 1:1 (v/v) methanol and 2mM 
EDTA and baked in an oven at 150°C until dried. A mixture of 42.9ml methanol, 30ml 
chloroform, 7.65ml 29.1% Ammonia and 9.45ml water was equilibrated in a 
chromatography tank for 90min. Samples were prepared for TLC by adding 150μl each of 
chloroform then 0.1M HCl and vortexed thoroughly followed by centrifugation at 2, 400 g 
10min room temperature. The lower and interphase was transferred to a fresh tube with 
addition of 600μl synthetic upper phase (chloroform:0.1M HCl, 1:1 v/v) and vortexed 
thoroughly and centrifuged as previously. The lower phase was transferred to a fresh 
eppendorf and dried in a speed vac for 30-90min. the dried lipid film was then 
resuspended in 35μl cholorform:methanol:HCl (200:100:1 v/v) and sonicated using a 
sonicating water bath. 10μl of each sample was dotted onto the cooled TLC plate and 
allowed to dry followed by a further 10μl and allowed to dry. The TLC with samples was 
then placed into the equilibrated chromatography tank and left for approximately 2h or 
until the solvent line reached 3cm from the top of the plate. The plate was allowed to dry 
and then left overnight with a phosphor-screen and developed the following day using the 
Typhoon phosphor-imager.   
2.4.14 In vitro mTOR Kinase Assays  
15μl aliquots of Raptor immunoprecipitated protein was incubated in 20μl kinase buffer E 
with 1μg recombinant GST-4E-BP1, 100µM ATP and 1µCi [γ-
32P]ATP for 20min at 30°C. 
The reaction was stopped by adding 5µl 4X sample buffer and denatured at 95°C for 
5min. Samples were run on an SDS-PAGE gel at 200V for 1h, the gel was then stained - 80 - 
with Commaisse blue for 30min and then destained (40% MeOH, 10% AcOH, 50% H2O) 
for 1h. Gels were dried for 1-2h at 80°C and incubated with X-ray film overnight at -80°C 
or a phosphor-screen and developed with the Konica Minolta SRX-101A X-ograph or 
Typhoon 700 imaging system.   
2.4.15 2-deoxyglucose Uptake Assay.  
Cells were grown to 80% confluence then starved of serum overnight, for 3T3-L1 cells at 8 
days post-differentiation cells were starved of serum overnight. The following morning 
cells were placed in serum free low glucose (1g/L) DMEM for 2h. During drug treatment 
cells were placed in KRH buffer and negative controls were treated with Cytochalasin B 
(Sigma). To start the reaction 100μl of 10X start solution: 1mM 2-deoxyglucose, 5μCi/ml 
[
3H]-2-deoxyglucose in KRH buffer, was added to the cells and placed in an incubator at 
37°C for 10min. The reaction was stopped by removing the label and washing the cells 
three times in ice cold KRH buffer. Cells were lysed in 1ml 0.1M NaOH, protein 
concentration was determined using the BCA method and 250μl of sample was mixed 
with 2.5ml scintillation fluid (Scintisafe 2, Fisher), the radioactive incorporation was 
counted using the 2450 Micro beta
2 microplate counter. Samples were normalised to 
protein concentration and expressed as specific activity.   
2.4.16 2-deoxyglucose Lipogenesis Assay.  
3T3-L1 cells were differentiated and on the 8
th day starved of serum overnight, the 
following morning cells were placed in serum free low glucose (1g/L) DMEM for 2h. During 
drug treatment cells were placed in KRH buffer. To start the reaction 100μl of 10X start 
solution: 1mM 2-deoxyglucose, 5μCi/ml [
3H]-2-deoxyglucose in KRH buffer, was added to 
the cells and placed in an incubator at 37°C for 2h. Cells were lysed in 0.8ml 0.1% SDS, 
protein concentration was determined using the BCA method. 0.6ml of cell lysate was 
mixed with 1.875ml chloroform:methanol (1:2), vortexed and left for 10min room 
temperature. To this 0.625ml chloroform and 0.625ml 0.5M KCl was added and samples 
centrifuged at 2, 400 g for 15min room temperature. The lowerphase was placed in a 
fresh microfuge tube and dried in a speed vac for 90min. The dried lipids were then 
resuspended in 100-200µl chloroform and counted in 2ml scintillation fluid (Ultima Gold, 
Perkin Elmer) using the the 2450 Micro beta
2 microplate counter. Samples were 
normalised to protein concentration and expressed as specific activity.   
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2.5 Animal Experimentation 
2.5.1 Transgenic Mouse Assessment 
Mnk2KO and DKO mice were bred under normal conditions from mice generously gifted 
by [45]. These mice were originally generated as follows; Mnk1 and Mnk2 genomic DNA 
clones were isolated from a mouse 129/Sv genomic DNA library using full-length mouse 
Mnk1 and Mnk2 cDNA probes, respectively. Vectors were created for Mnk1 and Mnk2 by 
inserting a neomycin resistance gene (Neo
r cassette) between the MunI site in intron 4 
and the AvrII site in intron 6 of the Mnk1 gene or between the NcoI site in intron 4 and the 
EcoT22I site in intron 9 of the Mnk2 gene. Mouse ES cells were transfected with the Mnk1 
or Mnk2 targeting vector by electroporation, and G418-resistant clones were assessed for 
homologous recombination by PCR. ES cells carrying the single Mnk1- or Mnk2-targeted 
allele were injected into BDF1 blastocysts, which were then implanted into recipient 
female mice. Mice with a high ES contribution were crossed to C57BL/6 females. Germ 
line knockout was confirmed by PCR. Single KO mice for either the Mnk1 or Mnk2 gene 
were generated by crossing the respective heterozygous mice. Mnk1
−/− Mnk2
−/− DKO mice 
were generated by crossing Mnk1
−/− Mnk2
+/− mice with Mnk1
+/− Mnk2
−/− mice. Mice were 
housed in a normal light/dark cycle and fed and watered according to Home Office 
regulations. Age matched C57BL/6 wildtype mice were used as controls for comparison 
with Mnk2KO and DKO mice [45]. To determine the genotype of mice, tail or ear samples 
were digested in tail lysis buffer H at 55°C overnight. Samples were centrifuged at 17, 000 
g for 15min room temperature, equal amounts of supernatant were taken into a new 
eppendorf and the pellet discarded. For 100µl supernatant, 30µl 5M NaCl was added and 
samples left for 5mins room temperature then centrifuged at 17, 000 g for 15mins. All 
supernatant was taken into a new eppendorf and 100µl Isopropanol was added to 
samples that were then incubated at room temperature for 10min. Samples were then 
centrifuged for 30min at 17, 000 g and the supernatant discarded. Pellets were incubated 
in 1ml 70% ethanol (-20⁰C) for 15min followed by centrifugation for 30min at 17, 000 g. 
Supernatant was discarded and pellet allowed to air-dry for approximately 1hr. Pellets 
were resuspended in 20µl MilliQ water. DNA concentration was determined using the 
Nanodrop spectrophotometer ND-100 (Labtech), where necessary samples were diluted 
to 100ng/µl. To prepare samples for PCR a master mix consisting of 0.5µl TAQ DNA 
polymerase (Promega), 10µl 5X buffer (Promega), 2µl dNTP, 2µl of forward and reverse 
primer (see table 2.4), 0.5µl 50mM MgCl2 and 32µl MilliQ water was made and centrifuged 
at 1, 500 g for 30secs. 47µl of master mix was added to 3µl of sample. Samples were 
then subject to the following PCR (BioRad My cycler) conditions; 94⁰C 5min, 35 cycles of; 
94⁰C 30sec, 60⁰C 1min and 72⁰C 1min30sec followed by 72⁰C 10min and held at 15⁰C ∞. - 82 - 
PCR products were subject to gel electrophoresis using a 2% agarose gel containing 
1:20000 gel red at 100V for 50min.    
2.5.2 Animal Husbandry and Diets 
Mice were cared for according to the Animals (Scientific Procedures) Act 1986 as set out 
by the Home Office. Mice were housed in groups with no more than 6 mice in a cage and 
had free access to food and water. They were maintained under a 12h light/dark cycle 
(lights on at 07.00h). Mice were weaned at approximately 3 weeks of age and were fed rat 
and mouse No.1 maintenance diets (Special Diet Services, RM1, normal chow)(table 2.5). 
Following weaning mice were either maintained on normal chow diets or fed Special Diet 
Services 45% AFE fat diet (high fat diet)(table 2.5).        
2.5.3 Glucose Tolerance Test  
Mice are fasted for 18 hours prior to the GTT with water but no food and a DO NOT FEED 
card is placed in the cardholder. The following morning the mice are prepared for the 
glucose tolerance test: animals are weighed and the tail end numbed with lidocaine 
cream, the tail is nicked with a fresh razor blade by a horizontal cut of the very end, ~35 to 
50 microliters of blood is very gently massaged from the tail to assess baseline blood 
glucose, which is measured by the glucose oxidase method using a Accu-chek 
glucometer, and 2 grams/kg body weight of 20% D-glucose is drawn up in a Beckton 
Dickenson D 29 gage 1/2" insulin syringe (one unit of D-glucose for every gram of body 
weight). Animals are transferred to individual cages. When all mice have been prepared 
the test is begun.  Glucose is injected into the intraperitoneal cavity.  At 15, 30, 60, 90 and 
120 minutes blood glucose is sampled from the tail of each mouse by gently massaging a 
small drop of blood onto the glucometer strip. Glucose injections and blood glucose 
sampling is timed to take approximately the same amount of time per animal (i.e. 25 
animals are injected in 12 minutes and blood glucose sampling of those same 25 animals 
should also take about 12 minutes) so that the sample times are accurate for each animal. 
At the end of the experiment the tips of the tail are cleaned and sprayed with Betadine and 
animals returned to their shared cages along with fresh food and water. Animals are 
checked the next day to ensure healing of the wound. This method was completed by 
Felino Cagampang with my assistance.  
 - 83 -   
2.5.4 DEXA Scanning and Organ Removal  
Mice were anaesthetised using Isoflurane or were euthanized by cervical dislocation and 
total blood removed by cardiac puncture. Bloods were placed in heparinised tubes and 
stored at 4°C until centrifugation for 10 minutes at 2, 400 g at 4°C. Blood glucose upon 
death was measured with the Accu-chek glucometer. The mice were scanned with a 
Skyscan 1176 in-vivo scanner with the following parameters: voltage: 50kV, current: 
500µA, scan Resolution: 35.1µm, exposure time: 83ms, rotation between images: 0.5° 
number of images: 395. The body of the mouse was scanned in 5 separate stages, the 
scans from all 5 stages were then combined during reconstruction to give a single 3D 
volume file. Body volume, tissue volume and fat volume were calculated using the 
Hounsfield scale [230], these calculations were then applied to the image using the 
VGStudio Max software. The DEXA scanning and analysis was carried out by Stuart 
Lanham (University of Southampton, Human Health and Development). Following DEXA 
scanning mice were dissected and the left and right lobes of the liver, the heart, pancreas, 
spleen, right kidney and brain were dissected, weighed, and snap frozen in liquid nitrogen 
prior to storage at -80°C. Abdominal (surrounding epididymal and vesicular glands in 
males and the ovaries and uterus in females) white adipose pads as well as interscapular 
(between shoulder blades) brown adipose tissue (SCAPULAR) were removed, weighed 
and stored as above to assess offspring fat deposition. Muscles from the upper segment 
of the hind limbs were also dissected, weighed and stored as above. A portion of the liver, 
abdominal fat, left kidney, scapular fat and muscle were also fixed in 10% formalin for 
histology. Dissection was mostly carried out by Felino Cagampang with assistance from 
myself.   
 
2.5.5 Metabolic Cage Assessment  
Mice were housed in individual metabolic chambers, in which they were accustomed for at 
least 12h before starting the measurements. Mice had free access to food and water, and 
were maintained under a 12h light/dark cycle (lights on at 07.00h). The temperature in the 
metabolic chamber (22 ± 2C) was stable and controlled throughout the experiment. 
Physical activities of the mice were monitored by an infrared photocell beam interruption 
method (Panlab SLU, Spain). Food intake was continuously measured using an 
extensiometric food weight transducer device (Panlab SLU, Spain); however this was not 
possible for high fat diet fed mice due to the consistency of the diet, which was not 
contained by the food device.   
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2.5.6 Tissue and Plasma Analysis  
Organs were processed by grinding frozen samples to a powdered form under liquid 
nitrogen using a mortar and pestle. For protein isolation 20-50mg of powdered samples 
were mixed with 200-700μl lysis buffer I and then homogenised with a microfuge 
homogeniser and centrifuged at 17, 000 g for 20min room temperature. The supernatant 
was removed to a fresh microfuge tube and protein concentration was checked using the 
BCA method. Samples were assessed by western blotting. RNA was isolated using an 
adaptation of the Trizol
© method. Approximately 30mg of powdered tissue was added to 
1ml Trizol reagent and homogenised with a microfuge homogeniser followed by 
centrifugation at 12,000g for 10min 4°C this was followed by the rest of the protocol as 
above in section 2.4.5. As described above total blood was removed by cardiac puncture 
and placed into heparinised tubes. Samples were spun at 6000g for 15min 4°C and the 
supernatant aliquoted into fresh microfuge tubes. Samples were sent to Keith Burling 
(Clinical Biochemistry, Cambridge University Hospitals NHS Foundation Trust) and 
analysed by gas chromatography for lipid based metabolites and ELISA for insulin, leptin 
and cytokines.  
 
Table 2.1 Antibodies for Western Blotting and Immunoprecipitations.   
Antibody  Dilution  Supplier and Product Number (if applicable) 
Phospho-eIF4E Ser
209  1:500  Eurogentec – custom made 
eIF4E  1:1000  Cell Signalling Technology – 9742 
eIF4GI  1:1000  Kind gift from Simon Morley (University of Sussex), for 
WB 
eIF4GI  1:500  Cell signalling Technology – 8701, for IP  
4E-BP1  1:1000  Raised in house  
Phospho-ERK 
Thr
202/Tyr
204 
1:1000  Cell Signalling Technology - 9101 
ERK  1:1000  Cell Signalling Technology - 9102 
Phospho-PKB Ser
473  1:2000  Cell Signalling Technology - 9271 - 85 -   
Phospho-PKB Thr
308  1:1000  Cell Signalling Technology - 9275 
PKB  1:2000  Cell Signalling Technology – 9272, for WB 
PKBʱ   1µg  Dario Alessi (University of Dundee), for IP 
HA  0.1µg  Roche - 11867423001  
Phospho-Mnk 
Thr
197/202 
1:1000  Cell Signalling Technology - 2111 
Mnk1  1:1000  Cell Signalling Technology - 2195 
Mnk2  1:1000  Sigma – M0696 
Raptor  1:1000 
WB 
1:500 
IP 
Cell Signalling Technology - 2280 
mTOR  1:1000 
WB 
1:500 
IP 
Raised in house 
Phospho-TSC2  
Thr
1462 
1:500  Cell Signalling Technology - 3611 
TSC2  1:500  Cell Signalling Technology - 3635 
Phospho-PRAS40 
Thr
246 
1:1000  Cell Signalling Technology - 2640 
PRAS40  1:1000  Cell Signalling Technology - 2610 
Phospho-S6 Ser
240/244  1:1000  Cell Signalling Technology - 2215 
S6  1:1000  Cell Signalling Technology - 2317 
β-Tubulin  1:200  Santa Cruz Biotechnology – sc5274 
Phospho-AS160 
Thr
642  
1:500  Cell Signalling Technology - 4288 - 86 - 
AS160  1:500  Cell Signalling Technology - 2447 
Phospho-tyrosine  1:500 
IP 
Santa Cruz Biotechnology – sc7020 
IRS1  1:500  Cell Signalling Technology - 2382 
IRβ  1:1000  Cell Signalling Technology - 3020 
Myc  1:500 
IP 
1:2000 
WB 
Sigma Aldrich – M4439 
p70S6K  1:1000  Cell Signalling Technology - 9202 
ATP Citrate Lyase  1:1000  Cell Signalling Technology - 4332 
aP2  1:1000  Cell Signalling Technology - 2120 
Phospho-acetyl CoA 
carboxylase Ser
79 
1:1000  Cell Signalling Technology - 3661 
Acetyl CoA 
carboxylase 
1:1000  Cell Signalling Technology - 3662 
PPARγ  1:500  Cell Signalling Technology - 2430 
IP denotes immunoprecipitations, WB denotes western blotting 
 
Table 2.2 Primers for Mutagenesis. 
Primer Name  Tm°  Sequence 
IRS1 S574A sense  69  GGGACACAGGCACGCCGCCTTCGTGC 
IRS1 S574A antisense  69  GCACGAAGGCGGCGTGCCTGTGTCCC 
IRS1 S629A sense  70.4  CAGTGGCCGAAAGGGCGCTGGAGACTATATGCCC 
IRS1 S629A antisense  70.4  GGGCATATAGTCTCCAGCGCCCTTTCGGCCACTG - 87 -   
IRS1 S766A sense  68.6  GCCTGTCCTCTCCTACTACGCATTACCAAGGTCCTTT
AAG 
IRS1 S766A antisense  68.6  CTTAAAGGACCTTGGTAATGCGTAGTAGGAGAGGAC
AGGC 
IRS1 T774A sense   70.6  GATCCTTTAAGCACGCCCAGCGCCCCGG 
IRS1 T774A antisense   70.6  CCGGGGCGCTGGGCGTGCTTAAAGGATC 
IRS1 S794A sense  70.6  CTCCGCCTTTCCACTGCCTCTGGTCGCCTTCTC 
IRS1 S794A antisense  70.6  GAGAAGGCGACCAGAGGCAGTGGAAAGGCGGAG 
Mnk2a S74A sense  70.6  CGGGCCACCGACGCCTTCTCGGGCAG 
Mnk2a S74A antisense  70.6  CTGCCCGAGAAGGCGTCGGTGGCCCG 
Mnk2a S437A sense  69  CTGCCTGCAGCTGGCTCCACCCTCCC 
Mnk2a S437A 
antisense 
69  GGGAGGGTGGAGCCAGCTGCAGGCAG 
Table 2.3 Primers for qPCR.  
Primer Name  Tm°  Sequence 
IRS1 sense  54.6  AGTTAGTAGAACCAAGCATTAAACAC 
IRS1 antisense  55.7  TGAGGAAGAGACTGAACCATCA 
ApoE sense  57  AGTGGCAAAGCAACCAACC 
ApoE antisense  56.3  CTTCCGTCATAGTGTCCTCCA 
UCP1 sense  55.2  GGCCTCTAGACTCAGTCCA 
UCP1 antisense  56.4  TAAGCCGGCTGAGATCTTGT 
PGC1ʱ sense  55.4  GTCAACAGCAAAAGCCACAA 
PGC1ʱ antisense  56.4  TCTGGGGTCAGAGGAAGAGA 
TNFʱ sense  57.3  CTCCAGGCGGTGCCTATG - 88 - 
TNFʱ antisense  53.8  GGGCCATAGAACTGAGAGG 
IFNγ sense  56.5  TCAAGTGGCATAGATGTGGAAGAA 
IFNγ antisense  55.8  TGGCTCTGCAGGATTTTCATG 
MCP1 sense  57.2  GGCTGGAGAGCTACAAGAGG 
MCP1 antisense  54.9  TCTTGAGCTTGGTGACAAAAAC 
RANTES sense  56.3  AGCAGCAAGTGCTCCAATC 
RANTES antisense  54.9  GGGAAGCGTATACAGGGTC 
CD3 sense  56.4  TCCCAACCCAGACTATGAGC 
CD3 antisense  56.4  GCGATGTCTCTCCTATCTGTCA 
CXCR3 sense  56.5  GCCAAGCCATGTACCTTGAG 
CXCR3 antisense  56.1  GGAGAGGTGCTGTTTTCCAG 
Mnk2 sense  57.3  CCAGTGCCAGGGACATAGG 
Mnk2 antisense  56.8  GCCACGCATCTTCTCAAACA 
Table 2.4 Primers for genotyping.  
Primer Name  Tm°  Sequence 
Mnk1 WT sense  55.5  GACCCAGGAATGACACCTTC 
Mnk1 mutant sense  65  GATTCGCAGCGCATCGCCTTCTATCG 
Mnk1 antisense  58.5  GCGCAAACCACATGTGCTTT 
Mnk2 WT sense  67.4  CCACATCCGCAGCAGGGTGTTCGC 
Mnk2 mutant sense  64.6  GATTCGCAGCGCATCGCCTTCTATCG 
Mnk2 antisense  68.4  GTCGCAGCGCTTGTCGTAGATGCTGGC 
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Table 2.5 Components of mouse diets used in this study.  
Diet  Carbohydrate 
(% w/w g) 
Protein  
(% w/w g) 
Fat  
(% w/w g) 
Fibre 
 (% w/w g) 
Energy  
(kcal/g) 
RM1 
Standard 
Chow 
63.51  14.38  4.98  17.05  3.53 
45% AFE 
Fat 
39.8  23.0  22.6  4.6  4.54 
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Chapter 3 
Rapamycin Induces eIF4E 
Phosphorylation by Increasing the 
Activity of Mnk2a. 
 
 
 
 
 
 
 
 
 
3.1 Introduction 
The Mnks were discovered as a result of screening for novel substrates or binding 
substrates of ERK. This revealed 4 different isoforms of Mnk1 and Mnk2 termed Mnk1a, 
Mnk1b, Mnk2a and Mnk2b [38, 39]. Humans express all Mnk isoforms whilst mice only - 91 -   
contain Mnk1a and Mnk2a, both of which contain a C-terminal MAPK-binding domain [38, 
39]The best known substrate of the Mnks is eIF4E, which binds to the 5’-cap structure of 
eukaryotic mRNAs and is phosphorylated by the Mnks on Ser209 [53, 231]. eIF4E 
interacts with the scaffold protein eIF4G to recruit other translation factors and the 40S 
ribosomal subunit to the mRNA, to facilitate efficient initiation of mRNA translation. eIF4G 
is also required for efficient phosphorylation of eIF4E by the Mnks because the Mnks 
cannot bind directly to eIF4E [85]. The Mnks show differing levels of activity towards 
eIF4E; Mnk1a shows low basal activity, which is markedly increased by stimuli that 
activate MAP kinase signalling [58, 232], whereas Mnk2a shows high basal activity which 
is only slightly changed by activating or inhibiting ERK signalling; this likely reflects the 
fact that phosphorylated, active ERK can bind stably to Mnk2a but not Mnk1a, causing its 
continuous activation [72, 73, 87]. 
There is strong evidence for a role of eIF4E in tumorigenesis; e.g., levels of eIF4E are 
raised in many cancers (reviewed [40, 233]), whilst artificial overexpression of eIF4E in 
mammalian cells or in animal models leads to transformation or accelerated 
tumorigenesis [234, 235]. The tumorigenic mechanism may involve the increased levels of 
available eIF4E leading to the translation or nucleocytoplasmic transport of certain 
mRNAs, whose products promote cell proliferation or survival [236]. The role of eIF4E 
phosphorylation has yet to be conclusively identified but has been linked to the expression 
of subsets of specific mRNAs and as such has been recently implicated in tumorigenesis 
[77-79].   
Rapamycin was discovered as a product of the bacterium Streptomyces hygroscopicus 
and was shown to have antifungal effects [237]. During trials of rapamycin as an 
antifungal it was discovered that rapamycin exhibited potent immunosuppressive effects 
and so has been used for immune suppression after organ transplantation [238]. 
Research to determine the target of rapamycin led to the discovery of the yeast 
homologues (TOR1, TOR2), followed by the mammalian target of rapamycin (mTOR) 
complex 1 and 2 [239, 240]. Rapamycin inhibits mTORC1 through an allosteric 
mechanism. Rapamycin binds the cytosolic protein FKBP12 and binds to the FKBP12-
rapamycin binding (FBR) domain of mTOR although the exact mechanism of inhibition is 
still not known [241]. The availability of eIF4E is restricted by its association with eIF4E-
binding proteins (4E-BPs) which block its binding to eIF4G; 4E-BPs are phosphoproteins, 
and their phosphorylation by the mTORC1 at specific sites causes their release from 
eIF4E allowing the latter to bind to eIF4G. mTORC1 is activated downstream of signalling 
pathways such as the ERK and protein kinase B (PKB) (reviewed [242, 243]), which 
include upstream components that become oncogenic (e.g, Ras, PI 3-kinase) or are 
regulated by tumour suppressor proteins. Thus, mTORC1 is hyperactive in many tumour - 92 - 
cells, favouring activation of eIF4E. This has prompted numerous studies of rapamycin 
and related compounds (‘rapalogs’) as anti-tumour agents, leading to approval of certain 
rapalogs in advanced renal cell carcinoma and other settings [244]. Active site-directed 
inhibitors of mTOR are now available; unlike rapamycin, they inhibit all mTOR’s functions 
[28, 245, 246]. 
In this study the cell line PC3 have been used. This cell line was originally generated from 
a grade IV prostate cancer that had metastasized to the bone of a 62 year old male [247]. 
PC3 cells are therefore highly metastatic and exhibit characteristics such as a lack of 
prostate-specific membrane antigen (PSMA) [248]. There is some debate about the 
expression of the androgen receptor (AR) in PC3 cells with evidence providing for both 
positive and negative expression [249, 250], but the majority of evidence favours an AR-
negative phenotype in PC3 cells [250-252]. Furthermore these cells do not express 
prostate-specific antigen (PSA) [250], although when used to generate xenografts in mice 
there is expression of PSA [253]. Another key characteristic of  PC3 cells is they are 
PTEN null [254], which suggests aberrant PI3K/PKB signalling is a key tumorigenic 
pathway used by these cells. Interestingly, 50-85% of prostate cancers do show high 
levels of PI3K/PKB signalling [255, 256]. Evidence from PC3 cells that shows the activity 
of PI3K/PKB is important for in proliferation, invasion and tumour size [253, 257, 258]. 
Therefore mTORC1 inhibitors such as rapamycin are an attractive treatment for advanced 
prostate cancer and there are a number of clinical trials in progress to test their efficacy. 
However the current data available is disappointing [259-261]. 
 
Considering the clear links between eIF4E phosphorylation and tumorigenesis and the 
increasing use of rapalogs in cancer therapy, it is a major concern that rapamycin actually 
enhances eIF4E phosphorylation in several cell types [29, 31, 262-264]. The aim of this 
chapter is to gain insights into the mechanisms underlying rapamycin’s ability to enhance 
eIF4E phosphorylation. 
3.2 Results 
3.2.1 Effect of Rapamycin in PC3 cells. 
To investigate the effect of rapamycin on eIF4E phosphorylation the prostate cancer cell 
line PC3 was used. To understand if there is a role for the Mnks in the lack of efficacy of 
rapamycin, PC3 cells were used as a model of advanced prostate cancer.              - 93 -   
3.2.1.1 Rapamycin-induced eIF4E phosphorylation can be blocked by inhibiting both the 
p110α and p110β subunits of PI3 kinase, in PC3 cells. 
Numerous studies have shown rapamycin can induce eIF4E phosphorylation[31, 265, 
266]. Evidence suggests this is caused by activation of PI3K. This has been postulated to 
occur through mTORC1 inhibition of S6K activity towards IRS1, which blocks the 
degradation of IRS1 and potentiates PI3K activity [31]. To further investigate the role of 
PI3K and its link to rapamycin-induced eIF4E phosphorylation, I studied whether specific 
PI3K p110 catalytic subunits are involved in this effect. Using PI3–KʱVIII, TGX-221 and 
LY294002 to inhibit PI3K p110ʱ, p110β and p110ʱ, β and γ, respectively, the importance 
of these subunits was tested in PC3 cells that had been starved of serum (Fig. 3.1). Data 
from LY294002 use in previous studies is unreliable as this compound also inhibits mTOR 
[267]. LY294002 is an ATP-competitive inhibitor of mTOR [268] and it is possible that 
blocking ATP binding to mTOR combined with allosteric inhibition by rapamycin is the 
reason for the decrease in phosphorylation of eIF4E. PP242 is also an ATP competitive 
mTOR inhibitor and so fully inhibits both mTOR complexes. Thus ATP-competitive 
inhibition of mTORC1 may not activate the negative feedback pathway involving PI3 
kinase. By using highly specific PI3 kinase inhibitors, TGX-221 and PI3-KʱVIII, which only 
block the PI3 kinase p110β and p110ʱ catalytic subunits, respectively, and not mTOR 
[269], it should be possible to determine if specific p110 subunits are involved and thus 
indicate whether LY294002 decreases rapamycin-induced eIF4E phosphorylation due to 
its ability to inhibit mTOR in a ATP-competitive manner. 
The results (Fig. 3.1) indicate that PI3-KʱVIII or TGX-221 did not block rapamycin-induced 
eIF4E phosphorylation when administered alone, but, when used in combination, 
produced a significant decrease in rapamycin-induced eIF4E phosphorylation (Fig. 3.1). 
The lack of inhibition when these compounds are used alone may be because PC3 cells 
express three of the four PI3 kinase p110 isoforms; ʱ, β and γ [270]. These results 
suggest both the p110ʱ and p110β subunits are necessary for rapamycin-induced eIF4E 
phosphorylation. This implies that particular downstream pathways may be important for 
rapamycin-induced eIF4E phosphorylation. This effect of LY294002 is not due to ATP-
competitive inhibition of mTOR and the decrease in rapamycin-induced eIF4E 
phosphorylation is as result of LY294002 inhibition of the p110ʱ and p110β subunits of 
PI3K. 
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Figure 3.1. Effects of rapamycin on phosphorylation of eIF4E. A) Western blot analysis of 
eIF4E phosphorylated on Ser209 and total eIF4E from m
7GTP-Sepharose purifications 
from extracts of PC3 cells which had been starved of serum overnight and then treated as 
indicated for 2h. B) Graphical representation of the ratio of p-eIF4E to total eIF4E. Bands 
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were quantified by densitometry using the Licor Odyssey software. Student’s t-test was 
used  to analyse  the  data,  *  indicates p<0.05 compared  to control,  #  indicates p<0.05 
compared to rapamycin. n=3  - 96 - 
3.2.1.2 Changes in eIF4E phosphorylation are independent of eIF4G or 4E-BP1 binding to 
eIF4E. 
The conventional model for the effect of rapamycin on eIF4E function suggests that 
decreased 4E-BP1 phosphorylation leads to sequestration of eIF4E and a concomitant 
decrease in eIF4G binding [271, 272]. This should lead to inhibition of the phosphorylation 
of eIF4E as the Mnks require the scaffold function of eIF4G to phosphorylate eIF4E 
efficiently [85]. The data from this study appear to conflict with the model described above: 
rapamycin significantly increases eIF4E phosphorylation (Fig. 3.1), which is in accordance 
with published work [29, 31]. It was therefore important to study the effect of rapamycin on 
eIF4E/eIF4G binding. PC3 cells were starved of serum and treated accordingly (Fig. 3.2) 
followed by purification by m
7GTP precipitation. The indicate that rapamycin increases 
eIF4G/eIF4E binding (although not significantly as seen in Fig. 3.2). In contrast when 
TGX-221, PI3–KʱVIII or LY294002 are used in combination with rapamycin eIF4G/eIF4E 
binding decreases (Fig. 3.2). The increase in eIF4G/eIF4E binding with rapamycin 
treatment could, in principle, explain the increase in eIF4E phosphorylation. However 
treatment with TGX-221 or PI3–KʱVIII with rapamycin led to a decrease in eIF4G/eIF4E 
binding (Fig. 3.2), despite the fact that eIF4E phosphorylation was not altered by 
rapamycin and TGX-221 or rapamycin and PI3-KʱVIII (Fig. 3.1). This suggests that 
eIF4G/eIF4E binding does not correlate with the levels of eIF4E phosphorylation and that 
changes in this parameter are not the reason for rapamycin-induced eIF4E 
phosphorylation. There is data that show the Mnks can phosphorylate eIF4E 
independently of eIF4G but, at a much slower rate [273, 274]. It is possible that inhibition 
of mTORC1 by rapamycin activates a pathway that allows eIF4E phosphorylation by the 
Mnks independently of eIF4G/eIF4E binding. This is likely to alter Mnk activity or 
Mnk/eIF4G binding.  
As previously mentioned mTORC1 activation leads to the phosphorylation of 4E-BP1, 
leading to the release of eIF4E, which allows binding to eIF4G. Rapamycin would be 
expected to block this, resulting in less eIF4E/eIF4G binding. The data show the response 
to PP242 conforms to the conventional model of mTORC1 inhibition by blocking eIF4E 
phosphorylation, probably through a combination of decreased eIF4G binding and 
increased 4E-BP binding (Fig. 3.2). However, the data for rapamycin do not agree with 
this model since eIF4G binding is not decreased and the amount of 4E-BP1/eIF4E binding 
increases marginally with all treatments (Fig. 3.2). The amount of 4E-BP1 bound to eIF4E 
when rapamycin and PI3-KʱVIII are combined (Fig. 3.2) is higher than rapamycin alone - 97 -   
despite eIF4E phosphorylation remaining high (Fig. 3.1). In addition, there is also a 
decrease in eIF4G binding (Fig. 3.2).   
These data indicate that neither eIF4G/eIF4E binding nor 4E-BP1/eIF4E binding correlate 
with eIF4E phosphorylation.     
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Figure 3.2. Effects of rapamycin on proteins associated with eIF4E. A) Western blot 
analysis of total eIF4E, total eIF4G and total 4E-BP1 from m
7GTP-Sepharose purifications 
from extracts of PC3 cells which had been starved of serum overnight and then treated as 
indicated for 2h. B) Graphical representation of total eIF4G to total eIF4E in material 
purified on m
7GTP-Sepharose. Bands were quantified by densitometry using the Licor 
Odyssey software. Student’s t-test was used to analyse the data, * indicates p<0.05 
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compared to control, #  indicates p<0.05 compared to rapamycin. n=3 for eIF4E and 
eIF4G and n=1 for 4E-BP1. 
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3.2.1.3 Increases in eIF4E phosphorylation are correlated to PKB but not ERK 
phosphorylation. 
The pathway that links PI3K to changes in the phosphorylation of eIF4E has been partially 
investigated by other studies, which employed MEK inhibitors to assess whether PI3K 
signalling leads to the activation of ERK. One of the studies used a combination of MEK 
inhibitors and p38 MAPK inhibitors and reported a decrease in rapamycin-induced eIF4E 
phosphorylation; however they did not show these data [29]. To confirm this was the case 
in PC3 cells I assessed ERK phosphorylation.  The data (Fig. 3.3A) show that there is a 
slight increase with LY294002 or rapamycin treatment but this is reduced by each of the 
inhibitors in combination with rapamycin and therefore does not correlate with eIF4E 
phosphorylation (Fig. 3.1).  
The role of PKB here is less clear; while one study reports that rapamycin-induced eIF4E 
phosphorylation is independent of PKB [31], other authors suggest the opposite [29, 266]. 
It was therefore important to assess PKB phosphorylation in this study. 
 PKB activation requires its phosphorylation at two sites; Ser
473 (phosphorylated by 
mTORC2) and Thr
308 (phosphorylated by PDK1) [275]. Phosphorylation of
 the latter 
appears to be more important for activity towards most substrates. Phosphorylation of 
PKB at Thr
308 and Ser
473 increased with rapamycin or rapamycin in combination with PI3-
KʱVIII (Fig. 3.3B). TGX-221, TGX-221 and PI3-KʱVIII or LY294002 decreased rapamycin-
induced PKB phosphorylation at both sites. The decrease in rapamycin-induced PKB 
phosphorylation seen with TGX-221 (Fig. 3.3B) does not correlate with eIF4E 
phosphorylation (Fig. 3.1). These data make it difficult to conclude whether or not PKB is 
involved in rapamycin-induced eIF4E phosphorylation.  
The PKB inhibitor Akti1/2 was employed to further assess the role of PKB in rapamycin-
induced eIF4E phosphorylation. The data revealed that inhibition of PKB trended to block 
rapamycin-induced eIF4E phosphorylation (Fig. 3.4), indicative of a potential role for PKB 
affecting eIF4E phosphorylation. This is, however, complicated by the reduction in PKB 
phosphorylation seen with PMA treatment, which significantly increases eIF4E 
phosphorylation. Furthermore, these data conflict with the effect of TGX-221 on 
rapamycin-induced PKB phosphorylation and subsequent eIF4E phosphorylation, which 
show no correlation (Figs 3.1, 3.3B).   - 101 -   
Figure 3.3. Effects of rapamycin on ERK and PKB. A) Western blot analysis phospho-ERK 
Thr
202/Tyr
204 and total ERK of crude lysates from PC3 cells starved of serum overnight and 
then treated as indicated for 2h. n=1 B) Western blot analysis for phospho-PKB Ser
473 and 
Thr
308 and total PKB of crude lysates from PC3 cells starved of serum overnight and then 
treated as indicated for 2h. n=1.  
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Figure 3.4 Effects of inhibition of PKB on rapamycin-induced eIF4E phosphorylation. A) 
Western  blot  analysis  of  p-eIF4E  Ser
209  and  total  eIF4E  from  m
7GTP-Sepharose 
purifications from extracts of PC3 cells which had been starved of serum overnight and 
then treated as indicated for 2h. B) Graphical representation of the ratio of p-eIF4E to total 
eIF4E expressed as a percentage of the control. Bands were quantified by densitometry 
using  the  Licor  Odyssey  software.  Student’s  t-test  was  used  to  analyse  the  data,  * 
indicates p<0.05 compared to control, t indicates p<0.1 compared to rapamycin. n=3  
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3.2.2 Role of the Mnks in Rapamycin-induced eIF4E phosphorylation. 
 The Mnks are the only kinases that are known to target eIF4E, as illustrated by the loss of 
eIF4E phosphorylation in Mnk1/2-DKO mice [31]. To establish if one isoform or both are 
responsible for rapamycin-induced eIF4E phosphorylation Mnk1 and Mnk2 single 
knockout cells were used. It has previously been suggested that both Mnks are 
responsible for this effect [31]. However in light of data just described, which show ERK 
does not appear to be involved, I decided to examine which of the Mnk isoforms were 
involved. 
3.2.2.1 Rapamycin-induced phosphorylation of eIF4E is dependent on Mnk2 function but 
not Mnk1.  
The data show that the loss of Mnk2, but not Mnk1, reduces basal eIF4E phosphorylation 
(Fig. 3.5). This was expected because Mnk2 has high basal activity and is not greatly 
activated further by ERK or p38 MAPK [72]. Knock-out of Mnk1 did not reduce rapamycin-
induced eIF4E phosphorylation and rapamycin still elicits a similar increase in eIF4E 
phosphorylation to that seen in wildtype cells (Fig. 3.5A, C). The converse is true with the 
knockout of Mnk2: there is no increase in phosphorylation of eIF4E in response to 
rapamycin (Fig. 3.5B, C). Interestingly, PMA caused a significant decrease in eIF4E 
phosphorylation in Mnk1-KO cells suggesting that ERK activation inhibits Mnk2 activity, 
which is unexpected. This phenomenon requires further investigation. 
Although the Mnk2-KO MEFs did not exhibit rapamycin-induced eIF4E phosphorylation, it 
was also important to determine if Mnk2 was the sole isoform responsible in PC3 cells. 
PC3 cells were incubated with siRNA specific to Mnk1 or Mnk2 or just Dharmafect 
(transfection reagent) for 48h and then serum starved followed by treatment with 
rapamycin or PMA. As can be seen, an efficient knockdown of either Mnk1 or Mnk2 was 
achieved (Fig. 3.6A). Those cells incubated with just Dharmafect or Mnk1 knockdown still 
showed similar levels of basal and rapamycin-induced eIF4E phosphorylation (Fig. 3.6A, 
B). Interestingly, Mnk1 siRNA did not lead to the decrease in eIF4E phosphorylation in 
response to PMA as was seen in Mnk1-KO cells (Fig. 3.5). As expected from the MEF 
data, PC3 cells treated with Mnk2-siRNA showed significantly lower basal eIF4E 
phosphorylation and no increase in response to rapamycin (Fig. 3.6).      - 105 -   
Figure 3.5 Mnk2 is required for rapamycin-induced phosphorylation of eIF4E. A) Western 
blot analysis of p-eIF4E and total eIF4E from m
7 GTP purifications from lysates from WT, 
Mnk1-KO and Mnk2-KO. Cells were starved of serum overnight then treated with 100nM 
rapamycin  for  2h.  These  blots  have  been  merged  to  remove  unnecessary  lanes  as 
indicated from the vertical lines. B) Graphical representation of the ratio of p-eIF4E/eIF4E 
expressed as a % of untreated WT cells. Intensities were quantified by densitometry using 
the Licor Odyssey software. Student’s t-test was used to analyse the data, * indicates 
p<0.05 compared to WT control. 
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Figure 3.6 Mnk2 is required for rapamycin-induced phosphorylation of eIF4E. A) PC3 cells 
treated with transfection reagent alone or with Mnk1 or Mnk2 siRNA for 48h followed by 
overnight serum starvation and subsequent treatment with 100nM rapamycin or 0.5µM 
PMA for 2h. B) Graphical representation of the ratio of p-eIF4E/total eIF4E expressed as 
% of those for control cells. Bands were quantified using the Licor Odyssey software. 
Student’s t-test was used to analyse the data, * indicates p<0.05 compared to control. 
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3.2.2.2 eIF4G/eIF4E binding is affected by the loss of either of the Mnks. 
The data described above show that the effects of rapamycin and combinations of PI3 
kinase inhibitors on eIF4E/eIF4G binding do not correlate with levels of eIF4E 
phosphorylation (Figs. 3.1, 3.2). However eIF4G/eIF4E binding has not been previously 
assessed in Mnk1-KO and Mnk2-KO cells. 
The loss of Mnk1 had an overall inhibitory effect on eIF4E/eIF4G binding, which is further 
decreased by the addition of rapamycin, an effect also seen in the wildtype cells (Fig. 3.7). 
In Mnk2-KO cells, there was a significant increase in eIF4G/eIF4E binding. This could be 
a compensatory mechanism employed by the cell to rescue the loss of basal eIF4E 
phosphorylation by promoting Mnk1-dependent phosphorylation of eIF4E. Another 
possible explanation is that Mnk2 negatively regulates eIF4G/eIF4E binding, while Mnk1 
positively regulates it.  
 In PC3 cells, rapamycin caused an increase in eIF4G/eIF4E binding and increased eIF4E 
phosphorylation (Figs. 3.1, 3.2). However, in PC3 cells, eIF4E phosphorylation does not 
correlate with eIF4G/eIF4E binding, as demonstrated by the addition of the individual PI3 
kinase inhibitors, which decreased eIF4G/eIF4E binding but did not affect rapamycin-
induced eIF4E phosphorylation (Figs. 3.1, 3.2). Similarly to PC3 cells, it is likely that in 
MEFs eIF4G/eIF4E binding is not important in rapamycin-induced eIF4E phosphorylation. 
In summary these data do show that the Mnks have an effect on eIF4G/eIF4E binding, 
which is interesting, but does not explain rapamycin-induced eIF4E phosphorylation.   
It therefore still remains to be determined as to how rapamycin increases eIF4E 
phosphorylation, whether there is a change in Mnk2/eIF4G binding or an increase in Mnk2 
activity.  
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Figure 3.7 Loss of the Mnks alters eIF4G-eIF4E binding. A) Western blot analysis of total 
eIF4G and total eIF4E from m
7 GTP purifications from lysates from WT, Mnk1-KO and 
Mnk2-KO. Cells were starved of serum overnight then treated with 100nM rapamycin for 
2h.  These  blots  have  been  merged  to  remove  unnecessary  lanes.  B)  Graphical 
representation  of  the  ratio  of  eIF4G/eIF4E  expressed  as  a  %  of  untreated  WT  cells. 
Intensities were quantified by densitometry using the Licor Odyssey software. Student’s t-
test was used to analyse the data, * indicates p<0.05 compared to WT control. 
0
50
100
150
200
250
300
Control Rapamycin PMA
%
 
R
a
t
i
o
 
e
I
F
4
G
/
e
I
F
4
E
 
c
o
m
p
a
r
e
d
 
t
o
 
W
T
 
c
o
n
t
r
o
l
 
(
=
1
0
0
)
WT
MNK1KO
MNK2KO
*
*
*
* *
*
*
WT Mnk1-KO
eIF4G
eIF4E
Mnk2-KO WT
A
B- 109 -   
3.2.2.3 mTORC1 inhibition increases the activity of Mnk2a independently of T-loop 
phosphorylation. 
The evidence presented so far has shown that Mnk2a is the isoform required for 
rapamycin-induced eIF4E phosphorylation (Figs. 3.5, 3.6). Since the activity of Mnk2a is 
dependent on its T-loop phosphorylation, it was important to assess if this was increased 
by rapamycin treatment and, if so, it was affected by inhibiting PI3K or PKB. PC3 cells 
were transfected with a vector encoding HA-tagged Mnk2a and treated as shown (Fig. 
3.8). The overexpressed Mnk2a was immunoprecipitated by the HA tag and processed by 
western blot analysis for phosphorylation using an antibody against the T-loop. This 
showed that rapamycin did not increase T-loop phosphorylation indicating that a different 
mechanism is responsible for Mnk2a dependent rapamycin-induced eIF4E 
phosphorylation (Fig. 3.8). Furthermore, the addition of Akti1/2 trended towards a 
decrease in T-loop phosphorylation when combined with rapamycin despite no increase in 
T-loop phosphorylation seen with rapamycin (Fig. 3.8). This implies that PKB inhibition 
causes a decrease in rapamycin-induced eIF4E phosphorylation because of decreased 
Mnk2a T-loop phosphorylation and not by blocking the actual mechanism through which 
rapamycin induces eIF4E phosphorylation.  
To determine whether rapamycin caused an increase in Mnk2a activity, PC3 cells 
overexpressing HA-tagged Mnk2 were lysed, HA-Mnk2a was immunoprecipitated and its 
activity assayed against recombinant eIF4E (Fig. 3.9A, B). Rapamycin markedly 
enhanced the activity of Mnk2a both in autophosphorylation, as indicated by the ratio of 
incorporated 
32P compared to immunoprecipitated levels of HA-Mnk2a (Fig. 3.9B), and 
against eIF4E (Fig. 3.9A). Interestingly, PP242 also enhanced Mnk2a activity (Fig. 3.9A, 
B), which indicates that inhibition of mTORC1 leads to increased Mnk2a activity. PP242 
does not increase eIF4E phosphorylation in vivo probably because it also decreases 
eIF4G/eIF4E and increases 4E-BP1/eIF4E binding (Fig. 3.1, 3.2). However, this is 
important when considering mTOR inhibitors for cancer therapy because it is possible 
increased Mnk2 activity will influence other Mnk substrates, potentially in a detrimental 
fashion. As shown previously (Fig. 3.8), neither rapamycin nor PP242 increased Mnk2a T-
loop phosphorylation (Fig. 3.9A, C). Thus, rapamycin enhances Mnk2a activity 
independently of changes in T-loop phosphorylation.  
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Figure 3.8 Effects of rapamycin on Mnk2 phosphorylation. A) Western blot analysis of p-
Mnk2 and HA input from HA immunoprecipitates from extracts of PC3 cells PC3 cells 
transfected with a vector for HA-Mnk2a, left for 48h, starved of serum overnight and then 
treated  as  indicated  for  2h.  B)  Graphical  representation  of  the  ratio  of  p-Mnk  to  HA 
expressed as a percentage of the control. Bands were quantified by densitometry using 
the Licor Odyssey software. Student’s t-test was used to analyse the data, t indicates 
p<0.1 compared to rapamycin. n=3  
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Figure.  3.9  Mnk2  activity  increases  in  response  to  mTORC1  inhibition.  A)  PC3  cells 
transfected with a vector for HA-Mnk2a, left for 48h, starved of serum overnight and then 
treated with 100nM rapamycin, or 1µM PP242 for 2h. After immunoprecipitation with anti-
HA,  an  in  vitro  kinase  assay  was  performed  for  the  activity  of  HA-Mnk2a  against 
recombinant eIF4E (Mnk2a also undergoes phosphorylation in the assay, as indicated). 
The lower part shows western blots of cell lysates using anti-HA and p-Mnk antisera. B) 
Graphical representation of 
32P incorporation Mnk2a normalised to HA input. Bands were 
quantified by densitometry using ImageJ and the Licor Odyssey software, respectively. n= 
4   C) Graphical representation of p-Mnk2a normalised to HA input. Bands were quantified 
by densitometry using the Licor Odyssey software. In B, C, Student’s t-test was used to 
analyse the data, * indicates p<0.05 compared to control.  
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3.2.2.4 Rapamycin increases Mnk2a activity through changes to one site in Mnk2a.   
The levels of autophosphorylation of Mnk2a increased with rapamycin treatment indicating 
that despite no changes to T-loop phosphorylation there was likely a change in 
phosphorylation of another site (Fig. 3.9A, C). Mnk2a from control or rapamycin-treated 
cells was analysed by mass spectrometry (kindly completed by Andrew Bottrill, University 
of Leicester). This revealed changes in the phosphorylation of two residues, Ser74 and 
Ser437 (data not shown). To determine if either of these sites was required for the 
rapamycin-induced activation of Mnk2a, mutants in which Ser
74 or Ser
437 was changed to 
alanine. The effects of rapamycin on Mnk2a [S74A] and Mnk2a[S437A] in parallel with 
wildtype Mnk2a were then examined. Mnk2a [S74A] phosphorylation still increased in 
response to rapamycin (Fig. 3.10A). The Mnk2a[S437A] mutant showed higher basal 
activity, in autophosphorylation and against eIF4E, than WT Mnk2a. Importantly, Mnk2a 
[S437A] autophosphorylation was not further increased by rapamycin (Fig. 3.10B, C). This 
suggests that Mnk2a is normally phosphorylated at this site impairing Mnk2a activity 
whereas rapamycin causes its dephosphorylation and a subsequent increase in activity.  It 
is possible that mTORC1 inhibition may result in the activation of a phosphatase that 
specifically dephosphorylates Ser
437 on Mnk2a or that mTORC1 is responsible for the 
phosphorylation of this site.    
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Figure 3.10 Rapamycin increases Mnk2a activity through one site Ser437. A) PC3 cells 
transfected  with  a  vector  for  HA-Mnk2a  or  a  S74A  mutant  and  treated  with  100nM 
rapamycin  for  2h.  After  HA  immunoprecipitation,  Mnk  activity  was  assayed;  the  figure 
shows an autoradiograph of the stained gel.
  Western blots of HA input and p-Mnk are 
shown below the main panel. B) PC3 cells transfected with a vector for HA-Mnk2a or a 
S437A mutant and treated with 100nM rapamycin for 2h. After HA immunoprecipitation, 
Mnk activity was assayed; the figure shows an autoradiograph of the stained gel.
  Western 
blots of HA input and p-Mnk are shown below the main panel. C) Graphical representation 
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of 
32P incorporation into Mnk2a or Mnk2a[Ser437Ala] normalised to HA input. Bands were 
quantified by densitometry using ImageJ and the Licor Odyssey software, respectively. 
Student’s  t-test  was  used  to  analyse  the  data,  *  indicates  p<0.05  compared  to  WT 
control.   
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3.2.3 mTORC1 inhibition increases eIF4G/Mnk2 binding but not p-ERK/Mnk2 
binding.  
Evidence presented here has shown that Mnk2a activity increases with rapamycin and 
PP242 treatment in a mechanism dependent on the phosphorylation of Ser
437 (Fig. 3.10B, 
C). These data were assessed in vitro and in the absence of eIF4G resulting in a 
requirement for excess Mnk2a and eIF4E. In vivo, Mnk2a requires eIF4G to act as a 
scaffold in order to efficiently phosphorylate eIF4E [72].   It was therefore important to test 
if mTOR inhibitors had any effect on the interaction between Mnk2a and eIF4G. HA-
tagged Mnk2a was overexpressed in PC3 cells, which were treated either with rapamycin 
or PP242. Cells were then lysed in a low salt buffer in order to retain Mnk2/eIF4G binding, 
which is mediated by three lysines in the N-terminus of Mnk2a [87]. Endogenous eIF4G 
was immunoprecipitated and then HA-Mnk2a binding was assessed by blotting for the HA 
tag on Mnk2a. This revealed that rapamycin and PP242 each caused a significant 
increase in eIF4G-Mnk2a binding (fig. 3.11A, B).  
Ser
437 is next to the MAPK binding site (Table 3.1) in Mnk2a raising the possibility that this 
site may alter p-ERK/Mnk2 binding, which is thought to be important for the high basal 
activity of Mnk2 [72]. In order to test if rapamycin or PP242 changes in p-ERK/Mnk2 
binding, within the context of the complex of Mnk2 and eIF4G, eIF4G 
immunoprecipitations were probed for p-ERK. This revealed that there was no discernible 
change in p-ERK/Mnk2 binding (Fig. 3.11A, C). Immunoprecipitates of HA-Mnk2a were 
also probed for p-ERK but no p-ERK was seen (data not shown) presumably because 
these samples were washed in LiCl, which would disrupt p-ERK/Mnk2 binding, further 
indicating that rapamycin and the site Ser
437 do not alter p-ERK/Mnk2 binding. The role of 
Ser
437 may be linked to a conformational change in the N-terminus of Mnk2 altering its 
activity as was demonstrated for other sites in the C-terminus [72].        
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Figure 3.11 Effect of rapamycin on Mnk2-eIF4G-p-ERK binding. A) Western blot analysis 
of HA-Mnk2a binding to phospho-ERK Thr
202/Tyr
204 and endogenous immunoprecipitated 
eIF4G. B) Graphical representation of the ratio HA-Mnk2a to eIF4G input. Bands were 
quantified by densitometry using the Licor Odyssey software. Student’s t-test was used to 
analyse the data, * indicates p<0.05 compared to control, t indicates p<0.1 compared to 
control.  C)  Graphical  representation  of  the  ratio  HA-Mnk2a  to  p-ERK.  Bands  were 
quantified by densitometry using the Licor Odyssey software.    
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Table 3.1. Sequences of human and mouse Mnk2. The residues whose phosphorylation 
was  altered  by  rapamycin  are  highlighted  in  red  and  the  MAP  kinase-binding  motif  is 
highlighted in green. The threonine residues in the activation loop that are phosphorylated 
by MAP kinases are shown in blue. 
   
Human Mnk2a 
    1 MVQKKPAELQGFHRSFKGQNPFELAFSLDQPDHGDSDFGLQCSARPDMPASQPIDIPDAK 
  61 KRGKKKKRGRATDSFSGRFEDVYQLQEDVLGEGAHARVQTCINLITSQEYAVKIIEKQPG 
121 HIRSRVFREVEMLYQCQGHRNVLELIEFFEEEDRFYLVFEKMRGGSILSHIHKRRHFNEL 
181 EASVVVQDVASALDFLHNKGIAHRDLKPENILCEHPNQVSPVKICDFDLGSGIKLNGDCS 
241 PISTPELLTPCGSAEYMAPEVVEAFSEEASIYDKRCDLWSLGVILYILLSGYPPFVGRCG 
301 SDCGWDRGEACPACQNMLFESIQEGKYEFPDKDWAHISCAAKDLISKLLVRDAKQRLSAA 
361 QVLQHPWVQGCAPENTLPTPMVLQRNSCAKDLTSFAAEAIAMNRQLAQHDEDLAEEEAAG 
421 QGQPVLVRATSRCLQLSPPSQSKLAQRRQRASLSSAPVVLVGDHA 
Mouse Mnk2 
  1 MVQKRTAELQGFHRSFKGQNPFELAFSLDLAQHRDSDFSPQCEARPDMPSSQPIDIPDAK 
  61 KRGRKKKRCRATDSFSGRFEDVYQLQEDVLGEGAHARVQTCVNLITNQEYAVKIIEKQLG 
121 HIRSRVFREVEMLYQCQGHRNVLELIEFFEEEDRFYLVFEKMRGGSILSHIHRRRHFNEL 
181 EASVVVQDVASALDFLHNKGIAHRDLKPENILCEHPNQVSPVKICDFDLGSGIKLNGDCS 
241 PISTPELLTPCGSAEYMAPEVVEAFSEEASIYDKRCDLWSLGVILYILLSGYPPFVGHCG 
301 SDCGWDRGEACPACQNMLFESIQEGKYEFPDKDWSHISFAAKDLISKLLVRDAKQRLSAA 
361 VLQHPWVQGCAPENTLPTPLVLQRNSCAKDLTSFAAEAIAMNRQLAQCEEDAGQDQPVV 
421 IRATSRCLQLSPPSQSKLAQRRQRASLSATPVVLVGDRA  - 118 - 
3.2.4 Mnk2 positively regulates mTORC1 activity.  
Here it has been shown that rapamycin is able to induce eIF4E phosphorylation as a 
result of changes in phosphorylation of a potential regulatory site Ser
437 in Mnk2a, leading 
to increased activity of Mnk2a. Furthermore, rapamycin also increases Mnk2/eIF4G 
binding, which may also contribute to the increased phosphorylation of eIF4E seen in the 
cell. Attempts to determine the mechanism by which this occurs have been complex, PI3K 
appears to have a role whilst PKB is not involved. Research published last year showed 
that Mnk2 regulated the phosphorylation of Ser
1108 on eIF4G in a mechanism related to 
serine-arginine-rich kinases (SRPK) and to mTORC1 activity [96]. The data presented in 
this article showed that Mnk2 is upstream of SRPK1 and suggest SPRK1 may 
phosphorylate Ser
1108 (although they show no direct evidence for this). The 
phosphorylation of Ser
1108 is decreased by rapamycin and alleviated by the knockdown of 
Mnk2, which suggests rapamycin causes an alteration to Mnk2 activity and therefore 
towards SRPK1 [96]. This represents a similar situation seen with rapamycin-induced 
eIF4E phosphorylation. During investigations into the mechanism of eIF4G 
phosphorylation the authors reported reduced p70S6K1 phosphorylation in the presence 
of Mnk2 overexpression. This would indicate that Mnk2 has an inhibitory influence on 
mTORC1 activity, which the authors suggest was due to an association between Mnk2 
and raptor [96]. To determine if this was related to the increase in Mnk2 activity presented 
here, HA-tagged Mnk2a was overexpressed followed by either mTOR (mTORC1 and 
mTORC2), raptor or HA immunoprecipitation and western blotting for raptor and HA. This 
revealed that Mnk2a was associated with raptor, and thus mTOR, as judged by the 
presence of HA-Mnk2a in both mTOR and raptor immunoprecipitates and the presence of 
raptor in HA immunoprecipitates (Fig. 3.12A). To determine if Mnk2 affected mTORC1 
activity as suggested by the reduction in p70S6K1 phosphorylation shown in [96], active 
purified Mnk2a was added to an mTORC1 kinase assay with 4E-BP1 as the substrate. 
This showed that Mnk2a actually enhanced mTORC1 activity towards 4E-BP1 (Fig. 
3.12B), which is contrary to what was expected based on the available literature [96]. 
These data also do not help the understanding of the mechanism underlying rapamycin-
induced increases in Mnk2 activity. This finding may represent a possible feedback 
mechanism of mTORC1 activity. Mnk2a activity is increased through reduced 
phosphorylation of Ser437 by mTORC1 inhibition resulting in increased Mnk2a activity. 
Mnk2a may then phosphorylate raptor and restore mTORC1 activity. This needs to be 
repeated and investigated further to determine if in fact raptor is a substrate of Mnk2.          
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Figure 3.12 Effect of Mnk2 on mTORC1 activity. A) Extracts of HEK-293 cells expressing 
HA-Mnk2a were immunoprecipitated with anti-mTOR, Raptor or HA, run on SDS-PA gels 
and blotted for Raptor or HA overnight. n=1. B) PC3 cell extracts were immunoprecipitated 
for  Raptor  and  then  incubated  with  1μg  recombinant  GST-4E-BP1,  +/-  200ng  Mnk2a, 
100µM ATP and 1µCi [γ-
32P]ATP for 20min at 30°C. Samples were subjected to SDS-
PAGE and then incubated with a phospho-imager screen overnight. n=1      
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3.3 Discussion 
The deregulation of the PI3 kinase/PKB pathway is a common event in many cancers and 
leads to an aggressive phenotype. It is important to understand the signalling events that 
lead to this. Indeed, this is central to the production of effective and non-toxic therapies. It 
is widely agreed that the Mnks are a viable drug target because Mnk1/2 DKO mice do not 
show an overt phenotype [45]. Furthermore, animal models of lymphoma and 
glioblastoma, treated with Mnk inhibitors or knockout of the Mnks, show significantly better 
prognosis and resistance to recurring tumours [78]. However, it remains to be clearly 
established the mRNAs whose translation is altered by eIF4E phosphorylation.  
Some of the data presented here agree with published findings; i) rapamycin does 
increase phosphorylation of eIF4E, ii) this effect appears independent of changes in 
binding of eIF4G and 4E-BP1 to eIF4E; iii) changes in phosphorylation of ERK is not 
involved in rapamycin-induced eIF4E phosphorylation. Previous studies have shown that 
rapamycin can increase phosphorylation of eIF4E in a PI3 kinase-dependent fashion [29, 
31]. In both reports, the authors suggest this pathway is independent of changes in ERK. 
However, they disagree on the role of PKB. Those studies used different cancer cell lines, 
which could explain the differences seen. In agreement with previous work, this study 
shows eIF4E phosphorylation increases in PC3 prostate cancer cells when treated with 
rapamycin, an effect that is reduced when the PI3 kinase inhibitor LY294002 is added in 
combination with rapamycin. This correlates with data that show the loss of the regulatory 
p85ʱ subunit of PI3 kinase also blocks rapamycin-induced eIF4E phosphorylation [31]. 
Rapamycin-induced eIF4E phosphorylation is also decreased with a combination of the 
PI3 kinase p110β inhibitor TGX-221 and the p110ʱ inhibitor PI3-KʱVIII. This suggests that 
both the p110ʱ and p110β isoforms of PI3K are responsible for the effect of rapamycin 
probably because PC3 cells express three of the p110 isoforms: ʱ, β and γ [270]. Since 
TGX-221 only inhibits the β isoform and PI3-KʱVIII only inhibits the ʱ isoform, it is 
possible that the other isoform can compensate when one is inhibited. These data also 
suggest the p110γ isoform is not involved, which may be because its expression is much 
lower than the other isoforms in PC3 cells and therefore cannot compensate when both 
p110ʱ and p110β are inhibited [270].   
The mechanism by which rapamycin leads to increased eIF4E phosphorylation was not 
understood and it was therefore of interest to determine how this occurs. Evidence 
presented here shows that rapamycin increases eIF4G/eIF4E binding, although not 
significantly, whilst slightly increasing 4E-BP1/eIF4E binding. This does not follow the 
conventional model such that it would be expected rapamycin would have a similar affect - 121 -   
as that seen with PP242. The data for PP242 are in line with expectations, by showing a 
decrease in eIF4G/eIF4E binding, an increase in 4E-BP1/eIF4E binding and decreased 
eIF4E phosphorylation. However, the data presented here show the combination of 
rapamycin and TGX-221 significantly decreases eIF4G/eIF4E binding and increases 4E-
BP1/eIF4E binding without affecting rapamycin-induced eIF4E phosphorylation. 
Furthermore, LY294002 does not significantly decrease eIF4G binding to eIF4E but doe 
cause a decrease in eIF4E phosphorylation. This would suggest the changes in 
eIF4G/eIF4E and 4E-BP1/eIF4E binding do not explain the changes in eIF4E 
phosphorylation. Some interesting data came from assessing the eIF4G/eIF4E binding in 
Mnk single KO cells. The single KO of Mnk1 leads to a significant decrease in 
eIF4G/eIF4E binding whereas loss of Mnk2 results in the opposite, increased 
eIF4G/eIF4E binding. It is possible that Mnk2 negatively regulates eIF4G/eIF4E binding, 
whilst Mnk1 positively regulates binding. In the wildtype and single Mnk-KO cells 
rapamycin causes a decrease in eIF4G/eIF4E binding, whereas in PC3 cells there is an 
increase. The decrease in eIF4G/eIF4E binding in wildtype MEFs in response to 
rapamycin is in line with the model that mTORC1 inhibition increases 4E-BP1/eIF4E 
binding, therefore resulting in a dissociation of eIF4G from eIF4E [271, 272]. PC3 cells are 
cancer cells so will exhibit characteristics that differ from normal cells; increased 
eIF4G/eIF4E binding in response to rapamycin could be a resistance mechanism to 
overcome mTORC1 inhibition.     
The role of PKB in rapamycin-induced eIF4E phosphorylation is not clear based on the 
available literature. The PTEN null status of PC3 cells is associated with low basal levels 
of eIF4E phosphorylation whilst DU145 prostate cancer cells express PTEN and show 
high levels of basal eIF4E phosphorylation[29]. This suggests that inhibiting PKB leads to 
increased eIF4E phosphorylation. Published data show PKB knockdown, by siRNA, 
increases eIF4E phosphorylation in apparent contradiction to the evidence that knockout 
of the regulatory p85ʱ PI3 kinase subunit decreases eIF4E phosphorylation [31]. In 
contrast to this there is evidence, in MCF7 cells and DU145 cells, that rapamycin 
promotes activation of PKB, as illustrated by measurements of PKB activity[29]. The 
authors of this study [29] also suggest the p70S6K and IRS1 feedback loop is responsible 
for stimulation of PI3 kinase [266]. In some instances, the evidence in this study conflicts 
with previous work, which has shown rapamycin-induced eIF4E phosphorylation is related 
to PKB activation [266]. This report implies that PKB does not have a role in the increased 
phosphorylation of eIF4E seen in response to rapamycin. The data here show 
phosphorylation of Ser
473 and Thr
308 increases with rapamycin treatment; however 
rapamycin combined with TGX-221 results in a decrease in Ser
473 and Thr
308 
phosphorylation whilst this is not the case for eIF4E phosphorylation. To further 
investigate this an inhibitor of PKB was employed, Akti1/2, which blocked rapamycin-- 122 - 
induced eIF4E phosphorylation; however PMA also decreased Thr
308 phosphorylation 
without a concomitant decrease in eIF4E phosphorylation. Phosphorylation of the T-loop 
in Mnk2a does not increase with rapamycin but when combined with Akti1/2 there is a 
trend towards decreased T-loop phosphorylation. This suggests that the decreased eIF4E 
phosphorylation in cells treated with rapamycin and Akti1/2 is caused by reduced Mnk2 T-
loop phosphorylation and is not related to the mechanism by which rapamycin increases 
Mnk2 activity. Therefore, in PC3 cells, there is more evidence to support a role for PKB in 
rapamycin-induced eIF4E phosphorylation.   
From earlier studies and data presented in this report, it seems there is little evidence for 
changes to ERK in the phenomenon of rapamycin-induced eIF4E phosphorylation. 
Interestingly, this supports the idea that Mnk1 is not involved, since this is the isoform 
activated by ERK. One report indicates the p38MAPK pathway is involved and suggests 
both ERK and p38MAPK must be inhibited but they do not show the data [29]. Further 
supporting this are published data from Mnk1-KO, Mnk2-KO and DKO MEFs, which show 
both isoforms must be lost to block rapamycin-induced eIF4E phosphorylation [31], this is 
not surprising since the Mnks are the only eIF4E kinases [45]. This is hard to explain 
because Mnk1 has very low basal activity whilst Mnk2 has high basal activity; if Mnk1 
alone was responsible then eIF4E phosphorylation in response to rapamycin would 
require either ERK or p38MAPK activation, which has not been shown to occur. The data 
here clearly show that Mnk2 is responsible for the increased phosphorylation of eIF4E in 
response to rapamycin because, as demonstrated, rapamycin does not induce eIF4E 
phosphorylation in Mnk2-KO cells, whilst in the wildtype cells and Mnk1-KO cells 
rapamycin elicits a similar response to that seen with PMA. A similar effect is seen in PC3 
cells treated with siRNA against either Mnk1 or Mnk2 where the data show that only the 
knockdown of Mnk2 prevents rapamycin-induced eIF4E phosphorylation.   
The mechanism by which rapamycin increases eIF4E phosphorylation is related to an 
increase in Mnk2a activity likely caused by decreased phosphorylation of Ser
437. This site 
is next to the MAP kinase-binding motif but it seems that changes in Mnk2a activity are 
not due to alterations in the phosphorylation of the T-loop by ERK, because rapamycin 
does not affect T-loop phosphorylation and there is no change in p-ERK/Mnk2 binding in 
response to mTORC1 inhibition. Dephosphorylation of Ser
437 may alter the overall 
conformation of Mnk2a leading to higher intrinsic activity, since the C-terminus of Mnk2a 
alters the accessibility of the N-terminus of the protein [72]. The basis of the effect of this 
site on Mnk2a activity requires further investigation. The nature of the pathway that may 
result in dephosphorylation of Ser
437 in response to rapamycin also requires future 
experiments, perhaps in relation to phosphatase activity. Mnk2 activity is linked to - 123 -   
eIF4G/Mnk2 binding and here rapamycin and PP242 result in increased eIF4G/Mnk2 
binding. However, it has been shown that kinase dead Mnk2 showed greater association 
with eIF4G suggesting that Mnk2 activity is inversely correlated with eIF4G binding [72]. 
This is clearly not the situation here and the increased phosphorylation of eIF4E in 
response to rapamycin is associated with increased Mnk2 activity and Mnk2/eIF4G 
binding.  
Interestingly, it also appears that raptor is a substrate for Mnk2a as there is an association 
between Mnk2a and raptor along with increased activity towards 4E-BP1 in the presence 
of Mnk2. These data do need repeating but may represent a novel feedback mechanism 
of mTORC1 activity in response to its inhibition. mTORC1 inhibition results in increased 
Mnk2a activity, which may result in increased phosphorylation of raptor and Mnk2a-
dependent increases in mTORC1 activity. This is not a desirable situation when 
considering the use of rapalogs as anti-cancer agents.  
These data further support the potential value of combined mTORC1 and Mnk inhibition in 
those cancers that do not respond well to inhibition of mTOR alone. The data presented 
here represents a potential resistance mechanism employed by cancers in response to 
mTOR inhibitors.   
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Chapter 4 
The Mnks Regulate Insulin Signalling. 
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4.1 Introduction 
The roles of the Mnks are still poorly understood even 15 years since their discovery and 
only a few substrates, other than eIF4E have been identified [41, 42, 74]. The research 
conducted on the Mnks has mostly focused on their tumorigenic potential in relation to 
eIF4E phosphorylation (reviewed [40, 79, 276]) [77, 78, 262, 277-279]. Other data 
available for the Mnks concerns their regulation of inflammatory signalling pathways and 
the expression of inflammatory cytokines [41-44, 81, 280-283].  
The roles of the Mnks in other physiological systems has not yet been investigated within 
the literature but there are a couple of patents linking the Mnks to glucose and lipid 
metabolism [106, 228]. The evidence presented in one of these patents suggested that 
Mnk inhibitors caused an improved glucose profile. Treatment of WT mice with an Mnk2 
inhibitor reduced blood glucose levels over 12 days of treatment [106]. The Mnk2 inhibitor 
(termed compound 15) was presented with little evidence to show its specificity and there 
are currently no other Mnk2 specific inhibitors available. Compound 15 also showed a 
similar efficacy in an insulin tolerance test compared to the PPARγ agonist rosiglitazone 
[106], which is being phased out as an antidiabetic drug [284]. The other data within this 
patent show compound 15 causes an increase in pancreatic insulin, although plasma 
insulin levels did not change [106]. Data from the other patent relating to the Mnks is more 
concerned with the treatment of obesity; however the authors did present expression data 
for the Mnks [228]. This revealed that Mnk1 is highly expressed in the lungs, spleen and 
muscle whilst Mnk2 is highly expressed in both white and brown adipose tissue and 
skeletal muscle [228]. When considering the data from both patents, it is clear there may 
be a role for the Mnks in glucose metabolism since Mnk inhibitors have a beneficial effect 
on insulin sensitivity and both Mnks are expressed in tissues related to glucose 
metabolism.  
The aim of this chapter was to investigate whether the Mnks do indeed have a role in 
glucose metabolism and insulin signalling and if so to establish the mechanism by which 
the Mnks may do so. - 126 - 
4.2 Results 
4.2.1 The Mnks are enriched in tissues related to glucose metabolism. 
The expression of the Mnks has previously been shown by northern blot analysis to be 
ubiquitous and levels of both Mnks were highest in skeletal muscle [39]. However this 
panel did not include many tissues related to glucose metabolism so it was important to 
use a panel of tissues that included the pancreas and fat deposits. The expression of 
Mnk1 protein is greatest in the pancreas with high levels in the skeletal muscle, spleen 
and abdominal adipose when compared to the brain (Fig. 4.1A). Interestingly there are 
band shifts for Mnk1 in some tissues, this may denote altered phosphorylation states or 
isoforms and would be of interest to research further. The loading control GAPDH does 
show reduced expression in the pancreas and this was observed consistently across each 
mouse (n=3). Unfortunately, the only specific antibody available for Mnk2 does not work in 
tissue samples and so, instead, qPCR was used to assess the mRNA levels of Mnk2. 
Interestingly the expression of Mnk2 mRNA is almost non-existent in the pancreas (Fig. 
4.1B), whilst the converse is true for Mnk1, which suggests Mnk1 has a key role in the 
pancreas. The expression of Mnk2 mRNA is greatest in abdominal adipose and scapular 
adipose with high levels also observed in the kidney (Fig. 4.1B). This would indicate that 
Mnk2 may have some important role in adipose tissue. The presence of both Mnks in 
tissues related to glucose metabolism would indicate the potential for a role of the Mnks in 
signalling pathways related to metabolism.  
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Figure 4.1. Expression of Mnk1 and Mnk2 in different mouse tissues. A) Western Blot 
analysis for Mnk1 in various tissues; 40μg of protein from each tissue were analysed. Fat-
G and Fat-S represent abdominal adipose and scapular  adipose respectively.  GAPDH 
was used as a loading control. B) RT-qPCR analysis for Mnk2 mRNA levels; data are 
normalised to 18S mRNA and compared to levels in the spleen.  
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4.2.2 PKB phosphorylation and activity is regulated by the Mnks.  
The data presented in patents related to the Mnks suggests they may play a role in insulin 
sensitivity [106, 228]. Furthermore there are high levels of the Mnks in insulin responsive 
tissues; however the data presented in these patents were conflicting as to whether Mnks 
play a positive or negative role in glucose metabolism. One of the most important targets 
of insulin signalling and a major starting point of multiple anabolic pathways is PKB, which 
is activated through phosphorylation at two sites; Ser
473 and Thr
308 [24]. It is an essential 
step in the initiation of glucose uptake by the cell and so represents a good indicator of 
insulin sensitivity [285]. 
The knockout of Mnk1 leads to a considerable impairment in the insulin induced 
phosphorylation of both sites (Ser
473 and Thr
308), in PKB, compared to WT MEFs (Fig. 
4.2A). In Mnk1-KO cells, there is overall reduction in phosphorylation of the site Ser
473, 
whereas the Thr
308 shows delayed as well as lower phosphorylation compared to WT cells 
(Fig. 4.2A). The impairment is especially evident during insulin stimulation between 5-
20min. These data suggest that Mnk1 has a positive effect on PKB phosphorylation, 
which in turn has a positive effect on PKB activity. The effect of insulin on PKB activity in 
Mnk1-KO MEFs was significantly lower at the 15min time point and there was a trend 
towards lower activity of PKB at 30min but returned to near normal levels after 45min (Fig. 
4.2B). This is consistent with phosphorylation of the Thr
308 site (the most important one for 
PKB activity [286]). This indicates that Mnk1 function is required for efficient activation of 
PKB following stimulation by insulin but is not required for generating a full response to 
insulin.   
The Mnk2-KO MEFs show a difference at both phosphorylation sites compared to the WT 
MEFs after insulin stimulation but are not different at basal levels (Fig. 4.2C). Both 
phosphorylation sites exhibit a major deficit in the response to insulin in Mnk2-KO MEFs 
(Fig. 4.2C). These data suggest that Mnk2 is necessary for normal and efficient 
phosphorylation of PKB. Consistent with this the loss of Mnk2 significantly reduced the 
activity of PKB at all-time points investigated (Fig. 4.2D).    
The differing effect of Mnk1 vs Mnk2 knockout is likely due to their differing activities; 
Mnk2 has higher levels of activity than Mnk1 [72] and so Mnk2 knockout has a greater 
effect on PKB phosphorylation and activity. Based on this evidence it was important to 
assess PKB phosphorylation in Mnk1/2DKO MEFs. The DKO MEFs show significantly 
lower levels of insulin-stimulated phosphorylation at both sites compared to the WT MEFs - 129 -   
and exhibit lower basal levels for the Ser
473 site (Fig. 4.2E). Phosphorylation of the Ser
473 
site is lower at all time-points after insulin stimulation, which is expected because loss of 
just Mnk1 or Mnk2 results in decreased phosphorylation at this site (Fig. 4.2A, C). The 
results for Thr
308 phosphorylation indicate lower basal levels and an inability to increase 
phosphorylation to similar levels as in the WT cells at the later time points after insulin 
stimulation (Fig. 4.2E). This is again expected because loss of Mnk2 had a strong effect 
on Thr
308 phosphorylation (Fig. 4.2C), whilst loss of Mnk1 only affects the early levels of 
phosphorylation after insulin stimulation (Fig. 4.2A).  
The PKB activity data show a significant reduction in PKB activation, whereby the DKO 
cells exhibit 65% lower activity than the WT cells (Fig. 4.2F). This suggests that, in the 
Mnk2-KO cells, Mnk1 does not rescue PKB activity, whereas the loss of Mnk1 may be 
rescued by Mnk2 to some extent. Consistent with this the loss of both Mnks means there 
is no remaining Mnk to compensate and in DKO cells the levels of activity are the lowest 
when compared to the WT cells, although the reduction in activity is very similar to that in 
Mnk2-KO cells indicating Mnk2 is the predominant isoform required for normal PKB 
activation in response to insulin.  
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Figure. 4.2. Effects of insulin on PKB phosphorylation and activity in WT and Mnk 
knockout MEFs. A) Western blot analysis of total PKB, p-PKB Ser
473 and p-PKB Thr
308 
over 45 min of insulin treatment in immortalised WT and Mnk1KO cells B) Effect of insulin 
on PKB activity over 45 min in immortalised WT and Mnk1KO MEFs. Cellular extracts 
were subjected to immunoprecipitation using an anti-PKBʱ antibody for 1h followed by 
incubation with Crosstide peptide and 1µCi [-
32P]ATP. Radioactivity was measured using 
the Čerenkov method. Student’s t-test was used to analyse significance by comparison of 
each respective time point for WT and Mnk knock-out. * indicates significance at p<0.05. 
C) Western blot analysis of total PKB, p-PKB Ser
473 and p-PKB Thr
308 over 45 min of 
insulin treatment in primary WT and Mnk2KO cells. D) Effect of insulin on PKB activity 
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over 45 min in primary WT and Mnk2KO MEFs. Cellular extracts were analysed as 
described in B. Student’s t-test was used to analyse significance by comparison of each 
respective time point for WT and Mnk knock-out. * indicates significance at p<0.05. E) 
Western blot analysis of total PKB, p-PKB Ser
473 and p-PKB Thr
308 over 45 min of insulin 
treatment in immortalised WT and Mnk1/2DKO cells F) Effect of insulin on PKB activity 
over 45 min in immortalised WT and Mnk1/2DKO MEFs. Cellular extracts were analysed 
as described in B. Student’s t-test was used to analyse significance by comparison of 
each respective time point for WT and Mnk knock-out. * indicates significance at p<0.05.  
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4.2.3 Assessment of components of the insulin signalling cascade.  
The effect of insulin involves numerous downstream pathways that control glucose 
uptake, cell survival, cell cycle progression, protein synthesis and other processes (as 
discussed in Chapter 1, sections 1.5.3 and 1.6.4). As discussed in the previous section, 
knockout of the Mnks results in a reduction in insulin-induced PKB phosphorylation and 
activation, which suggests that signalling downstream of PKB should also be affected. It 
was therefore important to study the contribution of each Mnk alone and of both to targets 
of PKB signalling.    
 
4.2.3.1 Mnk1 knockout alters downstream PKB signalling.  
A major downstream pathway activated by PKB is the mTORC1 pathway. The tuberous 
sclerosis complex (TSC1/2), which inhibits mTORC1 signalling is phosphorylated at Ser
939 
and Thr
1462 (TSC2) and inactivated by PKB leading to mTORC1 stimulation [287, 288]. 
Other controversial evidence shows that PKB can control mTORC1 activation by 
phosphorylation of PRAS40 at Thr
246, which results in further phosphorylation by 
mTORC1 at Ser
183 and Ser
221 This leads to the dissociation of PRAS40 from mTORC1 
and the subsequent removal of the inhibitory influence of PRAS40 [22, 25, 289]. Once 
activated, mTORC1 has numerous substrates one of which is 4E-BP1. mTORC1 
phosphorylates a number of sites on 4E-BP1 including Thr
37 and Thr
46, which are priming 
sites for Ser
65 and Thr
70 [290]. Insulin stimulation results in the phosphorylation of Ser
65 
and Thr
70 by mTORC1.  mTORC1 also phosphorylates S6 kinase (S6K), of which there 
are four isoforms; p70S6K ʱ1 & ʱ2 and p70S6K β1 & β2 [291], where the former are 
known as S6K1 and the latter S6K2. Activation of S6Ks occurs through their 
phosphorylation by mTORC1. This leads to phosphorylation of S6K substrates, which 
include the ribosomal protein S6 whose phosphorylation at Ser
240/244 acts as a readout of 
S6K activity.   
The data show changes in the pattern of insulin-stimulated TSC2 phosphorylation at 
Thr
1462 in Mnk1-KO cells. There are early increases in phosphorylation in Mnk1-KO MEFs, 
which occurs as rapidly as 2-5min after insulin stimulation, whilst in WT cells 
phosphorylation is lower in comparison (Fig. 4.3A). In WT cells the highest levels of 
phosphorylation occur at 20-30min, which is not seen in Mnk1-KO cells where the 
phosphorylation is lower. This suggests the lower insulin-induced PKB activity in Mnk1-KO 
cells has an effect on the pattern of TSC2 phosphorylation by PKB.  - 133 -   
Insulin rapidly induces phosphorylation of PRAS40 on Thr
246 with phosphorylation being 
seen by 2min of insulin treatment and being sustained for all times looked at in WT cells 
(Fig. 4.3A). This is not the case in Mnk1-KO cells where there is distinctly lower levels of 
phosphorylation in response to insulin, which would suggest that the deficit in early PKB 
activity has a major effect on PRAS40 phosphorylation.   
The total 4E-BP1 blot (Fig. 4.3A) shows three bands, which indicate the extent of 4E-BP1 
phosphorylation, the lowest, ʱ, band contains unphosphorylated 4E-BP1, the middle, β, 
band contains 4E-BP1 phosphorylated at Thr
36, Thr
45 and Thr
69 (humans Thr
37 and Thr
46 
Thr
70) whilst the highest, γ, band contains 4E-BP1 phosphorylated at all four sites (i.e. 
including Ser
64 in humans Ser
65). In serum starved WT MEFs, all of the 4E-BP1 is found in 
the β and γ forms and after 10min of insulin treatment the majority of 4E-BP1 is found in 
the most phosphorylated γ form (Fig. 4.3A). This is consistent with the behaviour of the 
Ser
64 site, which shows increased phosphorylation between 10-20min after insulin 
treatment (fig 4.3A). In Mnk1-KO cells there is more 4E-BP1 in the lowest ʱ form basally 
and up until 10min after insulin treatment after which an increased proportion is in the γ 
form (Fig. 4.3A).  
The phosphorylation of S6 on Ser
240/244 acts as a readout of S6K activity and therefore 
mTORC1 activation. The results show no obvious difference between WT and Mnk1-KO 
cells, with S6 phosphorylation increasing 20min after insulin stimulation in both types of 
cell (Fig. 4.3A). These data overall indicate the altered TSC2 phosphorylation and lower 
insulin-induced PRAS40 phosphorylation only affects 4E-BP1 and not S6K/S6 in Mnk1-
KO cells.  
To determine if the knockout of the Mnks affected other insulin-stimulated pathways the 
phosphorylation of ERK was assessed. There is a slight temporal shift in phosphorylation 
of ERK in Mnk1-KO MEFs (Fig. 4.3B) with a peak activation of 5min compared with 10min 
in WT cells.  
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Figure. 4.3. Effect of insulin on the phosphorylation of selected proteins in immortalised 
WT and Mnk1KO cells. Cells were seeded in 6 cm plates and at 70-80% confluence were 
starved of serum overnight, followed by treatment with insulin for the times indicated. A) 
Western blot analysis for total TSC2 and p-TSC2 Thr
1462 and total PRAS40 and p-PRAS40 
Thr
246, total 4E-BP1, p-4E-BP1 Ser
64 total S6 and p-S6 Ser
240/244. B) Western blot analysis 
for total ERK and p-ERK Tyr
202/Thr
204. 
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4.2.3.2 Mnk2KO has specific effects on downstream PKB signalling.   
The insulin-stimulated activity of PKB was 60% lower in Mnk2-KO cells compared with WT 
(Fig. 4.2D) and so it was expected downstream signalling might be affected.  
Mnk2-KO had a clear effect on TSC2 phosphorylation, with these cells showing a 
reduction in insulin-stimulated phosphorylation compared with WT MEFs (Fig. 4.4A). A 
similar effect of Mnk2-KO was seen for insulin-stimulated PRAS40 phosphorylation, a 
clear reduction being observed in the knockout cells (Fig. 4.4A).    
The deficit in PKB activation and phosphorylation of it substrates TSC2 and PRAS40 
suggests that there should also be a reduction in phosphorylation in downstream 
mTORC1 substrates. This was not the case for 4E-BP1 phosphorylation, which showed a 
rapid increase in the proportion of the γ band in Mnk2-KO cells in response to insulin; this 
was also reflected in the phosphorylation of the Ser
64, which showed slightly elevated 
phosphorylation in response to insulin in the Mnk2-KO cells when compared to WT cells 
(Fig. 4.4A). Interestingly there was some effect of Mnk2-KO on S6 phosphorylation. In 
Mnk2-KO cells, there were reduced levels of S6 phosphorylation at basal levels as well as 
a delay in its peak phosphorylation (Fig. 4.4A). In WT cells, S6 phosphorylation began to 
increase 10min after insulin stimulation whilst this did not occur until 30min in the Mnk2-
KO cells. 
These data indicate that Mnk1 and Mnk2 have differing roles in the regulation of 
downstream mTORC1 signalling where Mnk1 only affects insulin-induced 4E-BP1 
phosphorylation and Mnk2 only affects S6 phosphorylation. 
Because Mnk2 can bind to phosphorylated ERK, which is thought to play a role in the high 
basal activity of Mnk2 [72], ERK phosphorylation was therefore also examined. Peak ERK 
phosphorylation was shifted from 5/10min to 10min in Mnk2-KO cells and was slightly 
lower (Fig. 4.4B).  
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Figure. 4.4. Effect of insulin on the phosphorylation of selected proteins in primary WT and 
Mnk2KO cells. Cells were seeded in 6 cm plates and at 70-80% confluence were starved 
of serum overnight, followed by treatment with insulin for the times indicated. A) Western 
blot analysis for total TSC2 and p-TSC2 Thr
1462 and total PRAS40 and p-PRAS40 Thr
246, 
total 4E-BP1, p-4E-BP1 Ser
64 total S6 and p-S6 Ser
240/244. B) Western blot analysis for 
total ERK and p-ERK Tyr
202/Thr
204. 
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4.2.3.3 Knockout of both Mnks greatly reduces downstream PKB signalling. 
The insulin-induced activation of PKB in Mnk1/2-DKO cells was slightly lower (Fig. 4.2E) 
than the levels seen in Mnk2-KO cells compared to WT cells (Fig. 4.2D). This suggests 
that there would be an effect on PKB substrates TSC2 and PRAS40, which was the case 
with Mnk2-KO (Fig. 4.4A) but not so much Mnk1-KO (Fig. 4.3A). Loss of both Mnks led to 
a reduction in the phosphorylation of TSC2 and PRAS40 in response to insulin (Fig. 4.5A). 
The knockout of either Mnk1 or Mnk2 had less effect on downstream mTORC1 substrates 
S6 and 4E-BP1 (figs. 4.3A, 4.4A), which appears to be an isoform specific effect. 
Therefore it was important to assess these proteins in Mnk1/2-DKO cells. This revealed 
that loss of both Mnks has a clear effect on both 4E-BP1 phosphorylation and S6 
phosphorylation (Fig. 4.5A). There was distinctly lower insulin-stimulated phosphorylation 
of Ser
64 on 4E-BP1 in Mnk1/2-DKO cells, which was reflected in the reduced levels of the 
γ species of total 4E-BP1. Similarly, S6 phosphorylation was lower at all time points in 
Mnk1/2DKO cells compared with WT cells. 
These data suggest the knockout of both Mnks cause such a sufficient reduction in PKB 
activation in response to insulin, which culminates in a reduction in direct PKB substrates 
and mTORC1 signalling.  
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Figure. 4.5. Effect of insulin on the phosphorylation of selected proteins in immortalised 
WT and Mnk1/2DKO cells. Cells were seeded in 6 cm plates and at 70-80% confluence 
were starved of serum overnight, followed by treatment with insulin for the times indicated. 
A) Western blot analysis for total TSC2 and p-TSC2 Thr
1462 and total PRAS40 and p-
PRAS40 Thr
246, total 4E-BP1, p-4E-BP1 Ser
64 total S6 and p-S6 Ser
240/244. B) Western blot 
analysis for total ERK and p-ERK Tyr
202/Thr
204. 
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 4.2.4 Investigations into glucose uptake in Mnk-KO cells.  
One of the major effects of insulin is glucose uptake, which is controlled by both PKB 
dependent and independent pathways. The data already shown suggest that knockout of 
Mnk1, Mnk2 or loss of both Mnks has a detrimental effect on insulin-stimulated PKB 
activation. Therefore it was important to see if Mnk knockout has an effect on insulin-
induced glucose uptake. In order to investigate this three different methods were used, 
AS160 phosphorylation, GLUT4 translocation visualized by confocal microscopy and 
radioactive glucose uptake. As discussed in Chapter 1, section 1.5.3, AS160 is essential 
for insulin-stimulated glucose uptake and requires phosphorylation on numerous sites by 
PKB [220, 292], therefore this was a key target to look at in Mnk knockout cells. To 
visualize the effect of Mnk knockout on GLUT4 translocation cells were transfected with 
GFP-tagged GLUT4 and stained for the plasma membrane then confocal microscopy was 
used to look for any merging of GLUT4 with the plasma membrane. Finally using 
radioactively labelled 2-deoxyglucose the uptake of glucose into cells generated a 
quantitative assessment of the effect of Mnk knockout.       
Analysis of AS160 phosphorylation showed that Mnk1-KO led to a reduction in insulin-
stimulated phosphorylation of the PKB site Thr
642 at all times (Fig. 4.6A). This suggests 
that AS160 phosphorylation is a rapid event in insulin signalling. Knockout of Mnk2 led to 
reduced insulin-stimulated phosphorylation at the 10-45min time points although total 
AS160 at 2-5min appeared slightly elevated (Fig. 4.7A). In WT MEFs there was an 
increase in AS160 phosphorylation from 10min that was sustained up until 45min.   
Following this GLUT4 translocation was assessed in unstimulated and insulin-stimulated 
WT, Mnk1-KO, Mnk2-KO and Mnk1/2-DKO MEFs. This revealed that under basal 
conditions, GLUT4 resides around the nucleus in all cell types (Figs. 4.6B, 4.7B & 4.8B), 
which indicates its localization within the trans Golgi network (TGN) [293, 294]. Insulin 
stimulation leads to GLUT4 becoming dispersed throughout the WT cell, with some 
yellowing at points around the plasma membrane, presumably indicative of insertion into 
the membrane (Fig. 4.6B, 4.7B & 4.8B). However, this was not the case in Mnk1-KO cells 
where GLUT4 remained in the TGN (Fig. 4.6B). In Mnk2-KO cells GLUT4 does disperse 
throughout the cell but the amount localizing with the plasma membrane is low in 
comparison to WT cells (Fig. 4.7B). The Mnk1/2-DKO cells exhibit no yellow after insulin 
stimulation where it appears the GLUT4 is still in vesicles in the TGN (Fig. 4.8B). 
The uptake of radioactive glucose into cells was then measured. Mnk1-KO, Mnk2-KO or 
Mnk1/2-DKO had no significant effect on basal glucose uptake (Figs. 4. 6C, 4.7B & 4.8C). 
In WT cells insulin caused a significant increase in glucose uptake, which was not seen - 141 -   
with insulin treatment in Mnk1-KO, Mnk2-KO or Mnk1/2-DKO cells (Figs. 4.6C, 4.7C & 
4.8C). These data probably reflect the reduced insulin-stimulated PKB activation of Mnk-
KO cells (Figs. 4.2B, D & F).  
. 
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Figure 4.6. Effect of insulin on glucose transport into WT and Mnk1KO cells. A) Western 
blot analysis of phospho-AS160 Thr
642 and total AS160. B) Effect of insulin (20 min) on the 
translocation  of  HA-GLUT4-GFP  to  the  membrane  in  immortalised  WT  and  Mnk1KO 
MEFs. The plasma membrane was stained with WGA tagged to Alexa-Fluor 594 and the 
nucleus with DAPI. Images were captured with a confocal microscope. C) Effect of insulin 
on  [
3H]  2-deoxyglucose  uptake  into  immortalised  WT  and  Mnk1KO  MEFs.  Glucose 
transport was assessed as described in the research design and methods Student’s t-test 
was used to analyse significance, * indicates significance at p<0.05 by comparison of 
insulin treated vs. non-treated and # indicates significance at p<0.05 for WT vs. Mnk1-KO.  
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Figure 4.7. Effect of insulin on glucose transport into WT and Mnk2KO cells. A) Western 
blot analysis of phospho-AS160 Thr
642 and total AS160. B) Effect of insulin (20 min) on the 
translocation of HA-GLUT4-GFP to the membrane in primary WT and Mnk2KO MEFs. 
The plasma membrane was stained with WGA tagged to Alexa-Fluor 594 and the nucleus 
with DAPI.  Images were captured with a confocal microscope. C) Effect of insulin on [
3H] 
2-deoxyglucose  uptake  into  primary  WT  and  Mnk2KO  MEFs.  Glucose  transport  was 
assessed as described in the research design and methods Student’s t-test was used to 
analyse significance, * indicates significance at p<0.05 by comparison of insulin treated 
vs. non-treated and # indicates significance at p<0.05 for WT vs. DKO.  
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Figure  4.8.  Effect  of  insulin  on  glucose  transport  into  WT  and  Mnk1/2DKO  cells.  A) 
Western blot analysis of phospho-AS160 Thr
642 and total AS160. B) Effect of insulin (20 
min) on the translocation of HA-GLUT4-GFP to the membrane in immortalised WT and 
DKO MEFs. The plasma membrane was stained with WGA tagged to Alexa-Fluor 594 and 
the nucleus with DAPI. Images were captured with a confocal microscope. C) Effect of 
insulin  on  [
3H]  2-deoxyglucose  uptake  into  immortalised  WT  and  Mnk1/2-DKO  MEFs. 
Glucose  transport  was  assessed  as  described  in  the  research  design  and  methods 
Student’s t-test was used to analyse significance, * indicates significance at p<0.05 by 
comparison of insulin treated vs. non-treated and # indicates significance at p<0.05 for 
WT vs. DKO.  
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4.2.5 Knockout of the Mnks causes perturbed PI3K activation. 
The data so far indicate that the Mnks positively regulate insulin signalling by acting either 
directly at the level of PKB or somewhere upstream. In order to identify the mechanism(s) 
by which the Mnks control insulin signalling, it was important to assess PI3K activity, since 
PI3K is activated in response to insulin and results in the production of PIP3, which is 
required for PKB activation [212, 213]. In order to measure PI3K activity, PI3K was 
immunoprecipitated using a pan phospho-tyrosine antibody followed by incubation with a 
phosphatidylinositol substrate and [ -
32P] ATP. The reaction products were assessed by 
thin layer chromatography. 
The insulin-stimulated activity of PI3K in Mnk1-KO cells was not significantly different from 
WT cells (Fig. 4.9A, B), which does not correlate with the lower PKB activity at only 15min 
(Fig. 4.2B). However, the error between samples is large and so makes it difficult to 
discern any effect.   
The data for Mnk2-KO cells is made complicated because there is significantly higher 
activity at basal levels when compared to WT cells. Insulin stimulation resulted in a 
decrease in PI3K activity in Mnk2-KO cells compared with an increase in activity in WT 
cells (Fig. 4.9C, D). The activity of PI3K in WT and Mnk2-KO cells 15min after insulin 
treatment (Fig. 4.9C, D) correlates with PKB activity (Fig. 4.2D). The difference in basal 
PI3K activity between WT and Mnk2-KO cells does not correlate with PKB activity and it is 
not clear why this is observed. 
The complexity of the data from single Mnk1 and Mnk2 knockout cells meant it was 
imperative to investigate Mnk1/2-DKO cells in order to determine if the Mnks regulated 
signalling upstream of PKB or between PI3K and PKB. The results show a significant 
defect in PI3K activation in response to insulin in Mnk1/2-DKO cells (Fig. 4.9E, F). This 
implies that the Mnks either act upstream of PI3K or on PI3K itself.   
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Figure 4.9. Insulin signalling is deficient in WT and Mnk-KO cells. Cells were starved of 
serum for 150 min and treated with insulin for the time shown followed by 
immunoprecipitation for phospho-tyrosine and then incorporation of [-
32P]ATP into 
phosphatidylinositol. Densitometry of the phosphorimage of the TLC plate was corrected 
for background radioactivity and normalised for protein input. A) Effects of insulin on PI3-
kinase activity in WT and Mnk1KO MEFs. B) Graphs summarising data from triplicate PI3-
kinase assay experiments. Data are given as fold incorporation of radioactivity compared 
to WT control and normalised to protein input, n = 3. Student’s t-test was used to analyse 
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significance, * indicates significance at p<0.05 for WT vs. Mnk1KO
 at each respective time 
point. C) Effects of insulin on PI 3-kinase activity in WT and Mnk2KO MEFs. D) Graphs 
summarising data from triplicate PI3K assay experiments. Data are given as fold 
incorporation of radioactivity compared to WT control and normalised to protein input, n = 
3. Student’s t-test was used to analyse significance, * indicates significance at p<0.05 for 
WT vs. Mnk2KO
 at each respective time point. E) Effects of insulin on PI 3-kinase activity 
in WT and MNK1/2-DKO MEFs. F) Graphs summarising data from triplicate PI3K assay 
experiments. Data are given as fold incorporation of radioactivity compared to WT control 
and normalised to protein input, n = 3. Student’s t-test was used to analyse significance, * 
indicates significance at p<0.05 for WT vs. MNK1/2-DKO
 at each respective time point.   - 151 -   
4.2.6 Effects of Mnk Inhibitors on 3T3-L1 Cells. 
Evidence presented so far from MEFs indicates that the Mnks have a potent role in the 
regulation of insulin signalling and are therefore required for insulin-stimulated glucose 
uptake. To determine if the Mnks also play a role in highly insulin-responsive cells, Mnk 
inhibitors were employed. The best known Mnk inhibitor is CGP57380 and affects both 
Mnks [76]. It does however inhibit a number of other kinases (PIM3, BRSK2 and CK1ʴ) 
[295] and so a new, more specific inhibitor called compound E (from Janssen) was also 
used. As previously shown the Mnks are highly expressed in abdominal adipose and so 
the adipocyte cell line 3T3-L1 was employed.  
4.2.6.1 Mnk expression in 3T3-L1 cells.  
In order to assess if the Mnks are also expressed in 3T3-L1 cells, preadipocyte 3T3-L1 
cells were incubated in differentiation media (as described Chapter 2, section 2.4.1) for 
the times shown or left undifferentiated. Western blot analysis showed that both Mnk1 and 
Mnk2 were rapidly induced by 24h (Fig. 4.10). Levels peaked at day 7 of differentiation 
and were slightly greater than those seen in MEFs and so cells were used on the 7
th or 8
th 
day after differentiation began. 
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Figure 4.10. Expression of Mnk1 and Mnk2 in differentiated 3T3-L1 cells. Western Blot 
analysis for Mnk1 and Mnk2, cells were incubated in differentiation medium for the time 
indicated, control cells were undifferentiated and kept in maintenance medium. Mnk1KO 
and Mnk2KO are samples from knockout MEFs.    
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4.2.6.2 Effect of Mnk inhibition on PKB and PI3K activity. 
Data from Mnk knockout cells revealed that loss of the Mnks leads to a reduction in 
insulin-stimulated PKB and PI3K activity. Western blot analysis of PKB phosphorylation 
revealed that treating cells with CGP57380 decreased the initial insulin-induced 
phosphorylation of Ser
473 whilst after 20min levels were similar between samples (Fig. 
4.11A). The phosphorylation of PKB at Thr
308 was reduced at 5min and 20min after insulin 
stimulation in samples from CGP57380 treated cells. Insulin increased PKB activity 
around 12 fold at both 15min and 30min (Fig. 4.11B). This effect was significantly reduced 
in cells treated with compound E at the 30min time point, whilst CGP57380 reduced 
insulin-stimulated PKB activity at both the 15min and 30min time points (Fig. 4.11B). 
Compound E also exhibited a trend towards reduced PI3K activity in response to insulin 
whilst CGP57380 only had a marginal effect (Fig. 4.11C, D). 
This data indicated that Mnk inhibition had a negative effect on insulin stimulated 
signalling particularly in the case of PKB. Importantly this supports the conclusion that the 
Mnks promote acute effects of insulin.  
Inhibition of the Mnks has shown a negative effect on insulin-induced PKB activation, it 
was therefore relevant to study downstream targets of PKB. CGP57380 had little effect on 
TSC2 phosphorylation in response to insulin, although this was decreased at the 5min 
and 10min time points (Fig. 4.12A). A similar pattern was seen for PRAS40 with lower 
insulin-stimulated phosphorylation at 5min and 30min in the presence of CGP57380. 
Interestingly S6 phosphorylation was already high at basal levels and did not increase 
much with insulin treatment; however CGP57380 reduced S6 phosphorylation 5min and 
10min after insulin treatment as well as under basal conditions (Fig. 4.12A). This makes 
the data hard to interpret, it is possible this observation is an off target effect of CGP57380 
on S6K. The 4E-BP1 data shows CGP57380 reduces the shift from the β to γ form at 
5min after insulin treatment as well as reduced Ser
64 phosphorylation at 20 and 30min 
(Fig. 4.12A). These data indicate inhibition of the Mnks does have some effect on 
pathways downstream of PKB. 
In Mnk knockout cells there was a shift in the temporal peak phosphorylation of ERK. This 
was also evident in insulin and CGP57380 treated cells with a peak in phosphorylation at 
10min as opposed to a peak at 5min in just insulin treated cells (Fig. 4.12B). 
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Figure. 4.11. Insulin signalling is decreased in 3T3-L1 cells treated with Mnk inhibitors. 
Cells were starved of serum for 150 min and pre-treated with 3µM compound E or 50µM 
CGP57380 for 30min followed by insulin for the time shown. A) Western blot analysis of 
total PKB, p-PKB Ser
473 and p-PKB Thr
308. B) Effect of insulin on PKB activity over 30 min. 
Cellular extracts were subjected to immunoprecipitation using an anti-PKBʱ antibody for 
1h followed by incubation with Crosstide peptide and 1µCi [-
32P]ATP. Radioactivity was 
measured using the Čerenkov method. Student’s t-test was used to analyse significance * 
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indicates  significance  at  p<0.05  compared  to  control,  #  indicates  significance  p<0.05 
compared  to  insulin  treated.  C)  Measurement  of  PI3K  activity,  cell  extracts  were 
immunoprecipitated  for  phospho-tyrosine  and  then  incubated  with  [-
32P]ATP  and 
phosphatidylinositol. Densitometry of the phosphorimage of the TLC plate was corrected 
for background radioactivity and normalised for protein input. D) Graphs summarising data 
from  triplicate  PI3K  assay  experiments.  Data  are  given  as  fold  incorporation  of 
radioactivity compared to WT control and normalised to protein input, n = 3. Student’s t-
test  was  used  to analyse  significance, *  indicates  significance  at p<0.05  compared  to 
control, t indicates p<0.1 compared with insulin treated.  
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Figure.  4.12.  Effect  of  insulin  on  the  phosphorylation  of  selected  proteins  in  fully 
differentiated 3T3-L1 cells. Cells were starved of serum overnight, followed by treatment 
with insulin for the times indicated. A) Western blot analysis for total TSC2 and p-TSC2 
Thr
1462 and total PRAS40 and p-PRAS40 Thr
246, total S6, p-S6 Ser
240/244, total 4E-BP1 and 
p-4E-BP1 Ser
64. B) Western blot analysis for total ERK and p-ERK Tyr
202/Thr
204. 
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4.2.6.3 Inhibition of the Mnks leads to a decrease in insulin-stimulated glucose uptake and 
lipogenesis. 
In MEFs, knockout of either Mnk1 or Mnk2 led to impaired insulin-stimulated glucose 
uptake and AS160 phosphorylation. In differentiated 3T3-L1 cells, CGP57380 led to a 
decrease in insulin-stimulated AS160 phosphorylation at the 5min and 10min time points 
(Fig. 4.13A). Consistent with this Mnk inhibition also led to a significant reduction in 
insulin-dependent glucose uptake, without affecting basal levels (Fig. 4.13B). 
To further assess the impact of Mnk inhibition on insulin signalling the method for glucose 
uptake was adapted to isolate total lipids in order to measure lipogenesis. Cells were 
labelled with radioactive glucose for 2h followed by extraction of total lipids in a similar 
method to that used in the PI3K assay (method fully described in Chapter 2, section 
2.4.16). This revealed that compound E significantly decreased basal lipogenesis, an 
effect which was not seen with CGP57380 (Fig. 4.13C). Since compound E is a more 
specific Mnk inhibitor, it is possible that the Mnks do play a role in basal lipogenesis or 
lipolysis. Inhibition of the Mnks with either inhibitor did significantly reduce insulin-
stimulated lipogenesis (Fig. 4.13C). This effect may be a consequence of reduced glucose 
uptake and/or a result of decreased insulin signalling to lipogenic enzymes. 
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Figure  4.13.  Effect  of  Mnk  inhibitors  on  insulin-stimulated  glucose  transport  in  fully 
differentiated 3T3-L1 cells. A) Western blot analysis of phospho-AS160 Thr
642 and total 
AS160.  B)  Effect  of  Mnk  inhibition  on  insulin-stimulated  [
3H]2-deoxyglucose  uptake. 
Glucose  transport  was  assessed  as  described  in  the  research  design  and  methods 
Student’s  t-test  was  used  to  analyse  significance,  *  indicates  significance  at  p<0.05 
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compared to control and # indicates significance at p<0.05 for insulin treated vs insulin 
treated + Mnk inhibitor. C) Effect of Mnk inhibition on insulin-stimulated lipogenesis. Cells 
were treated as previously and incubated with [
3H]2-deoxyglucose for 2h followed by total 
lipid isolation. Radioactive incorporation was assessed by scintillation counting. Student’s 
t-test was used to analyse significance, * indicates significance at  p<0.05 compared to 
control and # indicates significance at p<0.05 for insulin treated vs insulin treated + Mnk 
inhibitor.    
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4.2.7 Investigations into the mechanism by which the Mnks regulate insulin 
signalling. 
Data so far suggest that the regulation of the insulin signalling pathway by the Mnks may 
involve: direct modulation of PI3K, alteration of protein or lipid phosphatases, IRS1 or the 
insulin receptor. Short-term Mnk inhibition led to decreased activation of PI3K and PKB as 
well as reduced glucose uptake, which suggests the Mnks act upon a target within the 
pathway in a mechanism dependent on their kinase activity. The most obvious potential 
target was insulin receptor substrate 1 (IRS1) because this protein is a major regulator of 
insulin signalling and is tightly controlled by serine/threonine phosphorylation (reviewed 
[229]).   
4.2.7.1 IRS1 levels are lower in knockout cells and in response to inhibition of the Mnks. 
In order to study this, the levels of IRS1 or the insulin receptor β (IRβ) were determined by 
western blot in WT MEFs, knockout MEFs and WT MEFs including cells treated with Mnk 
inhibitors or siRNA directed against the Mnks. This revealed that the levels of IRS1 were 
decreased in response Mnk inhibitors and siRNA knockdown of the Mnks. Considerably 
lower levels were also evident in Mnk knockout MEFs (Fig. 4.14A). The levels of IRβ were 
actually increased in knockout MEFs but slightly decreased in Mnk2 siRNA treated MEFs. 
This disparity might be caused by a compensation mechanism in Mnk knockout MEFs that 
is not triggered by short term depletion as with siRNA. These data indicate that the Mnks 
can regulate IRS1 protein levels. 
Changes in the level of any protein can be a consequence of differences in transcription, 
mRNA stability, and protein synthesis or protein stability. The levels of IRS1 mRNA were 
therefore assessed by qPCR. This showed that compound E significantly increased IRS1 
mRNA levels whilst Mnk2 knockout or Mnk2 knockdown with siRNA caused significant 
decreases in IRS1 mRNA (Fig. 4.14B). Similarly Mnk1/2-DKO cells showed significant 
reductions in IRS1 mRNA.  
These data suggest dual regulation of IRS1 at both the protein and mRNA levels. 
However the major effect appears to be at the protein level. This is supported by evidence 
that Mnk inhibitors and Mnk1 knockout both decrease protein levels but have little effect 
on mRNA levels. Furthermore Mnk2 knockout or knockdown led to bigger decreases in 
IRS1 protein than mRNA levels.     
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Figure. 4.14 Regulation of IRS1 by the Mnks A) Western blot analysis of WT, Mnk1-KO, 
Mnk2-KO,  Mnk1/2-DKO  MEFs  and WT MEFs  treated  with  CGP57380  (50M,  45min), 
compound E (3µM, 45min) or 15nM Mnk1 or Mnk2 siRNA (24h). Blots were probed for 
IRS1, IRβ, Mnk1, Mnk2 and tubulin as a loading control. B) qPCR analysis of IRS1 mRNA 
levels  using  qPCR  with  results  normalised  to  18S  rRNA  and  expressed  as  a  fold 
difference in expression compared to untreated WT MEFs. 
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4.2.7.2 IRS1 is phosphorylated and stabilized by the Mnks.         
The western blot data indicate that the Mnks can regulate IRS1 at the protein level. 
Because the Mnks are serine/threonine kinases it was possible that they phosphorylate 
IRS1. Since full length IRS1 is difficult to express, fragments of IRS1 were expressed and 
purified in E. coli. These fragments correspond to: residues 21-400 (B), 108-516 (C), 516-
896 (D) and 899-1235 (E). As can been seen (Fig. 4.15A) both Mnk1 and Mnk2 can 
phosphorylate fragments C and D of IRS1 in vitro. To determine whether this was a 
specific effect of the Mnks, Mnk inhibitors were added to the assay and showed that 
phosphorylation of fragment C was likely due to a contaminating kinase but fragment D 
was specifically phosphorylated by both Mnks with Mnk2 having the greatest activity 
towards IRS1 (D) (Fig. 4.15B).  
In order to identify the site/sites phosphorylated by the Mnks, the experiment was 
conducted as previously but the band corresponding to fragment D was excised from the 
gel and subjected to cyanogen bromide cleavage. The resulting cleaved product was then 
run on a 4-12% gel to determine which fragments were phosphorylated by the Mnks. This 
revealed that out of a possible 7 sites (predicted by determining the cleavage sites that 
would be excised by cyanogen bromide based on methionine in the fragment) that there 
were sites in the largest cleavage fragment and the two smallest (Fig. 4.15C).  
There is no general consensus sequence used by the Mnks but there is a requirement for 
basic residues and they appear to prefer serine [39, 41, 74]. Based on this, a number of 
possible sites were identified and serine to alanine mutants were generated and then 
assayed to determine if these were Mnk sites. This revealed that there were 5 sites 
phosphorylated by both Mnks: Ser
574, Ser
629, Ser
766, Thr
774 and Ser
794. Following this a 
mutant where all 5 sites were mutated to alanine was generated. This did not undergo 
Mnk-catalysed phosphorylation (Fig. 4.15D). 
These data show that the Mnks can phosphorylate IRS1 at 5 sites in the fragment of IRS1 
that is important for PI3K binding [210]. The effect of this phosphorylation required further 
investigation.  
Serine/threonine phosphorylation of IRS1 can alter its stability, although this is usually in a 
negative fashion [229], which was not expected to be the case with the Mnks since 
inhibition or knockout/knockdown of the Mnks reduces IRS1 levels (Fig. 4.14A). To test 
whether Mnk inhibition caused proteasomal degradation of IRS1 cells were treated with 
CGP57380 or compound E after 45min of treatment with MG132. The compound MG132 
is a proteasome inhibitor and was expected to block the degradation of IRS1 by the - 163 -   
proteasome [296]. The data showed that Mnk inhibition caused degradation of IRS1, 
which was prevented MG132 treatment (Fig. 4.16A). This suggests that Mnk 
phosphorylation was important for the stability of IRS1. To study this further a construct 
containing WT or the S-5-A mutant of IRS1 fragment D was created with a myc tag. This 
was then expressed in HEK293 cells with or without MG132 treatment. The data showed 
that the mutant fragment was expressed at lower levels than the WT and this difference 
was rescued by MG132 treatment (Fig. 4.16B). This implies that the Mnks regulate insulin 
signalling through stabilization of IRS1. 
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Figure. 4.15. A) In vitro phosphorylation of IRS1 fragments B (residues 21-400), C (108-
516),  D  (516-896)  and  E  (899-1235.  2  g  IRS1  were  incubated  with  HA 
immunoprecipitated Mnk1a or Mnk2a with 100µM ATP and 0.1µCi [-
32P]ATP for 20min. 
Samples were subjected to SDS-PAGE and the gels exposed to phosphor-screens. B) ) In 
vitro phosphorylation of IRS1. 2 g IRS1, was incubated with 200ng Mnk1a or Mnk2a with 
A
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or without 20nM CGP57380 or 3nM compound E with 100µM ATP and 0.1µCi [-
32P]ATP 
for 20min. Samples were subjected to SDS-PAGE and the gels exposed to phosphor-
screens. C) In vitro phosphorylation of IRS1 fragment D followed by cyanogen bromide 
cleavage. Samples were subjected to SDS-PAGE using 4-12% gels and then exposed to 
phosphor-screens. D) In vitro phosphorylation of IRS1. IRS1 2 g WT, S574A, S629A, 
S766A, T774A, S794A and S-5-A fragments were incubated with Mnk2a with 100µM ATP 
and 0.1µCi [-
32P]ATP for 20min. Samples were subjected to SDS-PAGE and the gels 
exposed to phosphor-screens.  
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Figure. 4.16 Stability of IRS1. A) WT MEFs were treated with MG132 (10M) for 45 min 
prior to treatment with or without 45 min CGP57380 (50M) or Compound E (3μM) and 
analysed for IRS1 by western blotting.  B) HEK293 cells were transfected with expression 
vectors encoding either the WT or S5A mutant IRS1, equipped with a myc-tag, using the 
PEI method. After 48h, cells were treated with or without 10M MG132 for 3h and lysates 
were then analysed by western blot for myc- IRS1 expression. n=1.  
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4.2.8 Analysis of Mnk1/2-DKO mice. 
To determine if the Mnks play a role in whole body insulin sensitivity, it was imperative to 
analyse Mnk1/2-DKO mice as this would give a clear indication as to whether the effect 
the Mnks have on IRS1 can lead to insulin resistance.  
4.2.8.1 Phenotypic investigations of DKO mice. 
The Mnk1/2-DKO mice have previously been reported to show no overt phenotype, 
however the authors did not show data about the weight of these mice or any differences 
in organ mass [45]. Here we have assessed 17 week old WT and Mnk1/2-DKO mice. 
Upon death, the mice were weighed and the organs dissected, weighed and snap frozen. 
This showed that Mnk1/2-DKO mice weigh significantly less than their age-matched 
counterparts (Fig. 4.17A). This is perhaps not surprising because the Mnks have been 
linked to tumorigenesis [77, 78, 277, 278] and so clearly have some role in growth, 
whether this is related to eIF4E phosphorylation or IGF1 signalling remains to be 
determined. Mnk1/2-DKO mice have hearts that trend towards having greater mass (Fig. 
4.17B). This may be important because both Mnks were shown to be expressed to 
moderate levels in the heart (Fig. 4.1) These effects may be important with regards to 
cardiac hypertrophy. There were no distinct differences in the left lobe of the liver, either 
abdominal adipose or scapular depots or the skeletal muscle (Fig. 4.17. C, E, F, G). The 
right lobe of the liver was in fact significantly larger in Mnk1/2-DKO mice (Fig. 4.17D), 
which was not expected given that neither Mnk1 nor Mnk2 is expressed in the livers at 
levels seen in other tissues.  
These data indicate there is a role for the Mnks in the overall growth of an animal.   
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Figure 4.17. Organ weight data for male WT C57/BL6 and MNK1/2DKO mice fed normal 
chow diets. N=4 for both groups. A) Bodyweight of 17 week old mice. Students’ t-test was 
used  to  analyse  the  data  **  indicates  p<0.01  compared  to  WT  B)  Weight  of  heart 
expressed as a % of bodyweight, Students’ t-test was used to analyse the data t indicates 
p<0.1 compared  to WT.    C) Weight  of the  left  lobe  of  the  liver  expressed  as a  % of 
bodyweight. D) Weight of the right lobe of the liver expressed as a % of bodyweight, 
Students’ t-test was used to analyse the data ** indicates p<0.01 compared to WT. E) 
Weight  of  the  abdominal  adipose  expressed  as  a  %  of  bodyweight.  F) Weight  of  the 
scapular  adipose  expressed  as  a  %  of  bodyweight.  G)  Weight  of  the  gastrocnemius 
skeletal muscle expressed as a % of bodyweight.   
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4.2.8.2 Biochemical analysis of IRS1 levels in DKO mice. 
Using qPCR the levels of IRS1 mRNA were determined in abdominal fat and skeletal 
muscle from WT and Mnk1/2-DKO mice, this showed that surprisingly there was 
increased expression of IRS1 mRNA in the abdominal adipose of Mnk1/2-DKO mice and 
no difference in skeletal muscle (Fig. 4.18A, B). This is contrary to the evidence from 
MEFs where IRS1 mRNA levels were much lower (Fig. 4.14B). The simple explanation for 
this is that full grown animals are able to compensate for reductions in mRNA levels 
where as embryonic cells have yet to develop this. The data presented previously showed 
that the Mnks regulate of IRS1 at the protein level by maintaining IRS1 stability (Fig. 4.16). 
Therefore the muscle and adipose were the strongest contenders for any difference since 
these were the tissues where both the Mnks and IRS1 are highly expressed. The 
abdominal adipose did show reduced levels of IRS1 in the Mnk1/2-DKO mice (Fig. 
4.18C). Assessment of muscle levels of IRS1 show a very slight difference between WT 
and Mnk1/2-DKO mice, with lower levels in the latter (Fig. 4.18D). 
Mnk1/2-DKO appears to have an effect on IRS1 only in the abdominal adipose, which is 
consistent with the fact that both Mnks are expressed in this tissue; however these data 
must be viewed with caution and studies on more mice are required to assess if this is 
indeed the case.  
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Figure. 4.18. Mnk1/2-DKO exhibit changes in IRS1 expression. A) qPCR analysis of IRS1 
mRNA  levels  in  abdominal  fat  using  qPCR  with  results  normalised  to  18S  rRNA  and 
expressed as fold difference in expression compared to WT (n=3 different animals). B) 
qPCR  analysis  of  IRS1  mRNA  levels  in  skeletal  muscle  using  qPCR  with  results 
normalised to 18S rRNA and expressed as fold difference in expression compared to WT 
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(n=3 different animals). C) Western blot analysis of IRS1 protein levels in WT and Mnk1/2-
DKO mice from abdominal adipose (n=3 different animals). D) Western blot analysis of 
IRS1  protein  levels  in  WT  and  Mnk1/2-DKO  mice  from  skeletal  muscle  (n=3  different 
animals).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 173 -   
4.2.8.3 Mnk1/2-DKO mice exhibit glucose intolerance.                
The data in this chapter have illustrated that the Mnks have a role in the regulation of 
IRS1 stability, which may explain the deficit in insulin-stimulated glucose uptake in cells 
lacking the Mnks.  
To determine if Mnk1/2-DKO mice exhibit any differences in glucose metabolism, 16 
week-old mice were subjected to a glucose tolerance test (GTT). Mice were fasted 
overnight and then the following day basal glucose levels were measured and mice were 
injected with glucose and tested at set time points thereafter (as described Chapter 2, 
section 2.5.3). This revealed that Mnk1/2-DKO mice show impaired glucose tolerance 
(Fig. 4.19A, B). Loss of both Mnks causes much slower glucose clearance as illustrated 
by persistent high levels of glucose at 30 and 60 min after glucose injection (Fig. 4.19A). 
The consequence of this effect is a significant increase in the area under the curve (AUC) 
in Mnk1/2-DKO mice (Fig. 4.19B). 
Thus, importantly, Mnks do play a role in glucose homeostasis and presumably insulin 
action in vivo.  
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Figure. 4.19. Mnk1/2-DKO exhibit impaired glucose tolerance. A) Glucose tolerance tests 
for WT and Mnk1/2-DKO mice, n=5 for each WT and Mnk1/2-DKO. B) Area-under-the-
curve (AUC) for glucose tolerance tests calculated using the trapezoid rule. Student’s t-
test was used to analyse the data; ** indicates p>0.01 compared to WT mice.  
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4.3 Discussion 
Very little is known about the physiological roles of the Mnks and their substrates with 
most research having focused on cancer and inflammatory diseases [40, 41, 43, 44, 79, 
276, 281]. The aim of this Chapter was to determine if the Mnks had any role in glucose 
metabolism and insulin signalling and, if so, the mechanism by which this occurred. The 
data shown in one patent suggested that Mnk inhibition resulted in improved insulin 
sensitivity [106] and so formed the trigger for the investigations described here, which 
were carried out using Mnk knockout cells and mice. Surprisingly, the opposite of the 
claims made in the patent were found here showing that the Mnks are required for normal 
insulin signalling and that knockout actually leads to defective glucose tolerance.    
The expression of the Mnks in different mouse tissues has previously been studied at the 
mRNA level [39, 228]. Here, the protein levels of Mnk1 and Mnk2 mRNA were examined 
in an expanded tissue panel. This revealed that Mnk1 was highly expressed in the 
pancreas and spleen, with high levels in the muscle and white adipose tissue. Mnk2 was 
the most highly expressed in white and brown adipose tissue and also in the kidney, 
muscle and heart. This suggests a role for the Mnks in tissues related to insulin signalling 
and glucose metabolism. To further investigate this, Mnk knockout cells were assessed 
for insulin-stimulated PKB activity and downstream signalling. In view of the expectation 
that there would be enhanced signalling in Mnk knockout cells due to the data presented 
with regards to Mnk inhibition and increased insulin sensitivity [106]. In contrast, the 
results indicated the opposite showing that knockout of Mnk2 led to a significant decrease 
in insulin-induced PKB activity, whilst knockout of Mnk1 had less effect and a combined 
knockout of both Mnk1 and Mnk2 had the most deleterious effect. These changes in PKB 
activation indicated probable changes in pathways downstream of PKB. This was the 
case for both TSC2 and PRAS40, whose phosphorylation was decreased in all knockout 
cells assessed. The effects on S6 and 4E-BP1 were not as clear; knockout of Mnk1 had 
no effect on insulin-induced S6 phosphorylation consistent with the mild effect on PKB 
activity and TSC2 phosphorylation, but interestingly led to reduced insulin-stimulation of 
4E-BP1 phosphorylation. In Mnk2-KO cells S6 phosphorylation was delayed whilst 4E-
BP1 phosphorylation was actually increased. The cause for this is not clear and could be 
related to the ability of Mnk2 to bind to raptor [96]; however in Chapter 3 I showed that the 
presence of Mnk2 in mTORC1 kinase assays increased 4E-BP1 in vitro phosphorylation 
and so Mnk2 knockout would be expected to reduce 4E-BP1 phosphorylation. These data 
suggest Mnk1 and Mnk2 have different effects on mTORC1 signalling, potentially 
downstream of PKB and not as a consequence of changes to IRS1 stability. It would be 
important to assess whether 4E-BP1 and S6K/S6 are direct substrates of the Mnks. The 
combined knock-out of Mnk1 and Mnk2 follows expectations of reduced mTORC1 - 176 - 
signalling caused by reduced insulin-stimulated PKB activation. Using inhibitors of the 
Mnks further supported this evidence whereby insulin-induced PKB activation and 
phosphorylation as well as downstream mTORC1 signalling was affected in an adverse 
fashion.  
In both Mnk knockout cells and cells treated with Mnk inhibitors there was a loss of 
insulin-stimulated glucose uptake, consistent with the reduced insulin-induced PKB 
activation. This again is contrary to what was expected based on the evidence presented 
in the patent [106]. This is a major finding in relation to the role of the Mnks and is clear 
evidence that the Mnks function to regulate insulin signalling. The mechanism by which 
the Mnks exert this is likely related to the evidence presented here showing that the Mnks 
can phosphorylate and stabilize IRS1. The majority of evidence has shown that the 
serine/threonine phosphorylation of IRS1 impairs insulin signalling, e.g. as a negative 
feedback mechanism [229]. The Mnks can phosphorylate five sites in IRS1: Ser
574, Ser
629, 
Ser
766, Thr
774 and Ser
794 Ser
574. Of these sites, only Ser
629 and Ser
794 have previously 
been described [297, 298]. Ser
794 is phosphorylated by AMPK, which has been shown to 
enhance insulin signalling in C2C12 muscle cells, while in white adipose tissue it actually 
leads to impaired insulin signalling [299]. Phosphorylation of Ser
574, in combination with 
Ser
307 and Ser
323, by PKCʴ has been shown to decrease tyrosine phosphorylation of IRS1 
and impair IRS1 function [297]. The Mnks do not phosphorylate Ser
307 which may be a 
critical inhibitory site targeted by numerous kinases as the phosphorylation of Ser
307 
disrupts insulin receptor binding [229, 300]. PKB is able to phosphorylate Ser
629, which 
enhances IRS1 function by decreasing the phosphorylation at Ser
636, an inhibitory site 
[298]. The Mnks can phosphorylate multiple sites in IRS1, which appears to stabilise IRS1 
as illustrated by the recovery of IRS1 levels in cells treated with CGP57380 and MG132. It 
is possible Mnk-mediated phosphorylation of IRS1 protects IRS1 from ubiquitination and 
thus subsequent proteasomal degradation. The mechanism by which Mnk mediated 
phosphorylation protects IRS1 from degradation will be the subject of further research. 
One such line of inquiry would be to investigate SOCS-1 and SOCS-3-dependent 
ubiquitination of IRS1, which has been shown to be important [301-303] in relation to 
tyrosine phosphorylation of IRS1 and might be regulated by Mnk-mediated 
phosphorylation. Similarly to the phosphorylation of IRS1 on Ser
629 by PKB, 
phosphorylation by Mnk2 may block phosphorylation of sites such as Ser
307, Ser 
312, Ser
527 
and Ser
636, which have been linked to ubiquitination of IRS1 [304-306]. Mnk2 also appears 
to modulate the level of expression of the IRS1 mRNA, but this is secondary in magnitude 
to regulation of IRS1 protein and probably of lesser importance. Given that the Mnks are - 177 -   
known to regulate mRNA translation, it is possible Mnk2 may regulate IRS1 message 
levels through altering the rate of translation or the stability of IRS1 mRNA.    
It appears that knocking out the Mnks leads to perturbed glucose tolerance as illustrated 
in Mnk1/2-DKO mice whose GTT shows a shift towards insulin resistance. This may be 
attributed to the reduced levels of IRS1 seen in abdominal adipose tissue. Further lines of 
investigation would involve assessing individual Mnk1 and Mnk2 single knockout mice to 
determine the individual contributions of each isoform. It would also be important to 
determine insulin levels in Mnk1/2-DKO mice because this may also be the cause of 
glucose intolerance and especially because there are high levels of Mnk1 in the pancreas 
suggesting a role for Mnk1 in this tissue.  
These data indicate that activation of the Mnks may be an option in T2DM. There is huge 
effort and investment into the causes and treatment of T2DM. A broad range of treatments 
are currently available to slow the progression of T2DM; however, the exact mechanism 
behind the development of T2DM remains unclear and so more work needs to be done. 
Furthermore, some of the drugs used have side effects e.g. Avandia (Rosiglitazone), 
which can cause cardiovascular disorders [135], although the incidence of this is 
decreasing due to better understanding and patient care. T2DM is a disease whereby 
there is defective insulin signalling that results in glucose intolerance and the eventual 
inability of an individual to control their blood glucose levels.  The deficiency in insulin 
signalling that causes T2DM results in the inability of insulin target tissues to respond to 
insulin and facilitate glucose uptake. The identification of the component(s) of the pathway 
from insulin receptor to glucose transport that are affected in T2DM is key to developing 
better treatments. Further studies into the expression of the Mnks in T2DM patients may 
prove interesting if there are reduced levels or if there are mutations within the Mnk genes 
that contribute to T2DM development.  
 
In conclusion, these data reveal a novel role for the Mnks in the control of insulin 
signalling likely via a mechanism involving the phosphorylation and stabilization of IRS1. 
The effect of Mnk1/2 double knockout is glucose intolerance and this may be important 
when considering future drug treatments for T2DM. 
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Chapter 5 
Mnk2 Knock-out Animals Exhibit a 
Novel Lipid and Glucose Metabolic 
Profile, and are Protected from Diet-
induced Type 2 Diabetes and Weight 
Gain. 
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5.1 Introduction  
The data described in Chapter 4 illustrated that the loss of either Mnk1 or Mnk2 or both 
the Mnks leads to a marked impairment in insulin signalling, indicative of intracellular 
insulin resistance. Furthermore data from Mnk1/2-DKO mice show that there is some 
degree of insulin resistance but only abdominal adipose shows decreased levels of IRS1 
protein. The tissue expression profile of the Mnks shows high levels of expression of 
Mnk2 in scapular and abdominal adipose. It was therefore important to examine Mnk2-KO 
mice to see if they too show perturbed glucose homeostasis. 
A number of patents have been filed that suggest a link between Mnk2 and diseases 
related to glucose and lipid homeostasis [106, 228]. Evidence from one of these patents 
shows a similar tissue expression profile of the Mnks as is shown in Chapter 4 (Fig. 4.1) 
as well as increased expression during 3T3-L1 cell differentiation [228] (Fig. 4.10). The 
authors also assessed the expression of Mnk2 in the ob/ob mouse, revealing a clear 
decrease compared with fasted WT mice. They also generated an Mnk2 dominant-
negative mouse (MNK2DN), which represents a loss of function of Mnk2. A major problem 
with the dominant-negative model is that the non-functional Mnk2 that is expressed may 
still be able to bind p-ERK resulting in impaired ERK signalling and therefore any 
conclusions made from this model must be viewed with caution. This is because dominant 
negative expression of genes leads to expression of a non-functional protein product, 
which interferes with upstream signalling whereas knock-out of genes abolishes the 
expression of protein products [307]. The weight of the MNK2DN mouse is increased 
compared with WT mice whilst the overexpression of Mnk2 in cells leads to decreased TG 
storage, decreased FA transport and reduced insulin-stimulated lipogenesis [228]. This 
suggests that Mnk2 functions to reduce fat storage and maintain a lean bodyweight 
indicating that treatment with an Mnk homologue would benefit patients with lipid 
disorders, e.g., obesity. However, the data in Chapter 4 showed a decrease in insulin-
dependent lipogenesis when differentiated 3T3-L1 cells were pre-treated with Mnk 
inhibitors (Fig. 4.13C). Information from a different patent shows the opposite with regard 
to bodyweight [106], treatment with an Mnk inhibitor called compound 15 reduced 
bodyweight in a similar fashion to the PPARγ agonist rosiglitazone [106]. Furthermore, 
this patent shows that Mnk inhibitors have the ability to lower blood glucose, increase 
insulin sensitivity and pancreatic insulin whilst reducing plasma triglyceride and NEFAs 
[228]. However, the data in Chapter 4 showed that Mnk inhibitors and Mnk knockout both 
lead to decreased IRS1 levels and loss of insulin-stimulated glucose uptake (Figs. 4.16, 
4.6-4.8, 4.13B respectively), which suggests Mnk2 knockout mice may present with insulin 
resistance.  - 180 - 
Neither of the patents discussed above tested the effect of Mnk inhibition in mice fed high 
fat diets, which given their claims would have been advisable. The evidence presented in 
either patent has not been published in peer-reviewed journals indicating that the data is 
either incomplete or has not been replicated. The use of the ob/ob mouse is also 
problematic (as discussed in Chapter 1, section 1.5.5), since leptin levels rise in obesity 
and a subsequent development of leptin resistance occurs [178]. Furthermore, the use of 
an MNK2DN mouse could cause unwanted side effects by altering the function of mnk2 
substrates or binding partners (e.g. ERK) in an off target mechanism that is not relevant 
physiologically.  
In Chapter 1 (section 1.5) the factors related to diet-induced obesity and T2DM were 
established with regard to lipid homeostasis and adipokines and their effects on the 
progression to T2DM. The current understanding simply suggests that the increase in 
dietary fat is stored in adipose tissue, which enters into a hypertrophic state resulting in 
low grade chronic inflammation and the increase in circulating inflammatory factors, 
adipokines, TGs and NEFAs (as discussed in Chapter 1, section 1.5.6). These factors 
account for both early stage insulin resistance and the subsequent dysfunction of β 
pancreatic cells culminating in a reduction in insulin secretion and the presentation of full 
blown T2DM [175].   
The aim of this Chapter was to establish whether Mnk2-KO mice exhibit any discernible 
phenotype when compared with age-matched WT mice. This Chapter also investigates 
whether Mnk2-KO mice show differences in glucose and lipid homeostasis and if they 
presented with insulin resistance. Furthermore, these experiments were designed to 
establish if feeding Mnk2-KO mice a high-fat diet led to any differences in development of 
diet-induced obesity or T2DM.  
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5.2 Results  
5.2.1 Phenotypic analysis of Mnk2 knockout mice. 
Mnk2-KO mice were bred from homozygous Mnk1 WT, homozygous Mnk2 knockout 
parents and were age-matched with Mnk1/2 WT C57BL/6 mice and fed either normal lab 
chow diets or 45% fat diets post weaning (approximately 3 weeks of age), as described in 
Chapter 2, section 2.5.2. Both male and female Mnk2-KO mice exhibited no visible 
defects in growth, coat colour/shine or alertness but appeared somewhat more docile than 
WT counterparts. 
Monitoring weight gain is a simple effective method of determining whether a drug or 
genetic knockout has an effect on a whole animal. Mice were weighed before allocation to 
diet groups and were then weighed once a week for a total of 12 weeks. The data in 
Chapter 4 showed that male 17 week old Mnk1/2-DKO mice weighed significantly less 
than age matched WT mice (Fig. 4.17A), which was not assessed in the original paper 
describing these mice, where organ size was described as showing no difference, similar 
to the data shown in Chapter 4 (Fig. 4.17) [45]. The authors of this paper did not assess 
the organ size or weight of Mnk2-KO mice and as such it was of interest to do so in this 
study.  
The initial post-weaning weights of male WT and Mnk2-KO mice showed some variability 
of 2-3g. WT males placed on the high fat diet initially weighed slightly more than all other 
groups but within one week there was no difference between the groups (Fig. 5.1A). At 
week 5, there were clear differences between experimental groups, Mnk2-KO mice on 
both the normal chow and high fat diets gained weight much more slowly than WT mice 
on either diet (Fig. 5.1A). At week 9, WT mice on the high fat diet weighed significantly 
more than WT mice on normal chow diets or Mnk2-KO mice fed a high fat diet. The WT 
high fat fed males continue to gain significantly more weight than WT mice on normal 
diets as is expected from this diet (Fig. 5.1A). Mnk2-KO mice on normal chow diets begin 
to show significantly less weight gain than WT mice on normal diets at week 9-10 and, 
very interestingly, Mnk2-KO mice fed a high fat diet show no difference to their normal diet 
fed counterparts (Fig. 5.1A). The weights of mice at week 12 illustrate clearly that WT 
mice fed high fat diets are significantly heavier (as expected), interestingly Mnk2-KO mice 
fed high fat diets or normal chow diets are similar in weight and significantly lighter than 
WT mice fed either diet (Fig. 5.1C).  
Female mice from the same litters as the male mice were also fed either normal chow 
diets or high fat diets at the same time as male mice for 12 weeks. The WT female mice 
show a similar pattern to the male mice when comparing chow-fed to high fat fed groups. - 182 - 
However it was not until week 10 that there was a significant difference between normal 
and high fat groups (Fig. 5.1B). Female Mnk2-KO mice do not show the same phenotype 
in this regard as their male counterparts and gained a large amount of weight on the high 
fat diet, beginning to gain this weight as early as 6 weeks after the start of high fat feeding 
(Fig. 5.1B). Furthermore at 12 weeks Mnk2-KO female mice weigh more on both the 
normal chow diets and high fat diet than WT mice (Fig. 5.1D). However it must be noted 
that upon death two of the WT females on chow diets exhibited severe kidney cancer and 
so this data must be taken with caution. 
These data show a clear sex difference between Mnk2-KO mice. In male Mnk2-KO mice 
the loss of Mnk2 results in reduced bodyweight whilst in female Mnk2-KO mice there is an 
increase in bodyweight. Therefore, further investigation was required.  
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Figure 5.1. Bodyweight data for WT C57/BL6 and MNK2KO mice fed either normal chow 
diets or high fat (45% fat) diets. n=5 for each group A) Bodyweight across 12 weeks of 
feeding post-weaning in male mice. B) Bodyweig ht across 12 weeks of feeding post-
weaning in female mice. C) Final Bodyweights of male mice, Students’ t-test was used to 
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analyse  the data  **  indicates  p<0.01  compared  to WT chow  fed,  ##  indicates p<0.01 
compared to WT high fat fed. These data are from n=5 mice in each experimental group. 
D) Final Bodyweights of female mice, Students’ t-test was used to analyse the data ** 
indicates p<0.01 compared to WT chow fed, ## indicates p<0.01 compared to WT high fat 
fed.  These  data  are  from  n=5  mice  in  each  experimental  group,  ++  indicates  p<0.01 
compared to MNK2KO high fat fed. 
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5.2.2 Studies of tissue from WT and Mnk2-KO mice. 
Evidence from Chapter 4 showed that male Mnk1/2-DKO mice showed no overt 
differences in the weight of muscle, left lobe of the liver, abdominal adipose or scapular 
adipose with respect to their bodyweight, which was significantly lower (Fig. 4. 17). These 
mice did however exhibit a trend towards increased heart size and significantly increased 
weight of the right lobe of the liver (Fig. 4.17B, D). This is mostly in agreement with 
observations from the group that generated these mice [45]. However based on the 
distinct differences in weight gain in Mnk2-KO mice it was of interest to examine select 
organs from these mice, especially those related to metabolism.  
 
5.2.2.1 Determination of organ size in relation to bodyweight from male and female WT 
and Mnk2-KO mice. 
The striking differences observed in the weight gain between the sexes of Mnk2-KO mice 
deserved further investigation with regard to organ size. WT and Mnk2-KO mice were fed 
either normal chow or high fat diets for 12 weeks post weaning (~15weeks of age) and 
were euthanized (as described in Chapter 2, section 2.5.4). Organs were dissected and 
weighed and then the data were expressed as a % of total bodyweight.  
Chow-fed male Mnk-2KO mice exhibit significantly increased heart weight in comparison 
to WT mice (Fig. 5.2A), which is similar to that seen in Mnk1/2-DKO mice (Fig. 4.17B). 
Feeding mice with a high fat diet results in significant decreases in heart weight/body 
weight in both WT and Mnk2-KO mice (Fig. 5.2A). This is perhaps expected as diet-
induced obesity leads to increased deposition of interstitial fat and since these mice are 
still developing increased fat around organs, this may lead to retardation of organ growth. 
Unlike Mnk1/2-DKO mice, Mnk2-KO mice have decreased gastrocnemius skeletal muscle 
mass compared to WT mice, when fed normal chow diets (Fig. 5.2B). WT mice fed high 
fat diets exhibit significantly decreased muscle mass whilst Mnk2-KO mice show no 
decreases when compared to chow-fed Mnk2-KO mice but remain smaller than WT chow-
fed mice (Fig. 5.2B). The decrease in muscle mass of WT mice fed high fat diets could be 
explained by increased intramyocellular fat accumulation and a reduction in muscle 
growth. However it is harder to explain why there is significantly lower muscle mass in 
chow-fed Mnk2-KO mice, but, the lack of further decrease with high fat diet feeding may 
suggest there is less intramyocellular fat accumulation, which is supported by the lack of 
weight gain in these mice (Fig. 5.1A, C).  
The liver is formed of multiple lobes, Cantlie's line defines the left and right lobe of the 
liver, which are further divided into sub-lobes [308]. In the Mnk1/2-DKO mice the right lobe - 186 - 
of the liver had a significantly increased mass (Fig. 4.17D); however, chow-fed Mnk2-KO 
mice show no difference compared to WT mice (Fig. 5.2C, D). A decrease in mass of both 
the left and right lobes of the liver occur with high fat diet feeding in both WT and Mnk2-
KO mice, although the left lobe of the liver is decreased significantly more in high fat fed 
Mnk2-KO mice than WT high fat fed mice (Fig. 5.2C). As with all the other organs, it is 
likely that high fat feeding leads to increased interstitial fat deposition and cellular TG 
accumulation leading to decreased organ size with respect to bodyweight . 
Female chow-fed Mnk2-KO mice also exhibit increased heart size compared to WT mice 
(Fig. 5.3A). High fat feeding causes a decrease in heart size in WT mice as with males, 
but female Mnk2-KO high fat fed mice show significantly decreased heart size compared 
to matched WT mice (Fig. 5.3A). This may be indicative of the increased weight gain seen 
in female high fat fed Mnk2-KO mice (Fig. 5.1B, D). The muscle of chow-fed female Mnk2-
KO mice shows a similar pattern to male mice in that Mnk2-KO mice show significantly 
lower muscle mass (Fig. 5.3B). However, and interestingly, muscle mass increases 
significantly in female Mnk2-KO mice fed a high fat diet and does not decrease in WT 
mice fed high fat diets (Fig. 5.3B). There does not appear to be an obvious explanation for 
this. Liver mass also follows a similar pattern to males; both the left and right lobes if the 
liver decrease in both WT and Mnk2-KO mice fed high fat diets accept this is more 
pronounced in Mnk2-KO mice (Fig. 5.3C, D). This is likely due to the increased 
bodyweight gain in female Mnk2-KO mice fed high fat diets (Fig. 5.1B, D).       
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Figure 5.2. Organ weight data for male WT C57/BL6 and MNK2KO mice fed either normal 
chow diets or high fat (45% fat) diets. WT chow fed n=9, WT HF fed n=5, MNK2KO chow 
fed  n=4,  MNK2KO  HF  fed  n=  5.  A)  Weight  of  heart  from  each  experimental  group 
expressed  as  a  %  of  bodyweight,  Students’  t-test  was  used  to  analyse  the  data  ** 
indicates p<0.01 compared to WT chow fed, ++ indicates p<0.01 compared to MNK2KO 
chow fed.  B) Weight of the gastrocnemius skeletal muscle from each experimental group 
expressed  as  a  %  of  bodyweight,  Students’  t-test  was  used  to  analyse  the  data  ** 
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indicates p<0.01 compared to WT chow fed. C) Weight of the left lobe of the liver from 
each experimental group expressed as a % of bodyweight, Students’ t-test was used to 
analyse  the  data  **  indicates  p<0.01 compared  to WT chow  fed,  ++  indicates p<0.01 
compared to MNK2KO chow fed, ## indicates p<0.01 compared to WT high fat fed. D) 
Weight of the right lobe of the liver from each experimental group expressed as a % of 
bodyweight, Students’ t-test was used to analyse the data ** indicates p<0.01 compared 
to WT chow fed, ++ indicates p<0.01 compared to MNK2KO chow fed.  
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Figure  5.3.  Organ  weight  data  for  female WT  C57/BL6 and  MNK2KO mice  fed  either 
normal  chow  diets  or  high  fat  (45%  fat)  diets.  WT  chow  fed  n=8,  WT  HF  fed  n=5, 
MNK2KO  chow  fed  n=4,  MNK2KO  HF  fed  n=  5.  A)  Weight  of  heart  from  each 
experimental group expressed as a % of bodyweight, Students’ t-test was used to analyse 
the data ** indicates p<0.01 compared to WT chow fed,  ## indicates p<0.01 compared to 
WT high fat fed++ indicates p<0.01 compared to MNK2KO chow fed.  B) Weight of the 
gastrocnemius  skeletal  muscle  from  each  experimental  group  expressed  as  a  %  of 
bodyweight, Students’ t-test was used to analyse the data ** indicates p<0.01 compared 
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to WT chow fed. C) Weight of the left lobe of the liver from each experimental group 
expressed  as  a  %  of  bodyweight,  Students’  t-test  was  used  to  analyse  the  data  ** 
indicates p<0.01 compared to WT chow fed, ++ indicates p<0.01 compared to MNK2KO 
chow fed, ## indicates p<0.01 compared to WT high fat fed. D) Weight of the right lobe of 
the liver from each experimental group expressed as a % of bodyweight, Students’ t-test 
was used to analyse the data ** indicates p<0.01 compared to WT chow fed, ++ indicates 
p<0.01 compared to MNK2KO chow fed.  - 191 -   
5.2.2.2 Microscopic analysis of gastrocnemius skeletal muscle from male WT and Mnk2-
KO mice.  
The gastrocnemius skeletal muscle of Mnk2-KO mice fed normal diets presented with 
significantly decreased mass (Fig. 5.2B), since this is a key site for insulin-stimulated 
glucose uptake, it was important to establish if there was any obvious reason for this 
phenotype. Samples of gastrocnemius muscle were fixed in formalin upon death and then 
embedded in paraffin followed by haematoxylin and eosin (H&E) staining to define cellular 
structure. This revealed no overt differences between experimental groups (Fig. 5.4A).  
Following on from the histological analysis of skeletal muscle tissue, it was important to 
determine if there was any differences in IRS1 levels since the data presented in Chapter 
4 would indicate that this may be the case. The evidence indicates that Mnk2 regulates 
the levels of IRS1 by phosphorylation and subsequently protects IRS1 from degradation 
(Figs. 4.14-4.16). Furthermore, there was also a modest change in the IRS1 mRNA levels 
(Fig. 4.14B). High fat diets have been strongly implicated in the negative regulation of 
IRS1 protein levels, which is a key cause of insulin resistance [309, 310], however as an 
apparent feedback loop, IRS1 mRNA levels increase [311]. The IRS1 mRNA levels in 
chow-fed Mnk2-KO mice are significantly higher (Fig. 5.4B), which is the opposite from the 
data seen in knockout cells (Fig. 4.14B) However; the IRS1 protein levels are clearly lower 
in Mnk2-KO chow-fed mice (Fig. 5.4C), which is consistent with the role of Mnk2 in 
stabilization of IRS1. High fat diet fed WT males express lower IRS1 protein (Fig. 5.4C) 
with higher mRNA levels as anticipated (Fig. 5.4B), which is similar to the pattern seen in 
Mnk2-KO high fat fed males.  
These data suggest Mnk2-KO mice may exhibit skeletal muscle insulin resistance.  
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Figure 5.4. Analysis of  the characteristics of muscle from WT and MNK2KO mice fed 
chow or high fat diets. A) Haematoxylin and eosin stained gastrocnemius skeletal muscle. 
B) qPCR analysis of IRS1 mRNA levels from gastrocnemius skeletal muscle, results were 
normalised to 18S rRNA and expressed as fold difference in expression compared to WT 
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chow fed. Students’ t-test was used to analyse the data * indicates p<0.05 compared to 
WT  chow  fed,  +  indicates  p<0.05  compared  to  MNK2KO  chow  fed.  C)  Western  blot 
analysis of IRS1 protein levels in WT and MNK2KO mice from gastrocnemius skeletal 
muscle. Tubulin provides a loading control.    
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5.2.2.3 Microscopic analysis of the left lobe of the liver from male WT and Mnk2-KO mice.  
In high fat fed Mnk2-KO mice the left lobe of the liver significantly decreased in mass 
compared with WT high fat fed mice, which had significantly lower liver mass than WT 
chow-fed mice (Fig. 5.2C). Thus, it was of interest to examine the properties of the liver in 
each group. 
Histological analysis shows no obvious difference between WT and Mnk2-KO chow-fed 
mice (Fig. 5.5A). High fat diet feeding led to clear morphological changes in WT and slight 
changes in Mnk2-KO mice. In WT high fat fed mice there are distinctly more lipid droplets 
within liver cells, which is not the case in Mnk2-KO mice, which show visibly fewer 
droplets (arrows indicate examples (Fig. 5.5A)). These droplet are primarily TGs, which 
are generated from lipogenesis and dietary fat intake from fatty acids transported from the 
adipose to the liver. This is expected as a response to increased dietary fat intake. The 
reduction of droplets in Mnk2-KO high fat fed mice indicates either reduced lipogenesis in 
the liver, increased export in VLDL or reduced fatty acid input from adipose tissue.   
The liver is a vital site of carbohydrate and lipid metabolism and so it was important to 
look at signalling pathways involved in these processes in each experimental group. Since 
IRS1 is the key mediator of insulin signalling the levels of mRNA were assessed, which 
showed some key differences. In chow-fed Mnk2-KO mice, there was significantly higher 
expression however interestingly this did not increase with high fat diet feeding as it did in 
the WT mice (Fig. 5.5B). The explanation for this could be that chow-fed Mnk2-KO mice 
are mildly insulin resistant leading to an increase in expression of IRS1 mRNA to 
compensate, as occurs in WT high fat fed mice; however why in high fat fed Mnk2-KO 
mice levels do not increase further is not clear. The effect of high fat diet feeding in WT 
mice does not lead to decreased protein levels as would be expected (Fig. 5.5C) and 
increase in correlation to mRNA levels (Fig.5 .5B). Furthermore in Mnk2-KO mice of both 
groups IRS1 protein levels are about the same as high fat fed mice. Perhaps 12 weeks of 
high fat diet feeding does not lead to hepatic insulin resistance and so IRS1 is acutely 
upregulated to compensate for adipose and skeletal muscle insulin resistance. Also Mnk2-
KO chow-fed mice may also upregulate IRS1 in order to compensate for peripheral insulin 
resistance. To see if other components of the insulin signalling pathway were altered, 
p70S6K levels and its substrate S6 were assessed. p70S6K is a key regulator of IRS1 
levels by phosphorylation of IRS1, which results in the degradation of IRS1; this is a 
negative feedback loop as p70S6K is activated by mTORC1, which itself is activated by 
insulin [229]. The data for the levels of p70S6K were not clear, but it appeared they 
increased with high fat diet feeding in both WT and Mnk2-KO groups (Fig. 5.5C), - 195 -   
suggesting the beginnings of insulin resistance. The levels of S6 phosphorylation also 
increased with high fat diet feeding, although the total levels of S6 also increased. 
Interestingly the levels of total S6 were higher in Mnk2-KO chow-fed mice and slightly 
lower in Mnk2-KO high fat fed mice.    
 
To assess liver lipid biochemistry the levels of ATP citrate lyase (ATPCL) were analysed. 
As discussed in Chapter 1, section 1.4.2, ATPCL is the first point of lipogenesis from 
carbohydrates. As would be expected ATPCL is down regulated by high fat diet feeding in 
WT mice (Fig. 5.5C), since the mass increase in dietary lipids would switch off 
endogenous lipogenesis [10]. However, very interestingly, in chow-fed Mnk2-KO mice 
ATPCL is also largely decreased, which would indicate a dysfunction of hepatic lipid and 
carbohydrate metabolism in these mice, furthermore high fat diet feeding almost 
completely abolished ATPCL levels in Mnk2-KO mice (Fig. 5.5C).    
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Figure  5.5  Analysis  of  the  characteristics  of  the  left  lobe  of  the  liver  from  WT  and 
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MNK2KO mice fed chow or high fat diets. A) Haematoxylin and eosin stained left lobe of 
the liver. B) qPCR analysis of IRS1 mRNA levels from left lobe of the liver, results were 
normalised to 18S rRNA and expressed as fold difference in expression compared to WT 
chow fed. Students’ t-test was used to analyse the data * indicates p<0.05 compared to 
WT chow fed, ** indicates p<0.01 compared to WT chow fed and ## indicates p<0.01 
compared  to  WT  high  fat  fed.  C)  Western  blot  analysis  of  IRS1,    ATP  citrate  lyase, 
p70S6K kinase, phospho-ribosomal protein S6 Ser
240/244 and total S6 protein levels in WT 
and MNK2KO mice from left lobe of the liver. Tubulin provides a loading control. 
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5.2.3 Investigations into whole animal lipid homeostasis in WT and Mnk2-KO mice. 
The results from skeletal muscle, bodyweight and the liver indicate Mnk2-KO mice had 
distinctive differences in their morphology on a macroscopic scale. The reductions in 
organ size, but lack of weight gain, as well as distinct differences in the biochemistry of 
their tissues are suggestive of differences in lipid distribution and metabolism. Most 
importantly, Mnk2 is highly expressed in abdominal adipose and scapular adipose of mice 
(Fig. 4.1B) and so knock-out mice would be expected to show changes in their lipid 
profiles.  
5.2.3.1 Mnk2-KO mice exhibit an unusual fat distribution. 
Dual-energy X-ray absorptiometry (DEXA) scans are being increasingly used in both 
clinical and research settings owing to the ability to rapidly and accurately quantify lean 
soft tissue, fat and bone density [312]. This method was employed to gain a greater 
understanding of the composition of Mnk2-KO mice. The results were very striking and 
readily show that Mnk2-KO mice have far greater subcutaneous fat (yellow)(Fig. 5.6) as 
well as infiltration of fat into the soft tissue leading to an increased fat volume of Mnk2-KO 
mice (Fig. 5.7C). This was completely unexpected since these mice weigh less than WT 
mice (Fig. 5.1A, C). However Mnk2-KO mice look distinctly slimmer than WT a mouse, 
which is reflected in the quantitative analysis of body volume, which shows significantly 
lower volume (Fig. 5.7A), furthermore, these mice exhibit significantly decreased length 
compared with WT mice (Fig.  5.7B). High fat feeding, as expected, led to significantly 
increased body volume of WT mice and Mnk2-KO although Mnk2-KO mice still have 
significantly lower body volume (Fig. 5.6A). There is also a significant increase in fat 
volume of both WT and Mnk2-KO mice (Figs. 5.6, 5.7C), which is again confusing since 
high fat-fed Mnk2-KO mice do not gain weight (Fig. 1A, C). This disparity may be 
explained by significantly reduced body volume (Fig. 5.7A) and tissue volume (Fig. 5.7D) 
in Mnk2-KO mice on either normal chow or high fat diets.  
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Figure 5.6. DEXA data for male WT C57/BL6 and MNK2KO mice fed either normal chow 
diets or high fat (45% fat) diets. DEXA images of examples of each WT and MNK2KO 
from chow fed and HF fed diets. Red indicates soft tissue, yellow indicates fat and white 
indicates bone. 
 
 
   
WT chow fed WT HF fed MNK2KO chow fed MNK2KO HF fed- 200 - 
Figure 5.7 Quantitative analysis of DEXA data. WT chow fed n=6, MNK2KO chow fed 
n=7, WT HF fed n=5 and MNK2KO HF fed n= 5.  A) Body volume measured as mm
3. B) 
Animal length measured as mm. C) Fat volume measured as mm
3. D) Tissue volume 
measured as mm
3.  Students’  t-test  was  used  to  analyse  the  data  **  indicates  p<0.01 
compared  to  WT  chow  fed,  ++  indicates  p<0.01  compared  to  MNK2KO  chow  fed,  # 
indicates p<0.05 compared to WT high fat fed, ## indicates p<0.01 compared to WT high 
fat fed.  
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5.2.3.2 Mnk2-KO mice display morphological and biochemical differences in key fat 
storage depots.  
The apparent contradiction between the DEXA data and weight gain data suggested it 
was important to investigate further the properties of fat depots within Mnk2-KO mice. The 
scapular found in mice is important for non-shivering thermogenesis and is also found in 
human new-borns but has recently also been found in adult humans [313]. The abdominal 
adipose in mice is generally considered the equivalent of abdominal fat in humans, which 
is a depot that contributes to obesity [314]. These two fat depots were dissected from 
mice in each experimental group from male and female mice.  
The scapular adipose from male Mnk2-KO fed normal diets was significantly heavier than 
WT mice and remained increased to a greater extent when fed high fat diets (Fig. 5.8A). 
However, female Mnk2-KO mice only had significantly greater levels of scapular adipose 
when fed high fat diets (Fig. 5.8C). This is important when considering the lack of weight 
gain in male high fat fed Mnk2-KO mice because scapular adipose functions as a “sink” 
for disposing of glucose and NEFAs as it  rapidly generates energy due to its high 
mitochondrial content [315]. Interestingly, the presence of abdominal adipose is 
significantly reduced in chow-fed Mnk-2KO mice (Fig. 5.8B, D). This is important when 
considering whole animal lipid and glucose metabolism. However, when male Mnk2-KO 
mice are fed a high fat diet, there is still an increase in abdominal adipose although this is 
marginally lower (although not significant) than in WT mice (Fig. 5.8B). Female Mnk2-KO 
mice are distinctly different in this regard in that their abdominal adipose increases 
markedly with high fat diet feeding resulting in significantly greater amounts than high fat 
fed WT mice (Fig. 5.8D). This may account for the distinctive differences in weight gain 
when comparing high fat fed male and female Mnk2-KO mice (Fig. 5.1).  
The distinct difference in scapular adipose weight in male Mnk2-KO mice required further 
investigation in order to try to establish the role of Mnk2 in this tissue. As with the skeletal 
muscle and liver, it was of interest to assess scapular adipose by H&E staining. 
As with other highly metabolically active tissues, scapular adipose expresses IRS1. Since 
it has already been already shown that Mnk2 regulates the stability of IRS1 (Chapter 4), it 
was important to determine if scapular adipose showed any alterations in IRS1 levels. 
Surprisingly, the levels of both IRS1 mRNA and protein were increased in scapular 
adipose from Mnk2-KO mice fed normal chow diets (Fig. 5.9B, C). This would imply that 
scapular adipose in Mnk2-KO animals is better equipped to metabolize glucose. In WT 
and Mnk2-KO high fat fed mice, the IRS1 mRNA levels increased whilst protein levels 
decreased suggesting a degree of insulin resistance (Fig. 5.9B, C). This implies that if - 203 -   
there is a compensatory mechanism in chow-fed Mnk2-KO mice that boosts IRS1 levels, 
this mechanism is inactive when fed high fat diets.  
The histological analysis of scapular adipose showed no overt differences between chow-
fed WT and Mnk2-KO mice, however high fat diet feeding led to substantial increases in 
lipid droplets in Mnk2-KO mice compared with WT mice (Fig. 5.9A). Therefore, levels of 
adipocyte protein 2 (aP2, also known as fatty acid binding protein 4) were also checked. 
This protein plays a role in intracellular fatty acid trafficking [316]. Mnk2-KO mice fed 
normal chow diets exhibited increased levels of aP2 similar to those seen in high fat fed 
WT mice, but levels did not increase further with high fat diet feeding (Fig. 5.9C). 
Knockout of aP2 has been shown to ameliorate insulin resistance caused by diet induced 
obesity [317, 318] and this may therefore contribute to insulin resistance in chow-fed 
Mnk2-KO mice.    
Mnk2 is also highly expressed in the abdominal adipose of mice (Fig. 4.1B) and given that 
there are distinct differences in scapular adipose it was pertinent to assess abdominal 
adipose in the same way. Histological analysis showed that the abdominal adipose from 
chow-fed Mnk2-KO mice exhibited adipocytes that were visibly larger than those from 
chow-fed WT mice (Fig. 5.10A). This is perhaps consistent with the DEXA data (Fig. 5.6, 
5.7C), but does not follow with the weight data (Fig. 5.1A, C). High fat diet feeding results 
in hypertrophy of adipocytes from WT mice; however high fat fed Mnk-2KO mice do not 
show the same degree of hypertrophy (fig 5.10A). This is most evident when assessing 
the number of adipocytes in a given field; chow-fed Mnk2-KO mice have significantly 
fewer due to their moderate hypertrophy. High fat diet feeding causes a significant 
reduction in their numbers in both WT and Mnk2-KO mice although there is a trend 
towards a lesser reduction in high fat fed Mnk2-KO mice (Fig. 5.10B). These data 
indicated a potential difference in the balance of lipogenesis and lipolysis in Mnk2-KO 
mice, which is especially relevant given the differences in the amount of abdominal 
adipose in Mnk2-KO mice (Fig. 5.8B).  
 The evidence presented in Chapter 4 showed that Mnk1/2-DKO mice exhibit glucose 
intolerance, which may result from insulin resistance in abdominal adipose due to reduced 
IRS1 expression (Fig. 4.18B) Therefore, the mRNA levels of IRS1 were assessed in 
abdominal adipose. This showed that, on chow-fed diets, there was no difference between 
WT and Mnk2-KO mice; however upon high fat diet feeding IRS1 levels are significantly 
lower in Mnk2-KO mice whereas they do not change in WT mice (Fig. 5.11A). Analysis of 
the levels of IRS1 protein showed that high fat feeding in WT mice leads to reductions in 
the level of IRS1 protein, which could contribute to insulin resistance (Fig. 5.11C). As 
expected, chow-fed Mnk2-KO mice also show reduced levels of the protein, which given 
the evidence presented in Chapter 4, is consistent with Mnk2 positively regulating IRS1 - 204 - 
stability. Interestingly, high fat feeding only leads to a slight reduction in IRS1 levels in 
Mnk2-KO mice but this is less than the decrease in the mRNA levels, which could suggest 
some stabilisation of IRS1 in high-fat fed Mnk2-KO mice (Fig. 5.11C). Further down the 
insulin signalling pathway, there is an increase in total and phosphorylated S6 in high fat 
fed WT and Mnk2-KO mice, with no discernible difference between WT and Mnk2-KO 
mice on either diet (Fig. 5.11C). This indicates no change in mTORC1 signalling.  
Histological analysis of abdominal adipose revealed a difference in adipocyte size and 
number in Mnk2-KO mice and so the levels of mRNA for apolipoprotein E (ApoE) were 
assessed, because this protein has been linked to controlling adipocyte size [319, 320]. 
This analysis revealed that high fat diet feeding caused a reduction in ApoE levels in both 
Mnk2-KO mice and WT mice, which may be a protective mechanism to try to reduce 
hypertrophy (Fig. 5.11B). Further analysis revealed that chow-fed and high fat fed Mnk2-
KO mice show reduced levels of phosphorylated and total levels of acetyl CoA 
carboxylase (ACC) (Fig. 5.11C). This was also seen in high fat fed WT animals and has 
previously been shown to occur in animals fed a high fat diet, since lipogenesis is no 
longer necessary when dietary fat intake is high  [321, 322]. Furthermore insulin 
resistance caused by high fat diet feeding would lead to reduced ACC phosphorylation in 
response to insulin [138].  
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Figure 5.8. Organ weights of abdominal white adipose and scapular brown adipose from 
WT and MNK2KO mice fed chow or high fat diets WT chow fed n=6, MNK2KO chow fed 
n=4, WT HF fed n=5 and MNK2KO HF fed n= 5.  A) Weight of scapular adipose tissue 
from male mice expressed as a % of bodyweight. B) Weight of abdominal adipose tissue 
from male mice expressed as a % of bodyweight.  C) Weight of scapular adipose tissue 
from  female  mice  expressed as  a  % of  bodyweight.  D)  Weight  of  abdominal  adipose 
tissue from female mice expressed as a % of bodyweight. Students’ t-test was used to 
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analyse  the  data  **  indicates  p<0.01  compared  to  WT  chow  fed,  +  indicates  p<0.05 
compared to MNK2KO chow fed, ++ indicates p<0.01 compared to MNK2KO chow fed 
and ## indicates p<0.01 compared to WT high fat fed.   
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Figure 5.9. Analysis of the characteristics of scapular adipose in WT and MNK2KO mice 
fed chow or high fat diets. A) Haematoxylin and eosin stained scapular adipose. B) qPCR 
analysis of IRS1 mRNA levels from scapular adipose, results were normalised to 18S 
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rRNA  and  expressed  as  fold  difference  in  expression  compared  to  WT  chow  fed. 
Students’ t-test was used to analyse the data * indicates p<0.05 compared to WT chow 
fed, T indicates p<0.1 compared to WT high fat fed. C) Western blot analysis of IRS1 and 
aP2 protein levels from scapular adipose. Tubulin provides a loading control.  
   - 209 -   
 
Figure 5.10. Analysis of the characteristics of abdominal adipose in WT and MNK2KO 
mice fed chow or high fat diets. A) Haematoxylin and eosin stained abdominal adipose. B) 
Adipocyte  numbers  from  10  consecutive  fields  from  3  different  mice  per  experimental 
group. Students’ t-test was used to analyse the data * indicates p<0.05 compared to WT 
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chow fed, ** indicates p<0.01 compared to WT chow fed, ++ indicates p<0.01 compared 
to MNK2KO chow fed and t indicates p<0.1 compared to WT high fat fed. 
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Figure 5.11. Analysis of  the characteristics of abdominal adipose in WT and MNK2KO 
mice fed chow or high fat diets. A) qPCR analysis of IRS1 mRNA levels from abdominal 
adipose,  results  were  normalised  to  18S  rRNA  and  expressed  as  fold  difference  in 
expression compared to WT chow fed. Students’ t-test was used to analyse the data + 
indicates p<0.05 compared to MNK2KO chow fed and t indicates p<0.1 compared to WT 
high fat fed. B) qPCR analysis of ApoE mRNA levels from  abdominal adipose, results 
were normalised to 18S rRNA and expressed as fold difference in expression compared 
to  WT  chow  fed.  Students’  t-test  was  used  to  analyse  the  data  t  indicates  p<0.05 
compared to WT chow fed and t+ indicates p<0.1 compared to MNK2KO chow fed. C) 
Western blot analysis of IRS1, phospho-acetyl CoA carboxylase (ACC) Ser
79, total ACC, 
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phospho-S6  Ser240/244  and  total  S6  protein  levels  from  abdominal  adipose.  Tubulin 
provides a loading control.  - 213 -   
5.2.3.3 Mnk2-KO mice display altered levels of plasma lipid metabolites. 
The data presented so far show that Mnk2-KO mice have an unusual phenotype with 
regards to their fat distribution and weight gain in response to normal and high fat diets. 
Plasma levels of lipid metabolites were therefore analysed (at the Cambridge NHS 
Hospitals Trust).  
As discussed in Chapter 1 (section 1.4.5), leptin is a key adipokine that regulates food 
intake and insulin sensitivity. In Mnk2-KO chow-fed mice leptin was significantly elevated 
(Fig. 5.12A); this may be a consequence of increased subcutaneous fat levels in these 
mice (Fig. 5.6). With high fat diet feeding, there is a very substantial increase in plasma 
leptin levels in both WT and Mnk2-KO mice, as expected [153] (Fig. 5.12A).  
The regulation of NEFAs, TGs and cholesterol is tightly mediated by the liver and adipose 
in response to insulin, nutrients, glucose and peripheral energy requirements. The levels 
of NEFAs in chow-fed Mnk2-KO mice were no different from those in WT mice. However, 
there was a significant increase in NEFAs in Mnk2-KO mice with high fat diet feeding, 
which was not seen in high fat fed WT mice (Fig. 5.12B). This may indicate an increase in 
NEFA spillover from the hydrolysis of TGs, a point that is supported by the observation 
that high fat fed Mnk2-KO mice have significantly increased TG levels (Fig. 5.12C). 
Interestingly chow-fed Mnk2-KO mice have reduced TG levels compared with chow-fed 
WT mice, which may be a result of the significantly lower levels of abdominal adipose 
(Fig. 5.8B). Furthermore, this suggests increased lipolysis of adipose tissue, followed by 
the repacking into VLDL by the liver and therefore the reduced size of adipocytes in high 
fat fed Mnk-2KO mice (Fig. 5.10B). The levels of total cholesterol are significantly lower in 
chow-fed Mnk2-KO mice and increase significantly with high fat diet feeding whilst there is 
only a trend in high fat fed WT mice for increased levels (Fig. 5.12D). The combination of 
increased NEFAs, TGs and cholesterol in high fat fed Mnk2-KO mice would suggest in 
combination with reduced levels of tissue IRS1 that these mice would be severely insulin 
resistant. The difference in plasma lipids is also reflected in the levels of the ketone body 
β-hydroxybutyrate, which are lower in chow-fed Mnk2-KO mice but substantially increased 
with high fat diet feeding (Fig. 5.12E). These results suggest that the reduction in stored 
fat in the adipose tissue reflects its use by the liver and possibly peripheral tissues as an 
energy source.  
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Figure 5.12  Fasting levels of plasma proteins in male WT and MNK2KO mice fed on 
either chow of high fat diets. For Leptin n= 4 WT chow fed, n=5 MNK2KO chow fed and 
high fat fed, n=5 WT high fat fed. For all other analyses n= 6 WT chow fed, n=6 MNK2KO 
chow fed, n=5 WT and MNK2KO high fat fed.  A) Fasting leptin levels. B) Fasting non-
esterified  fatty  acid  (NEFA)  levels  C)  Fasting  triglyceride.  D)  Fasting  Cholesterol.  E) 
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Fasting β hydroxybutyrate levels n= 6 WT chow fed, n=7 MNK2KO chow fed, n=5 WT and 
MNK2KO high fat fed. Data was analyzed using Student’s t-test; * indicates p>0.05 when 
compared  to WT chow  fed,  **  indicates  p>0.01  when  compared  to WT  chow  fed,  ## 
indicates p>0.01 when compared to WT high fat fed, + indicates p<0.05 when compared 
to MNK2KO chow fed, ++ indicates p<0.01 when compared to MNK2KO chow fed.  
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5.2.4 Investigations into whole animal metabolism. 
A simple and informative method to assess the basic behaviour and metabolism of mice is 
to place them into a metabolic cage. This apparatus measures food intake and overall 
activity of its residents.  
5.2.4.1 Mnk2-KO mice exhibit differences in metabolic parameters. 
The most obvious difference that could account for any differences in metabolism and 
weight gain is the amount of food consumed and thus energy intake. This was assessed 
in the chow-fed mice; the results show there is no difference between WT and Mnk2-KO 
mice (Fig. 5.13A). Due to the consistency of the high fat diet, which was easily crumbled 
in the food hopper, it was not appropriate to measure its intake and so the diet was placed 
into the cage in a small bowl instead.  
The disparity between weight gain of high fat fed WT and Mnk2-KO mice could be 
explained by changes in activity. When the activity of Mnk2-KO mice was assessed a 
contradictory effect was seen, which showed a significant increase in activity on chow 
diets but significant decreases with the high fat diet (Fig. 5.13D). The WT mice were not 
different between diets. Assessment of the consumption of oxygen and production of CO2 
would be useful to identify substrate utilization in each experimental group and can also 
be used to generate energy expenditure profiles. Unfortunately due to a malfunction of 
this part of the metabolic cage although this was measured the data are invalid. A repeat 
of this experiment would be very important.      
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Figure 5.13. Metabolic assessment of WT and MNK2KO mice fed either chow or high fat 
diets. WT chow fed n=9, WT and MNK2KO high fat fed n=5 and MNK2KO chow fed n=8. 
A)  Food  intake  was  continuously  measured  using  an  extensiometric  food  weight 
transducer device (Panlab SLU, Spain). B) Physical activities of the mice were monitored 
by an infrared photocell beam interruption method (Panlab SLU, Spain). Student’s t-test 
was used to analyse the results * indicates p<0.05 compared to WT chow fed and ++ 
indicates p<0.01 compared to MNK2KO chow fed.  
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5.2.4.2 Mnk2-KO mice display altered biochemistry of energy regulators in scapular 
adipose. 
The scapular adipose is a major site of energy regulation in mice and so it is important to 
assess the biochemistry of this fat depot. Assessment of the uncoupling protein 1 (UCP1) 
was important because this protein is associated with increased substrate oxidation 
coupled with low ATP production [323]. This analysis revealed that UCP1 expression was 
significantly increased in high fat fed WT mice as expected (Fig. 5.14A) [323]. 
Interestingly, UCP1 expression was significantly increased in chow-fed Mnk2-KO mice, 
trending towards lower levels in high fat fed Mnk2-KO mice compared with WT high fat fed 
mice (Fig. 5.14A). It would be expected that increased UCP1 expression would lead to 
increased energy expenditure. However data from UCP1 knockout mice actually show the 
loss of UCP1 led to increased energy expenditure [324-326]. The reasons for this effect 
are not overtly clear. The expression of UCP1 is controlled by PPARγ and the PPARγ 
coactivator-1ʱ (PGC1ʱ) and so possible changes in expression in both PGC1ʱ and 
PPARγ in scapular adipose were investigated [327]. Analysis of the mRNA levels of 
PGC1ʱ were confusing since chow-fed Mnk2-KO mice had significantly decreased levels, 
which did not change with high fat diet feeding, whilst WT high fed mice also exhibited 
significantly reduced expression (Fig. 5.14B). This did not correlate with the changes in 
UCP1 expression (Fig. 5.14A). The levels of PPARγ protein exhibited the opposite pattern 
to PGC1ʱ expression, such that there was an increase in expression levels in Mnk2-KO 
chow-fed, WT and Mnk2-KO high fat fed mice (Fig. 5.14C). Therefore, it is likely there are 
additional mechanisms controlling UCP1 expression such as transcript stability.    
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Figure 5.14. Analysis of the components of fat utilization of scapular adipose in WT and 
MNK2KO mice fed chow or high fat diets. A) qPCR analysis of UCP1 mRNA levels from 
scapular adipose, results were normalised to 18S rRNA and expressed as fold difference 
in expression compared to WT chow fed. Students’ t-test was used to analyse the data * 
indicates p<0.05 compared to WT chow fed, t indicates p<0.1 compared to WT high fat 
fed and t+ indciates p<.0.1 compared to MNK2KO chow fed. B) qPCR analysis of PGC1ʱ 
mRNA levels from scapular adipose, results were normalised to 18S rRNA and expressed 
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as fold difference in expression compared to WT chow fed. Students’ t-test was used to 
analyse  the  data  **  indicate  p<0.01  compared  to  WT  chow  fed  *  indicates  p<0.05 
compared  to  WT  chow  fed.  C)  Western  blot  analysis  of  PPAR  γ  protein  levels  from 
scapular adipose. Tubulin provides a loading control.  
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5.2.5 Investigations into whole animal glucose homeostasis in WT and Mnk2-KO 
mice. 
The standard assessment for glucose homeostasis is the glucose tolerance test. This test 
indicates the presence of insulin resistance and is very simple to conduct. Information 
from this test can be analysed in combination with the differences in insulin levels to 
determine the progression of insulin resistance towards fully developed T2DM.  
 
5.2.5.1 Mnk2-KO mice show insulin resistance on chow-fed diets but resistant to diet 
induced insulin resistance.  
To determine the relationship between fasting glucose and insulin in WT and Mnk2-KO 
mice fed normal and high fat diets, upon death total blood was removed by cardiac 
puncture (as described in Chapter 2, section 2.5.5). Normal fasting glucose levels are 
around 5-6.1 mmol/L in both mice and humans [107, 120], whilst fasted insulin levels vary 
considerably within the C57BL/6 strain [328, 329]. Fasting glucose levels for chow-fed 
Mnk2-KO mice were significantly increased compared with chow-fed WT mice (Fig. 
5.15A), this was expected given the reduction in IRS1 levels in insulin-sensitive tissues as 
described throughout this chapter. Furthermore, WT high fat fed mice exhibited 
substantially increased fasted glucose levels indicative of severe insulin resistance, which 
again was expected based on the literature [329] and the data presented throughout this 
chapter. Very surprisingly high fat fed Mnk2-KO mice had significantly lower fasting 
glucose compared with WT high fat fed and trended towards a reduction compared to 
Mnk2-KO chow-fed mice to a level similar to WT chow-fed mice (Fig. 5.15A). This was 
completely unexpected and indicates high fat fed Mnk2-KO mice are protected from the 
detrimental effects of increased plasma NEFAs, TGs and cholesterol (Fig. 5.12B, C & D). 
This meant it was essential to determine the fasting levels of insulin and to calculate 
insulin resistance within the groups. This analysis revealed that chow-fed Mnk2-KO have 
significantly increased fasting insulin levels (Fig. 5.15B), likely in an attempt to 
compensate for reduced glucose clearance by target tissues. High fat diet feeding also led 
to a significant increase in fasting insulin levels in WT mice, again as would be expected 
to compensate for insulin resistance. Insulin levels were also increased in high fat fed 
Mnk2-KO mice, but this was not significant (Fig. 5.15B). A widely-used calculation to 
determine insulin resistance is the homeostatic model assessment of insulin resistance 
(HOMA-IR). This equation was developed to describe the relationship between fasting 
insulin and glucose; although originally developed for humans, it is accurate for use with 
mice and rats [329-331]. This calculation revealed that chow-fed Mnk2-KO mice are - 222 - 
insulin resistant but upon high fat diet feeding this does not change where as high fat fed 
WT mice are severely insulin resistant (Fig. 5.15C).     
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Figure 5.15  Fasting levels of plasma proteins in male WT and MNK2KO mice fed on 
either chow of high fat diets, n=5 WT and MNK2KO chow fed, n=4 WT and MNK2KO high 
fat fed. A) Fasting glucose levels. B) Fasting insulin levels. C) Fasting glucose and fasting 
insulin were used to calculate HOMA-IR using the normalization factor of 22.5 (fasting 
glucose  X  fasting  insulin  /  22.5).  Data  was  analyzed  by  Student's  t-test;  **  indicates 
p>0.01 when compared to WT chow fed, ## indicates p>0.01 when compared to WT high 
fat fed, t indicates p<0.1 when compared to MNK2KO chow fed.  
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5.2.5.2 Mnk2-KO mice are protected from diet induced glucose intolerance.  
In order to better understand the effect of Mnk2 knockout on glucose homeostasis the 
glucose tolerance test (GTT) approach was used. Mice were fasted overnight and an 
initial basal reading was taken before intraperitoneal injection of glucose and 
measurements across 2hrs (as described in Chapter 2, section 2.5.3).  
Male chow-fed Mnk-2KO mice exhibited no difference in GTT; accept for elevated fasting 
glucose levels (Fig. 5.16A, B). However, high fat diet feeding revealed stark differences 
between WT and Mnk2-KO mice; as expected WT high fat fed mice had significantly 
elevated fasting glucose as well as poor glucose clearance (Fig. 5.16A, B). Mnk2-KO high 
fat fed mice exhibited significantly better glucose clearance than high fat fed WT mice, 
although not as good as chow-fed mice (Fig. 5.16A, B). This is consistent with the data 
presented in section 5.2.5.1, which provides strong evidence for a protective mechanism 
of Mnk2 knockout. 
Female Mnk-2KO mice similar results as males. The only clear difference is that chow-fed 
female Mnk2-KO mice have significantly improved glucose tolerance compared to WT 
chow-fed mice, which although is significantly poorer with high fat diet feeding, is still 
better than high fat fed WT females (Fig. 5.16C, D). 
The fact that the same glucose homeostasis phenotype is exhibited by both male and 
female high fat fed Mnk2-KO mice strongly supports the notion that an unidentified 
mechanism compensates for high fat diet induced insulin resistance.  
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Figure  5.16. Assessment of  glucose metabolism  in WT  and  MNK2KO mice  fed  either 
chow or high at diets. A) Glucose tolerance tests in male mice, n=9 WT chow fed, n=10 
MNK2KO chow fed, N=5 WT and MNK2KO high fat fed. Mice were fasted for 18 hours 
prior to the GTT, glucose was injected into the intraperitoneal cavity and at 15, 30, 60, 90 
and 120 minutes blood glucose was sampled from the tail of each mouse. B) Area under 
the curve for male mice calculated using the trapezoid rule and Student's t-test used to 
analyze the data. C) Glucose tolerance tests in female mice, n= 5 WT chow fed, n=4 
MNK2KO chow fed, n= WT and MNK2KO high fat fed. Mice were fasted for 18 hours prior 
to the GTT, glucose was injected into the intraperitoneal cavity and at 15, 30, 60, 90 and 
120 minutes blood glucose was sampled from the tail of each mouse. D) Area under the 
0
5
10
15
20
25
30
35
0 15 30 60 90 120
G
l
u
c
o
s
e
 
(
m
m
o
l
/
L
)
Time Post IP (min)
WT Chow Fed
MNK2KO Chow Fed
WT High Fat Fed
MNK2KO High Fat Fed
0
500
1000
1500
2000
2500
3000
3500
Chow Fed High Fat Fed
A
U
C
WT MNK2KO
##
** ++
0
500
1000
1500
2000
2500
3000
3500
Chow Fed High Fat Fed
A
U
C
WT MNK2KO
##
**
**
++
0
5
10
15
20
25
30
35
0 15 30 60 90 120
G
l
u
c
o
s
e
 
(
m
m
o
l
/
L
)
Time Post IP (min)
WT Chow Fed
MNK2KO Chow Fed
WT High Fat Fed
C
A B
D- 226 - 
curve for female mice calculated using the trapezoid rule and Student's t-test used to 
analyze the data.  
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5.2.6 Mnk2-KO mice exhibit a beneficial inflammatory profile in response to high fat 
feeding.  
The surprising finding that shows improved glucose tolerance in Mnk2-KO mice compared 
with WT mice fed high fat diets meant it was necessary to investigate the potential 
mechanism(s) for this. Since the lipid profile of Mnk2-KO mice suggested there would be 
very poor glucose tolerance, it was important to assess the inflammatory aspects of 
obesity-induced insulin resistance.  
There is a wealth of evidence to suggest alterations in adipose T-cell populations in 
relation to the low grade inflammation associated with obesity (as discussed in Chapter 1, 
section 1.4.6). In order to investigate this, RT-qPCR was used to determine the levels of a 
number of different mRNAs associated with inflammation in the abdominal adipose of 
mice. Assessment of the pan T-cell marker CD3 revealed no discernible differences 
between experimental groups (Fig. 5.17A). The Th1 cell specific marker CXC chemokine 
receptor 3 (CXCR3) [332] was therefore examined to assess any changes in expression, 
which may be indicative of increased Th1 cell activation. This revealed some unexpected 
results; chow-fed Mnk2-KO mice had significantly higher levels of CXCR3, which were 
much greater than those in WT and Mnk2-KO high fat fed mice (Fig. 5.17B). WT high fat 
fed mice had significantly higher levels compared with chow-fed mice and Mnk2-KO high 
fat fed mice exhibited similar levels. It is interesting that high fat diet feeding in Mnk2-KO 
mice causes a complete reversal of this effect. A possible explanation for this 
phenomenon is the expression of a chemotactic factor for T cells called ‘regulated on 
activation normal T cell expressed and secreted’ (RANTES). This chemokine attracts T 
cells and macrophages resulting in infiltration into sites of inflammation [332, 333]. In 
Mnk2-KO chow-fed mice there are significantly higher levels of RANTES compared to WT 
chow-fed mice (Fig. 5.17C); however importantly this does not increase with high fat diet 
feeding as compared with WT high fat fed mice (Fig. 5.17C). Another chemokine 
associated with the inflammatory state of high fat diet feeding is monocyte 
chemoattractant protein 1 (MCP-1), which is linked to the infiltration of macrophages into 
abdominal adipose [334]. Again, there is an increase in expression in chow-fed Mnk2-KO 
mice, which does not increase with high fat diet feeding unlike in WT high fat fed mice 
(Fig. 5.17D). These data indicate Mnk2-KO mice fed normal diets have a low but 
significantly increased level of inflammation, which may account for the insulin resistance 
seen in these mice (Fig. 5.15C). Furthermore, this inflammation may be linked to the lower 
levels of abdominal adipose (Fig. 5.8A) and increased levels of subcutaneous fat (Fig. 
5.6).  
Increases in infiltration of Th1 cells and macrophages into abdominal adipose as a result 
of obesity are strongly correlated with increases in inflammatory cytokines produced by - 228 - 
these cells. There is strong evidence to support an increase in IFNγ protein and mRNA 
expression by Th1 cells, which is associated with increased TNFʱ expression and the 
increase in macrophage expression of TNFʱ [335, 336]. The expression of both IFNγ and 
TNFʱ was significantly increased in WT mice fed high fat diets but importantly this was not 
the case for high fat fed Mnk2-KO mice (Figs. 5.17E, F). This is further supported by 
reduced plasma levels of IFNγ (Fig. 5.18A). Additionally high fat fed Mnk2-KO mice exhibit 
increased plasma CXCL-1 levels (fig 5.18B), which may be beneficial due to a link with 
muscle fatty acid oxidation [337]. Another plasma cytokine that was elevated in Mnk2-KO 
mice was IL-6 (levels were below threshold in chow-fed mice and only detectable in 2 high 
fat fed WT and 3 high fat fed Mnk2-KO mice), which has both beneficial and damaging 
effects (as discussed in Chapter 1, section 1.5.5) (Fig. 5.18C). These data indicate a 
mechanism for improved glucose tolerance in high fat fed Mnk2-KO mice (Fig. 5.16).  
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Figure 5.17. Analysis of the inflammatory characteristics of abdominal adipose in WT and 
MNK2KO mice fed chow or high fat diets. For CXCR3 n=3, for all experimental groups 
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and for all other analyses n=4. A) qPCR analysis of CD3 mRNA levels from abdominal 
adipose,  results  were  normalised  to  18S  rRNA  and  expressed  as  fold  difference  in 
expression compared to WT chow fed. B) qPCR analysis of CXCR3 mRNA levels from 
abdominal  adipose,  results  were  normalised  to  18S  rRNA  and  expressed  as  fold 
difference in expression compared to WT chow fed. C) qPCR analysis of RANTES mRNA 
levels from abdominal adipose, results were normalised to 18S rRNA and expressed as 
fold difference in expression compared to WT chow fed. D) qPCR analysis of  MCP-1 
mRNA  levels  from  abdominal  adipose,  results  were  normalised  to  18S  rRNA  and 
expressed as fold difference in expression compared to WT chow fed. E) qPCR analysis 
of IFNγ mRNA levels from abdominal adipose, results were normalised to 18S rRNA and 
expressed as fold difference in expression compared to WT chow fed. F) qPCR analysis 
of TNFʱ mRNA levels from abdominal adipose, results were normalised to 18S rRNA and 
expressed as fold difference in expression compared to WT chow fed. Students’ t-test was 
used  to  analyse  the  data  *  indicates  p<0.05  compared  to  WT  chow  fed,  **  indicates 
p<0.01 compared to WT chow fed, + indicated p<0.05 compared to MNK2KO chow fed 
and # indicates p<0.05 compared to WT high fat fed.   
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Figure 5.18. Analysis of the inflammatory characteristics in plasma of WT and MNK2KO 
mice fed chow or high fat diets.  A) Fasting plasma levels of INFγ WT chow fed n=3, 
MNK2KO chow  fed n=5, WT high  fat  fed n=5,  MNK2KO high  fat  fed n=3.  B) Fasting 
plasma levels of CXCL-1 WT chow fed n=6, MNK2KO chow fed n=7, WT high fat fed n=5, 
MNK2KO high fat fed n=4 C) Fasting plasma levels of IL-6 WT high fat fed n=2, MNK2KO 
high  fat  fed  n=3.  Students’  t-test  was  used  to  analyse  the  data  *  indicates  p<0.05 
compared to WT chow fed, + indicated p<0.05 compared to MNK2KO chow fed and # 
indicates p<0.05 compared to WT high fat fed.   
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5.3 Discussion 
The Mnks were discovered over 15 years ago [38, 39] and have since been widely 
researched within the context of tumorigenesis [31, 40, 78, 279]. However, apart from one 
report that suggested no overt phenotype in Mnk1/2-DKO mice [45], very little research 
has been conducted with regards to other functions of the Mnks. Patents concerning the 
use of Mnk agents to treat metabolic disease have been registered [106, 228]. The data 
presented in these patents led to the investigation into the role of the Mnks in metabolism. 
In this Chapter, the data show that knockout of only Mnk2 has a profound effect on both 
lipid and glucose metabolism. Challenging these mice with a high fat diet led to further 
distinctive differences compared with high fat fed WT mice. This raises important 
considerations in terms of obesity and T2DM.  
 
The effect of high fat diet feeding in Mnk2-KO mice showed stark differences dependent 
on gender, with males gaining no weight and females gaining more weight compared with 
their WT counterparts. This disparity was not further investigated here but is of interest for 
future work. There were some consistencies between male and female mice when 
assessing the organs of these mice; Mnk2-KO mice exhibited increased heart size, 
reduced muscle mass and reduced abdominal adipose mass. Furthermore, when fed a 
high fat diet changes to muscle and fat mass may account for the reduced body weight in 
males and increased body weight in females. In males muscle mass and abdominal 
adipose mass did not increase to the extent seen in female mice. The interpretation of 
lack of weight gain by high fat fed male Mnk2-KO mice was further complicated when the 
DEXA data was analysed. This revealed an increased fat volume and reduced tissue 
volume in both chow and high fat diet fed Mnk2-KO mice, which is contradictory with 
regards to their lower weight. The explanation for this may be their reduced length, body 
volume, muscle mass and amount of abdominal adipose. The problem with DEXA 
analysis is that total fat volume is measured and cannot be divided into subcutaneous, 
retroperitoneal, abdominal and so forth. The images from the DEXA analysis appear to 
show that Mnk2-KO have more subcutaneous fat whilst dissection revealed less 
abdominal fat, however, there appeared to be more interstitial fat between the organs. 
This is important when considering the contributions of different fat depots to the 
consequences of obesity. Subcutaneous fat releases adipokines but is not as 
metabolically active as visceral fat [338]. Furthermore there is evidence subcutaneous fat 
can be protective, its removal does not improve glucose metabolism [339] whilst 
thiazolidinediones increase subcutaneous fat deposition with an improvement in insulin - 233 -   
sensitivity [340] and furthermore, transplantation of subcutaneous fat in place of visceral 
fat leads to improved glucose metabolism [341]. This could be one of the factors that 
contribute towards the improved glucose tolerance seen in high fat fed Mnk2-KO mice.  
The original expectation was that Mnk2-KO mice would exhibit increased insulin 
resistance compared with WT mice due to the observations seen in Chapter 4. Both Mnks 
regulate IRS1 stability by reducing its degradation as a consequence of their 
phosphorylation of this protein. This meant that knockout of both Mnks leads to impaired 
glucose tolerance as seen in chow-fed Mnk1/2-DKO mice. This is likely attributable to 
reduced IRS1 expression in abdominal adipose. A similar result was seen in chow-fed 
Mnk2-KO mice but the decrease in IRS1 in Mnk2-KO high fat fed mice was not as great 
as in high fat fed WT mice. However, there were slightly reduced levels of IRS1 in the 
muscle of Mnk2-KO animals, which were reduced by high fat feeding to similar levels as 
high fat fed WT mice. In the liver mRNA levels of IRS1 did not correlate with protein 
levels, in chow-fed Mnk2-KO mice IRS1 mRNA was increased but not changed with high 
fat diet feeding whilst WT high fat fed mice had much higher levels. IRS1 protein 
appeared slightly greater in high fat fed Mnk2-KO mice compared with high fat fed WT 
mice despite lower mRNA levels. The mild insulin resistance and increased fasting 
glucose levels seen in chow-fed Mnk2-KO mice may be attributed to the amount of IRS1 
in insulin sensitive tissues but the lack of any increases in insulin resistance with high fat 
diet feeding was not correlated with IRS1. These data imply that Mnk2-KO mice have a 
protective mechanism that allows them to maintain insulin sensitivity. The evidence from 
IRS1 knockout mice shows that, although they do develop insulin resistance, they do not 
exhibit T2DM and more importantly IRS2 knockout mice display T2DM due to reduced 
insulin secretion and severe hepatic insulin resistance [342, 343].  
 
One of the major contributing factors to diet-induced insulin resistance and T2DM is the 
increase in plasma NEFAs, TGs and cholesterol [175]. In chow-fed Mnk2-KO mice there 
were distinctly lower levels of TGs and cholesterol, which probably reflects their reduced 
abdominal adipose mass and increased UCP1 expression, indicating a utilization of fat for 
energy. Interestingly, in high fat Mnk2-KO mice, the reduced abdominal adipose mass and 
number/size of adipocytes may lead to overspill of TGs, NEFAs and cholesterol, into 
circulation causing levels of these lipid metabolites to be much higher in high fat fed 
Mnk2-KO mice. Furthermore the data is indicative of a reduction in the storage of TGs in 
the liver as demonstrated by reduced droplets observed in H&E stains. This suggests that 
although there is an increase in fatty acids, which would be generated by lipolysis from 
adipose tissue, there is a reduction in TG storage in the liver. This indicates that there is 
an increase in TG export as VLDL and therefore explains the increased plasma TG levels - 234 - 
in high fat fed Mnk2-KO mice. The increased size of adipocytes from scapular adipose 
suggests the increased TGs are being deposited in this organ instead of the liver or even 
possibly the muscle. A diagram demonstrating this model can be seen Fig. 5.19. Further 
analysis of liver and muscle TG levels would be important to verify this. It would be 
expected that increased plasma TGs would contribute to insulin resistance and β cell 
dysfunction and thus that Mnk2-KO mice would present with T2DM. In fact, this is not the 
case perhaps because there is a reduction in UCP1 expression and increased β-
hydroxybutyrate indicating more efficient fatty acid oxidation. This may also be helped by 
the increase in CXCL-1, which can activate fatty acid oxidation in muscle [322]. 
Furthermore, these data indicate that the altered lipid levels are not the major factor 
contributing to insulin resistance in the WT high fat fed mice when compared with the 
better performing Mnk2-KO mice. 
The other major contributing factor to insulin resistance in diet-induced obesity is adipose 
inflammation [177, 183, 184]. As presented in Chapter 4, the Mnks and especially Mnk2, 
are highly expressed in the abdominal adipose and appear to have a major role in lipid 
metabolism; however the Mnks have also been strongly linked to enhancing the 
expression of inflammatory cytokines [41, 42, 44, 80]. The investigation into the levels of 
inflammatory cytokines and chemokines in high fat fed mice lead to what is probably the 
causative component that explains improved glucose tolerance in Mnk2-KO mice.  
However, this is not simple because there are increases in RANTES, CXCR3 and MCP-1 
in chow-fed Mnk2-KO mice. The expression of RANTES has previously been shown to be 
regulated by Mnk1 through modulating the translation of the transcription factor RANTES 
factor of late-activated T lymphocytes-1 (RFLAT-1) [283]. Activation of Mnk1 was 
associated with increased RFLAT-1 protein and RANTES. In Chapter 3 the activation of 
Mnk1 in response to PMA was significantly greater in Mnk2-KO cells compared to WT 
cells, it is possible the knockout of Mnk2 may lead to the moderate increase in RANTES 
seen in chow-fed Mnk2-KO mice due to increased activity of Mnk1. However the stimulus 
for inflammation caused by high fat diet feeding must require Mnk2 for RANTES 
expression and so there is no increase in high fat fed Mnk2-KO mice and this may also be 
the case for MCP1 and CXCR3, presenting an interesting avenue for further investigation.  
The major finding of this work is that neither IFNγ nor TNFʱ is induced by high fat diet 
feeding in Mnk2-KO mice, which may be the most convincing evidence for the improved 
glucose tolerance in these mice. Very recently the expression of IFNγ has been shown to 
be reduced in Mnk1/2-DKO mice specifically from Th1 cells in response to myelin 
oligodendrocyte glycoprotein in a model of autoimmune encephalomyelitis, although the  - 235 -   
 Figure 5.19. Model of Lipid Metabolism in WT and MNK2KO mice fed high fat diets. 
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into fatty acids, which are released into the hepatic portal vein as non-esterified fatty acids 
(NEFAs), most of which enter the liver. In the liver NEFAs are re-esterified in TGs and 
exported as very low density lipoprotein (VLDL). VLDL interacts with lipoprotein lipase 
(LPL) at numerous organs and releases NEFAs, which are either taken up by the target 
tissue and stored as TGs or used for energy in β-oxidation.   
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authors do not show any direct evidence for the mechanism but allude to the potential role 
of eIF4E phosphorylation [281]. The translation of TNFʱ has been shown to be regulated 
by the Mnks through phosphorylation of hnRNPA1 and PSF.p54
nrb [41, 42], which 
suggests the loss of Mnk2, may result in reduced translation of TNFʱ and the subsequent 
degradation of TNFʱ mRNA leading to the results seen in this study. It would be very 
interesting to see if mice expressing the non-phosphorylatable S209A eIF4E mutant are 
also resistance to diet-induced insulin resistance and show reduced adipose inflammation. 
If this was the case then it indicates that Mnk-dependent eIF4E phosphorylation is the 
mechanism by which the Mnks contribute to diet-induced insulin resistance in a normal 
mouse.  
Despite the differences in weight gain between male and female Mnk2-KO mice, a similar 
protection from insulin resistance was seen, suggesting inflammation is more important 
than the amount of fat. The reductions in inflammatory cytokines alone may well explain 
this protection based on evidence from IFNγ knockout mice, which show a very similar 
protection from diet-induced insulin resistance and exhibit similar reductions in RANTES, 
MCP-1 and TNFʱ [336]. TNFʱ null mice showed a moderate protection against diet-
induced obesity [344] and there is a wealth of evidence supporting the role of TNFʱ in 
mediating insulin resistance (reviewed [188]).  
The avenues for further research from the data presented here are numerous and 
potentially very interesting. The overt differences in weight gain between males and 
females should be investigated with regard to hormonal differences. One anticipates that 
detailed analysis of the intricate mechanisms by which Mnk2 controls particularly lipid 
metabolism will provide insights into the substrates of Mnk2 that are responsible for the 
differences seen. Finally, an in-depth investigation into the cell-type(s) responsible for the 
differences in the inflammatory profile seen in Mnk2-KO mice would be valuable. This is 
true in particular with regard to the potential for targeting Mnk activity for the treatment of 
inflammatory disease.   
 
In summary, Mnk2KO mice are able to use glucose and lipids as energy sources in a 
novel fashion compared with WT mice, this means that, when fed normal chow diet, they 
use up lipids rapidly and subsequently have reduced visceral fat deposits but an increase 
in subcutaneous fat tissue. Consequently, when fed a high fat diet, their ability to use 
lipids as an energy resource and balance this with glucose utilization results in a 
protection against diet-induced obesity. Furthermore, the reduction in the expression of 
inflammatory mediators such as IFNγ and TNFʱ also helps to protect these mice from 
perturbed glucose tolerance and insulin resistance. This may indicate that specific Mnk2 - 238 - 
inhibitors may be an appropriate and novel treatment for insulin resistance in obese 
patients.  
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Role of Mnk2a in rapamycin-induced eIF4E phosphorylation 
The observations that rapamycin had potential for anti-cancer therapy led to the approval 
of derivatives of rapamycin (rapalogs) in the treatment of renal cell carcinoma [244]. The 
use of rapalogs in other cancers such as prostate cancer has proved less than desirable 
[259, 261, 345]. There is substantial evidence that rapamycin results in eIF4E 
phosphorylation in numerous cell types [29, 31, 262, 263], which represents a potential 
resistance mechanism to rapamycin since eIF4E phosphorylation has been linked to 
tumorigenesis [77-79]. Attempts to determine the pathway responsible for rapamycin-
induced eIF4E phosphorylation have shown a role for PI3K and conflicting evidence for 
the role of PKB [29, 31, 263]. Furthermore, there is only one piece of data that 
investigates the Mnk isoform responsible and shows that both the Mnks are involved in 
rapamycin-induced eIF4E phosphorylation. This is despite evidence that neither ERK nor 
p38MAPK are activated, which are required for Mnk1 activity [29, 31].   
In this study the evidence shows that inhibition of both the p110ʱ and p110β subunits of 
PI3K is necessary to block rapamycin-induced eIF4E phosphorylation. This is consistent 
with evidence that shows the use of LY294002 and knockout of the p85ʱ subunit of PI3K 
also blocks rapamycin-induced eIF4E phosphorylation [31]. PKB was shown to not be part 
of the signalling cascade responsible for rapamycin-induced eIF4E phosphorylation in this 
study.  
Subsequent experiments demonstrated that Mnk2a was responsible for rapamycin-
induced eIF4E phosphorylation in a mechanism that involved rapamycin-induced 
increases in Mnk2a activity independent of T-loop phosphorylation. Mass spectrometry 
analysis showed that two sites in Mnk2a exhibited changes in phosphorylation (although 
not quantitatively): Ser
74 and Ser
437 and subsequent mutagenesis experiments revealed 
that Ser
437 was important for rapamycin-induced eIF4E phosphorylation. Interestingly the 
data suggested that dephosphorylation of Ser
437 in a rapamycin induced fashion lead to 
increases in Mnk2a activity. These data also indicated that PP242 also increased Mnk2a 
activity indicating that this is a phenomenon related to mTORC1 inhibition irrespective of 
the mode of mTOR inhibition. This is very important when considering mTOR inhibitors as 
cancer therapies as increased Mnk2a activity may be oncogenic with regards to 
substrates other than eIF4E. 
Regulation of insulin signalling by the Mnks 
The majority of research involving the Mnks has focused on their best known substrate 
eIF4E and the link between its phosphorylation and tumorigenesis (reviewed [40, 79, 
276]), whilst other research links the Mnks with inflammatory pathways and cytokine - 242 - 
translation [41, 42, 81, 282, 283]. There is evidence of only one other Mnk substrate that 
is not related to translation, which is Sprouty [74, 105]. There are however a couple of 
patents that relate the Mnks to glucose and lipid homeostasis [106, 228], which present 
evidence that the Mnks may modulate insulin sensitivity, albeit there is a distinct 
confliction as to the role the Mnks play.  
Research presented here shows the Mnks are highly enriched in tissues related to 
glucose metabolism where both Mnk1 and Mnk2 are expressed in the skeletal muscle and 
fat depots whilst Mnk1 was the most enriched in the pancreas. Investigations using Mnk 
knockout cells revealed that loss of particularly Mnk2 resulted in a significant reduction in 
PKB activity, whilst the loss of both Mnks abrogated this further. PKB signalling to 
mTORC1 was disrupted to the greatest extent in Mnk1/2-DKO cells with some changes in 
Mnk1-KO and Mnk2-KO cells. There was a very strong effect of knockout of either of the 
Mnks on glucose uptake, which showed loss of the Mnks results in the inhibition of insulin-
stimulated glucose. This was further corroborated with the use of Mnk inhibitors, which 
caused a reduction in insulin-stimulated glucose uptake, consistent with the Mnks 
regulating insulin signalling in a mechanism related to their kinase activity. Investigations 
into the mechanism by which the Mnks regulate insulin signalling revealed that PI3K 
activity was also reduced in Mnk1/2-DKO cells although the data from Mnk1-KO or Mnk2-
KO cells was not as clear. Reduced PI3K activity in response to insulin was also seen in 
3T3-L1 cells treated with Mnk inhibitors. These data indicated that the Mnks either acted 
directly on, or, upstream of PI3K.  
IRS1 is highly regulated by phosphorylation (reviewed [229]) and therefore represented a 
potential target of the Mnks. Levels of IRS1 protein were distinctly lower in Mnk knockout, 
Mnk knockdown (siRNA treated WT cells) and Mnk inhibitor treated cells. Further 
investigation revealed that both Mnk1 and Mnk2 were able to phosphorylate IRS1 at 5 
sites and subsequent experiments revealed these sites may be important for the 
stabilization of IRS1 by the Mnks.  
The low levels of IRS1 in Mnk knockout cells suggested that tissues such as the muscle 
and white adipose from Mnk1/2-DKO mice would also show low levels of IRS1. This was 
not the case for skeletal muscle, but, adipose tissue appeared to have lower levels of 
IRS1 in Mnk1/2-DKO mice, although there was considerable mouse to mouse variation. 
The knockout of IRS1 in mice leads to systemic insulin resistance [342], whilst mice 
expressing a mutant of IRS1 that is resistant to degradation are protected from insulin 
resistance [309].  These observations led to the discovery, shown here, that Mnk1/2-DKO - 243 -   
mice are insulin resistant as revealed by a shift in glucose clearance when challenged 
with a glucose tolerance test. 
These findings would indicate that insulin sensitivity might be improved by agents that 
increase the activity or expression of the Mnks. This is contradictive with regards to the 
data presented in a patent relating to Mnk inhibitors improving insulin sensitivity [106]. 
Analysis of Mnk2-KO mice revealed that IRS1 protein levels were reduced in both the 
skeletal muscle and white adipose tissue of chow-fed mice but they did not show insulin 
resistance as demonstrated by a normal glucose tolerance test. These observations 
reveal that the control of IRS1 levels by the Mnks is complex and requires further research 
to ascertain the role of Mnk1. The levels of Mnk1 are the greatest in the pancreas, whilst 
Mnk2 is not expressed in the pancreas, which is suggestive of a specific role for Mnk1 in 
this tissue. One explanation for the disparity seen with regards to insulin resistance when 
comparing Mnk2-KO and Mnk1/2-DKO mice is that the perturbed glucose tolerance of 
Mnk1/2-DKO mice is caused by changes to the levels of insulin. It would be very 
interesting to investigate if Mnk1 has any role in the pancreas with regards to insulin 
secretion or expression.  
 
Role of Mnk2 in whole body glucose and lipid homeostasis 
Perhaps the most interesting data presented here pertains to the effect of Mnk2 knockout 
on the metabolism of lipids and glucose and the effect high fat diet feeding has on these 
animals.  
Evidence from  one patent regarding the Mnks showed that an Mnk2DN mouse weighed 
more than WT mice whilst overexpression of Mnk2 in cells led to decreased TG storage 
and reduced lipogenesis [228]. The opposite was shown in another patent regarding and 
Mnk2 inhibitor, which showed insulin sensitizing properties and mice treated with the 
compound showed reduced bodyweight [106]. These observations are consistent with the 
data shown here where male Mnk2-KO mice weighed less than their WT counterparts 
even when challenged with a high fat diet. Furthermore both male and female Mnk2-KO 
mice were protected from diet-induced insulin resistance as shown in glucose tolerance 
tests and HOMA-IR calculations.  
The lack of weight gain by male Mnk2-KO mice fed high fat diets is a desirable feature 
when considering the epidemic of obesity. It was therefore surprising when DEXA analysis 
revealed that even chow-fed Mnk2-KO mice exhibited increased subcutaneous fat and fat 
between the organs. Furthermore, Mnk2-KO mice fed high fat diets appeared to show 
similar increases in fat accumulation as high fat fed WT mice. Potential explanations for - 244 - 
the disparity between weight and the DEXA data came from the observations that Mnk2-
KO are, overall, smaller than WT mice in terms of length and body volume whilst the 
amount of white fat was significantly lower in chow-fed Mnk2-KO mice and marginally 
reduced in high fat fed Mnk2-KO mice. Investigations into the histology and biochemistry 
of the fat depots revealed some interesting data. The brown adipose tissue of chow-fed 
and high fat fed Mnk2-KO mice weighed more with respect to bodyweight compared to 
WT mice, whilst the converse was true for white adipose tissue. The histology of both fats 
depots was also altered in Mnk2-KO mice; the brown adipose of high fat fed Mnk2-KO 
mice exhibited larger adipocytes. Chow-fed Mnk2-KO mice presented with larger 
adipocytes in white adipose that did not increase in size to the same extent as adipocytes 
from high fat fed WT mice. These observations indicate Mnk2 may have a role in fatty acid 
synthesis, lipolysis or adipogenesis and represents a novel area of research with regards 
to the physiological role of Mnk2. The data from plasma lipid metabolites shows chow-fed 
Mnk2-KO mice have lower levels of TGs, cholesterol and β-hydroxybutyrate, which is 
again a desirable phenotype. However in high fat fed Mnk2-KO mice plasma TGs, 
cholesterol, NEFAs and β-hydroxybutyrate increase significantly and to a greater extent 
than high fat fed WT mice. The explanation may be linked to the observations that Mnk2-
KO mice fed chow diets had increased UCP-1 expression and reduced abdominal 
adipose mass, which may explain the lower levels of plasma lipids due to their use for 
energy. The increased plasma lipid levels in high fat fed Mnk2-KO mice may be a 
consequence of reduced storage of TGs in abdominal adipose and therefore spill-over 
into circulation.       
Evidence currently suggests that diet-induced insulin resistance is caused by increased 
plasma NEFAs and TGs in combination with increased levels of inflammatory cytokines, 
and perturbed adipokine release (reviewed [157, 175, 177]). The mechanisms related to 
the protection of Mnk2-KO mice from diet-induced insulin resistance were not explained 
by differences in lipid metabolites as would be expected given the lack of weight gain. The 
analysis of inflammatory cytokines revealed that the protection from insulin resistance in 
high fat fed Mnk2-KO mice may be related to a reduced expression of inflammatory 
cytokines such as TNFʱ, IFNγ MCP-1 and RANTES. Furthermore, this suggests reducing 
the chronic inflammation associated with obesity is more beneficial than reducing plasma 
lipids. This is supported by the observation that high fat fed Mnk2-KO mice have higher 
levels of TGs and NEFAs than WT mice but exhibit improved insulin sensitivity.  
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Future directions for research involving the Mnks 
There is still a distinct lack of information regarding the physiological roles of the Mnks 
and whilst this study presents an insight into novel functions of the Mnks there are still a 
number of unanswered questions with regards to distinct roles for the Mnks.  
The increase in activity of Mnk2a in response to mTOR inhibition must be further 
investigated to determine the mechanism by which Ser
437 modulates Mnk2a activity. 
Furthermore, it is important to identify substrates of Mnk2a that may be oncogenic whilst 
the role of eIF4E phosphorylation on translation of specific mRNAs still requires further 
investigation.  
This study has revealed a novel substrate of the Mnks, IRS1 whose stability is regulated 
through phosphorylation. Future research would need to address if Mnk-dependent 
phosphorylation was required for signalling through IRS1 by testing whether the S-5-A 
IRS1 mutant exhibited reduced PKB activity and downstream signalling as seen in the 
Mnk knockout cells. Furthermore, the insulin levels in Mnk1/2-DKO and Mnk-1KO mice 
need to be assessed and a GTT needs to be conducted in Mnk1-KO mice. The role of 
Mnk1 in the pancreas is another exciting area of research, which may yield a physiological 
role for this kinase.  
The role of Mnk2 in a whole animal model has been investigated here but there is still a lot 
of research required to identify how Mnk2 regulates fat distribution, adipocyte size, fatty 
acid synthesis and lipolysis, one or all of which may explain the phenotype presented by 
Mnk2-KO mice. Another interesting area of research with regards to Mnk2 would be to 
determine if translation of cytokines are regulated in diseases other than diet-induced 
obesity, representing another use of Mnk inhibitors in disease.       
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